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I                                                                         
  ﻤﻠﺨﺹ ﺍﻻﻁﺭﻭﺤﺔ
ﻫﺩﻑ ﻫﺫﺍ ﺍﻟﺒﺤﺙ ﻫﻭ ﺩﺭﺍﺴﺔ ﻭﺘﺼﻤﻴﻡ ﺍﻗﺭﺍﺹ ﻏﻴﺭ ﻤﻐﻠﻔﺔ ﻤﺴﺘﻤﺭﺓ ﺍﻻﻁﻼﻕ ﺘﺘﻜﻭﻥ ﻤﻥ ﺒﻭﻟﻴﻤﺭ ﻴﺄﻟﻑ ﺍﻟﻤﺎﺀ ﺘﺤﺘﻭﻱ ﻋﻠﻰ 
ﺍﻟﺘﻲ ﺘﺴﺘﺨﺩﻡ ﻟﺒﻌﺩ ﺍﻟﺜﻼﺜﺔ ﺍﺸﻬﺭ ﺍﻻﻭﻟﻰ ﻋﻨﺩ ﺍﻟﺤﻤل ﻜﻤﻌﺎﻟﺠﺔ ﻭﻗﺎﺌﻴﺔ ﻟﺴﺩ ﻨﻘﺼﺎﻥ ( ﺤﻤﺽ ﺍﻟﻔﻭﻟﻴﻙ+ ﻓﻴﻭﻤﺎﺭﺍﺕ ﺍﻟﺤﺩﻴﺩ )
ﻓﻲ ﺍﻟﻭﺴﻁ ( ﺤﺩﻴﺩ)ﻜﻭﻥ ﺍﻻﻗﺭﺍﺹ ﻗﺎﺩﺭﺓ ﻹﻋﻁﺎﺀ ﺍﻗل ﻨﺴﺒﺔ ﻤﻥ ﺍﻟﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻥ ﺘ. ﺍﻟﻤﺎﺩﺘﻴﻥ ﺍﻟﺫﻱ ﻗﺩ ﻴﺤﺩﺙ ﻓﻲ ﺍﻟﺠﺴﻡ
ﻓﻲ ﺍﻜﺒﺭ ﺯﻤﻥ ﻤﻤﻜﻥ ﻓﻲ ﻤﺤﻠﻭل % 09ﺍﻟﺤﻤﻀﻲ ﺍﻟﻤﺸﺎﺒﻪ ﻟﻤﺤﻠﻭل ﺍﻟﻤﻌﺩﺓ ، ﻭﺍﻴﻀﺎﹰ ﺍﻋﻁﺎﺀ ﻨﺴﺒﺔ ﻤﻥ ﺍﻟﺩﻭﺍﺀ ﻟﻴﺱ ﺍﻗل ﻤﻥ 
ﺍﻟﻤﻌﻭﻴﺔ ﻭﺫﻟﻙ ﺒﻐﺭﺽ ﺘﺠﻨﺏ ﺍﻻﻀﻁﺭﺍﺒﺎﺕ .  ﻜﻤﺤﻠﻭل ﻤﺸﺎﺒﻪ ﻟﻤﺤﻠﻭل ﺍﻻﻤﻌﺎﺀ6ﺍﻟﻤﺎﺀ ﺍﻟﻤﻨﺯﻭﻉ ﺍﻟﻤﻌﺎﺩﻥ ﺭﻗﻤﻪ ﺍﻟﻬﻴﺩﺭﻭﺠﻴﻨﻲ 
ﺍﻟﺘﻲ ﻴﺴﺒﺒﻬﺎ ﺍﻁﻼﻕ ﺩﻭﺍﺀ ﺍﻜﺒﺭ ﻓﻲ ﺯﻤﻥ ﺍﻗﺼﺭ ﻭﺨﺼﻭﺼﺎﹰ ﺍﻥ ﺍﻟﺤﺩﻴﺩ ﻭﺤﻤﺽ ﺍﻟﻔﻭﻟﻴﻙ ﻴﺸﻜﻼﻥ ﺍﻟﻤﻜﻭﻨﺎﺕ ﺍﻻﺴﺎﺴﻴﺔ ﻓﻲ 
ﻭﺤﻤﺽ ﺍﻟﻔﻭﻟﻴﻙ ﻴﺨﺘﺯل ﻓﻲ ﺍﻟﺠﺴﻡ ﺍﻟﻰ ﻓﻭﻟﻴﺕ ﺭﺒﺎﻋﻲ ﺍﻟﻤﺎﺌﻴﺔ ( ﺼﺒﻐﺔ ﺍﻟﺩﻡ)ﺍﻟﺠﺴﻡ ، ﺍﻟﺤﺩﻴﺩ ﺍﺴﺎﺱ ﺘﻜﻭﻴﻥ ﺍﻟﻬﻴﻤﻭﻏﻠﻭﺒﻴﻥ 
  .ﻜﺄﻨﺯﻴﻡ ﺘﻤﻴﻤﻲ ﻓﻲ ﻋﺩﺓ ﻋﻤﻠﻴﺎﺕ ﺍﺴﺘﻘﻼﺏ
ﺒﺘﻘﻨﻴﺔ ﺍﻟﺘﺤﺒﻴﺏ ( ﺱ.ﻡ.ﺏ.ﻫـ)ﻋﺩﺓ ﺼﻴﻎ ﺼﻴﺩﻻﻨﻴﺔ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ﻨﺴﺏ ﻤﺨﺘﻠﻔﺔ ﻤﻥ ﺍﻟﺒﻭﻟﻴﻤﺭ ﺍﻟﺫﻱ ﻴﺄﻟﻑ ﺍﻟﻤﺎﺀ ﺘﻡ ﺘﺤﻀﻴﺭ 
ﺍﻟﺭﻁﺏ ﺤﻴﺙ ﺘﻡ ﺍﺴﺘﻌﻤﺎل ﻁﺭﻴﻘﺔ ﺘﺎﻗﻭﺘﺸﻲ ﺍﻻﺨﺘﺒﺎﺭﻴﺔ ﻟﺩﺭﺍﺴﺔ ﺍﺜﺭ ﺍﻟﻨﺴﺏ ﺍﻟﻤﺨﺘﻠﻔﺔ ﻤﻥ ﺍﻟﻤﻭﺍﺩ ﺍﻟﻤﺴﺎﻋﺩﺓ ﺍﻟﻐﻴﺭ ﻓﻌﺎﻟﺔ ﻓﻲ  
ﻕ ﺍﻟﺩﻭﺍﺀ ﻭﺤﺭﻜﺘﻪ ، ﻭﺫﻟﻙ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻼﻗﺭﺍﺹ ﺍﻟﺘﻘﻠﻴﺩﻴﺔ ﻭﺍﻴﻀﺎﹰ ﻓﻰ ﻤﻌﺩل ﺍﻁﻼ. ﺍﻟﺨﺼﺎﺌﺹ ﺍﻟﻔﻴﺯﻴﺎﺌﻴﺔ ﻟﻠﺤﺒﻴﺒﺎﺕ ﻭﺍﻻﻗﺭﺍﺹ 
ﻭﺍﻻﻗﺭﺍﺹ ﺫﺍﺕ ﺍﻻﻁﻼﻕ ﺍﻟﻤﺴﺘﻤﺭ ﺍﻟﻤﺘﺤﻜﻡ ﻓﻴﻪ ، ﻋﻨﺩ ﺩﺭﺍﺴﺘﻬﺎ ﻓﻲ ﻤﺤﺎﻟﻴل ﺫﺍﺕ ﺍﺭﻗﺎﻡ ﻫﻴﺩﺭﻭﺠﻴﻨﻴﺔ ﻤﺨﺘﻠﻔﺔ ﺒﺈﻀﺎﻓﺔ ﺍﻭ ﻤﻥ 
ﻴﺭ ﺍﻟﻐﺎﺩﻭﻑ ﻤﻥ ﺩﺴﺘﻭﺭ ﺍﻟﻌﻘﺎﻗ( 2)ﻏﻴﺭ ﺇﻀﺎﻓﺔ ﺨﻭﺍﻓﺽ ﻟﻠﺘﻭﺘﺭ ﺍﻟﺴﻁﺤﻲ ﻓﻲ ﺍﻻﻨﺒﻭﺒﺔ ﺍﻟﻤﺨﺒﺭﻴﺔ ﻭﺫﻟﻙ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻟﻁﺭﻴﻘﺔ 
ﺜﻨﺎﺌﻲ )ﺒﻁﺭﻴﻘﺔ ﻗﻴﺎﺱ ﺍﻟﻀﻭﺀ ﺍﻟﻁﻴﻔﻲ ﺤﻠﻠﺕ ﺠﻤﻴﻊ ﺍﻟﻌﻴﻨﺎﺕ ﺍﻟﻤﺴﺤﻭﺒﺔ ﺍﻟﺫﺍﺌﺒﺔ ﻟﺘﺤﺩﻴﺩ ﻨﺴﺏ ﺍﻟﺤﺩﻴﺩ .ﻭﺍﻻﺩﻭﻴﺔ ﺍﻻﻤﺭﻴﻜﻲ
  . ﻤﻴﻜﺭﻭﻤﻴﺘﺭ015ﺍﻟﻤﻨﻁﻠﻕ ﻓﻲ ﺍﻻﺯﻤﺎﻥ ﺍﻟﻤﺤﺩﺩﺓ ﺴﻠﻔﺎﹰ ﺒﻁﻭل ﻤﻭﺠﻲ ( ﺍﻟﺘﻜﺎﻓﻭﺀ
ﻭﻟﺔ ﻁﺎﺒﻘﺕ ﺍﻟﻤﻭﺍﺼﻔﺎﺕ ﺤﺒﻴﺒﺎﺕ ﻭﺍﻗﺭﺍﺹ ﻜل ﺍﻟﺼﻴﻎ ﺍﻟﻤﺤﻀﺭﺓ ﺤﻘﻘﺕ ﻨﺘﺎﺌﺞ ﻋﻘﺎﻗﻴﺭﻴﺔ ﺘﻜﻨﻴﻜﻴﺔ ﻤﻘﺒ ﺃﻥ ﺃﺘﻀﺢ ﻤﻥ ﺍﻟﺩﺭﺍﺴﺔ
ﻓﻲ ﺍﻟﻭﺴﻁ ﺍﻟﺤﻤﻀﻲ ﻋﻨﺩ ﻨﻬﺎﻴﺔ ﺍﻟﺴﺎﻋﺔ ﺍﻻﻭﻟﻰ ( ﺍﻟﺤﺩﻴﺩ ﺜﻨﺎﺌﻲ ﺍﻟﺘﻜﺎﻓﻭﺀ)ﺍﻻﻗﺭﺍﺹ ﺍﻟﺘﻘﻠﻴﺩﻴﺔ ﺘﻁﻠﻕ ﻜل ﺍﻟﺩﻭﺍﺀ .ﺍﻟﻤﻁﻠﻭﺒﺔ
ﻭﺠﺩ ﺃﻴﻀﺎ ﺃﻥ ﻜل . ﻤﻥ ﺍﻟﺩﻭﺍﺀ ﻓﻲ ﻨﻔﺱ ﺍﻟﺯﻤﻥ04%ﺒﺎﻟﻤﻘﺎﺭﻨﺔ ﻤﻊ ﺍﻻﻗﺭﺍﺹ ﺍﻟﻤﺘﺤﻜﻡ ﻓﻲ ﺍﻁﻼﻗﻬﺎ ﺍﻟﺘﻲ ﺘﻌﻁﻲ ﺤﻭﺍﻟﻲ 
 ﻭﻻﺘﻌﻁﻲ ﺍﻱ ﺍﻁﻼﻕ ﻓﻲ ﺍﻟﻭﺴﻁ 5.4 ﺍﻟﻭﺴﻁ ﺍﻟﺤﻤﻀﻰ ﺫﻭ ﺍﻟﺭﻗﻡ ﺍﻟﻬﻴﺩﺭﻭﺠﻴﻨﻲ ﺍﻻﻗﺭﺍﺹ ﺘﻌﻁﻲ ﺍﻁﻼﻕ ﻟﻠﺩﻭﺍﺀ ﺒﻁﺊ ﻓﻲ
ﺃﺘﻀﺢ ﺃﻨﻪ  ﻻﻴﻭﺠﺩ ﻓﺭﻕ ﻤﻼﺤﻅ ﻓﻲ ﺍﻁﻼﻕ ﺍﻟﺩﻭﺍﺀ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻼﻗﺭﺍﺹ ﺍﻟﻤﺘﺤﻜﻡ ﻓﻴﻬﺎ   .8.6ﺍﻟﻘﺎﻋﺩﻱ ﺫﻭ ﺍﻟﺭﻗﻡ ﺍﻟﻬﻴﺩﺭﻭﺠﻴﻨﻲ 
ﺍﻟﻨﺸﺎﺀ ، )ﺎﻓﺔ ﺍﻻﺨﺭﻯ ﺴﻭﺍﺀ ﻜﺎﻥ ﺘﺭﻜﻴﺯ ﺍﻟﺒﻭﻟﻴﻤﺭ ﻓﻲ ﺍﻋﻠﻰ ﺍﻭ ﺍﻗل ﻤﺴﺘﻭﻯ ﻟﻪ ﻭﻟﻜﻥ ﻟﻭﺤﻅ ﺍﻥ ﺍﺨﺘﻼﻑ ﺘﺭﻜﻴﺯ ﺍﻟﻤﻭﺍﺩ ﺍﻟﻤﻀ
ﻤﻌﻅﻡ ﺍﻟﻤﻅﺎﻫﺭ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻟﻼﻁﻼﻕ ﺒﺎﻟﻨﺴﺒﺔ .ﺘﺅﺜﺭ ﻓﻲ ﺍﻟﻤﻅﻬﺭ ﺍﻟﺠﺎﻨﺒﻲ ﻻﻁﻼﻕ ﺍﻟﺩﻭﺍﺀ( ﻤﻴﻜﺭﻭ ﻜﺭﻴﺴﺘﺎﻟﻴﻥ ﺴﻴﻠﻠﻭﺯ ، ﻭﺍﻟﻼﻜﺘﻭﺯ
ﺒﺘﺤﻠﻴل ﻁﺭﻴﻘﺔ ﺘﺎﻗﻭﺘﺸﻲ ﺍﻻﺨﺘﺒﺎﺭﻴﺔ ﻨﺠﺩ ﺍﻥ ﺍﺤﺴﻥ ﺘﺭﻜﻴﺒﺔ . ﻟﻼﻗﺭﺍﺹ ﺍﻟﻤﺘﺤﻜﻡ ﻓﻴﻬﺎ ﺘﻅﻬﺭ ﻤﻴﻭل ﻻﺘﺒﺎﻉ ﺤﺭﻜﺔ ﺍﻨﻌﺩﺍﻡ ﺘﺭﺘﻴﺏ
 52)% ﺍﻁﻼﻕ ﻤﻥ ﺍﻟﺩﻭﺍﺀ ﺘﺘﻜﻭﻥ ﻤﻥ 09% ﻠﺩﻭﺍﺀ ﻓﻲ ﺍﻟﻭﺴﻁ ﺍﻟﺤﻤﻀﻲ ﻭﺍﻓﻀل ﺯﻤﻥ ﻤﺭﺍﺩ ﻟﻠﻭﺼل ﺍﻟﻰﺘﻌﻁﻲ ﺍﻗل ﺍﻁﻼﻕ ﻟ
ﻤﻥ ﺍﻟﻭﺯﻥ (  ﻻﻜﺘﻭﺯ64.5% ﻨﺸﺎﺀ ، 64.5% ﻤﻴﻜﺭﻭ ﻜﺭﻴﺴﺘﺎﻟﻴﻥ ﺴﻴﻠﻠﻭﺯ ، 5%ﺍﻟﻬﻴﺩﺭﻭﻜﺴﻲ ﺒﺭﻭﺒﺎﻴل ﻤﻴﺜﺎﻴل ﺴﻴﻠﻠﻭﺯ ، 
ﻲ ﺍﻟﻁﺒﻴﻌﺔ ﺍﻟﻜﻴﻤﻴﺎﺌﻴﺔ ﻟﻠﺩﻭﺍﺀ  ﺍﻟﻤﻅﻬﺭ ﺍﻟﺠﺎﻨﺒﻲ ﻭﺤﺭﻜﻴﺎﺕ ﺍﻁﻼﻕ ﺍﻟﺩﻭﺍﺀ ﺩﻭﺍل ﻓ ﺨﻠﺼﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻰ ﺃﻥ  .ﺍﻟﻜﻠﻲ ﻟﻠﻘﺭﺹ
ﻭﺃﻥ ﻤﺩﻯ ﺍﻨﺘﻔﺎﺥ ﺍﻟﻘﺭﺹ ﻭﻜﻤﻴﺔ ﺍﻟﺴﺎﺌل ﺍﻟﻤﺘﻭﻏل ﺍﻟﻰ ﺩﺍﺨل ﺍﻟﻘﺭﺹ   .ﻭﺍﻨﻭﺍﻉ ﺍﻻﻀﺎﻓﺎﺕ ﺍﻟﻐﻴﺭ ﻓﻌﺎﻟﺔ ﺍﻟﻤﺴﺘﻌﻤﻠﺔ( ﺍﻟﺫﻭﺒﺎﻨﻴﺔ)
     (.ﺍﻟﻨﺸﺎﺀ ، ﻤﻴﻜﺭﻭ ﻜﺭﻴﺴﺘﺎﻟﻴﻥ ﺴﻴﻠﻠﻭﺯ ، ﻭﺍﻟﻼﻜﺘﻭﺯ)ﺘﺅﺜﺭ ﻓﻴﻪ ﺍﻨﻭﺍﻉ ﺍﻻﻀﺎﻓﺎﺕ ﺍﻟﻐﻴﺭ ﻓﻌﺎﻟﺔ 
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ABSTRACT 
 
The objective of the present research was to design a suitable uncoated matrix tablet that 
contains ferrous fumarate + folic acid. This tablet was designed in a way to be capable of 
giving the least release of drug in the first hour in acidic medium 0.1N HCl which simulated 
the gastric fluid. Moreover, it should be capable of giving not less than 90% in the maximum 
time in D.M Water at pH 6 dissolution medium which was considered to simulate the 
intestinal fluid. This sustained release dosage form would decrease gastro intestinal 
disturbances most likely caused by increasing the drug release in shorter time. Especially that 
combination is used second and third trimester of pregnancy as prophylaxis of iron & folic 
acid deficiency.  
In this research, several formulations containing hydrophilic polymer HPMC, were prepared 
by wet granulation technique. Statistical Taguchi experimental method was used to study the 
impact of different content levels of HPMC, MCC, Starch and Lactose in: (1) physical 
characterization for granules and matrix tablet. Also (2) Drug release rate and its kinetics for 
hydrophilic matrix tablets compared with conventional tablets when studied in a variety of 
dissolution media, pH buffer media with and without addition of various surfactants, to 
perform this in vitro studies, USP paddle method II was used. The spectrophotometry method 
was used to analyse all withdrawn dissolution samples to determine the percentage of iron 
(Fe+2) released in the pre-determined times using spectrometer UV\VIS double beam at 
wavelength 510nm. 
The granules for all prepared formulations showed satisfactory flow and compressibility 
properties. All tablets showed acceptable pharmacotechmical properties and complied with in-
house specifications for tested parameters. The conventional tablet released all drug (Fe+2) in 
acidic medium by the end of the 1st hour compared with about only 40% of the drug release 
for hydrophilic matrix tablets at the same time. Also, conventional tablets released all drug in 
about 4 hours in D.M Water at pH 6 whereas most of the hydrophilic matrix tablets released 
all the drug by the end of the 17th hour in D.M Water at pH 6. All the tablets showed slower 
drug (Fe+2) release in acidic medium (pH 4.5) and gives no drug release in dissolution medium 
pH 6.8. There is no significant difference in drug release of hydrophilic matrix tablets if the 
concentration of polymers HPMC increased whereas the increase in the concentrations of 
MCC, Starch, or Lactose affect drug (Fe+2) release profiles. Release profiles for most of 
hydrophilic matrix tablets showed a tendency to follow zero order kinetic (Non-fiction - Case 
II) Analysis with Taguchi experimental method showed that the best combination that gives 
the least drug release in the acidic medium at the 1st hour, and required time for 90% of drug 
release was found to be the one containing 25% HPMC, 5% MCC, 5.46% Starch and 5.46% 
Lactose out of total tablet weight. 
The release profile and kinetic of drug release were functions of physio-chemical nature of 
drug (e.g. solubility) and types of selected excipients used. Swelling rate of the matrix tablets 
and quantity of fluid penetration in the matrix tablets were found to be influenced by the 
excipients (MCC, Starch, and Lactose). Food has strong influence in drug release profile.  
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CHAPTER ONE 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
  
1-1General Chemistry and Pharmacology of Folic acid 
1-1-1 Introduction: 
Folic acid is a B vitamin needed for cell replication and growth. Folic acid helps form 
building blocks of DNA, the body's genetic information, and building blocks of RNA, 
needed for protein synthesis in all cells (Truswell, 1985). 
Therefore, rapidly growing tissues, such as those of a fetus, and rapidly regenerating 
cells, like red blood cells and immune cells, have a high need for folic acid. Folic acid 
deficiency results in a form of anemia that responds quickly to folic acid 
supplementation. The requirement for folic acid increases considerably during 
pregnancy (Daly et al, 1995). 
Deficiencies of folic acid during pregnancy are associated with low birth weight and an 
increased incidence of neural tube in infants. Folic acid is needed to keep 
homocystemine (an amino acid by- product) level s in blood from rising. A growing 
body of evidence suggests that an elevated homocysteine level is a risk factor for heart 
diseases, and may also be linked to several other diseases (Bostom et al, 1999). 
Folic acid and certain other B vitamins function as cofactors for enzymes that can lower 
homocysteine levels. Research has shown that supplementing with folic acid reduces 
homocysteine levels of the B vitamins with a role in homocysteine metabolism; folic 
acid appears to be the most important in lowering homocysteine levels for the average 
person (Dierkes, 1998 and Ubbink, 1993). 
A deficiency of folic acid has also been associated with peripheral vascular disease and 
coronary artery disease even in people with normal homocysteine levels, suggesting 
that the vitamin may have protective effects that extend beyond its role in maintaining 
normal homocysteine levels (Bunout et al, 2000). 
Folic acid is not generally associated with side effects.  However, folic acid 
supplementation can interfere with the laboratory diagnosis of vitamin B12 deficiency, 
possibly allowing the deficiency to progress undetected to the point of irreversible 
nerve damage (Wald, 1994 and Butterworth, 1989). 
Body stores of folate in healthy persons have been reported as being between 5 to 10 
mg, but may be much higher. About 150 to 200 mg of folate a day is considered a 
suitable average intake for all healthy persons except women of child-bearing potential  
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and pregnant women who require additional folic acid to protect against neural tube 
defects (Sutcliffe, 1994 and Schorah, 1993). 
1-1-2 Deficiency symptoms:  
A deficiency of folic acid limits cell function (cell division and protein synthesis) and 
affects the normal growth and repair of all cells and tissues in the body. The tissues that 
have the fastest rate of cell replacement are affected first.  
Symptoms are:   
• Anemia.  
• Gastrointestinal upset.  
• Memory problems.  
• Impaired brain and nerve function. 
• Birth defects.    
1-1-3 Physico – Chemical Properties:  
1-1-3-1 Origin of the substance:  
Folic acid is naturally found in food such as bean, leafy green vegetables, brewer's 
yeast, orange, banana, citrus fruits, beet, wheat germ, and meat. Folic acid was isolated 
in 1941 by Mitchell and from green leafy vegetables, liver, yeast and synthetic folic 
acid is commercially available. 
In 1990, more than one – third of the folate in the American diet was provided by fruits 
and vegetables. Grain products contributed a little more than one –fifth. Food that 
contain a small amount, of folate but are not considered good sources can contribute 
significant amount, of folate to an individual’s diet if these goods are eaten often or in 
large amounts. See Fig (1-1)  
 
 
 
 
 
 
 
 
 
 
Fig (1-1): Average intake of folate in the typical American diet, the (other foods) category 
includes fat, and oil (0.1%) and miscellaneous foods (2.0%). (Source; gerrior SA  zizzac, 1994 
Nutrient content, of the U.S food supply research report No: 52.U.S.) 
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1-1-3-2 Chemical structure:  
  (a) Structural formula:- 
 
 
 
 
 
 
  (b) Molecular formula:  
       C19 H19 N7 O6  
  (c) Molecular weight:  
       441.4  
  (d) Chemical names:  
(a) N – [4 (2 –Amino – 4 – hydroxyl – pteridine – 6 –yl methyl – amino) benzoyl] – L 
(+) – glutamic acid. 
(b) N – [4 – [{(2–Amino – 1, 4 – dihydro – 4 – oxo – 6 – pteridinyl) methyl] amino]      
benzoyl} – L – glutamic acid. 
(c) 4– (2– Amino – 4 – hydroxy – 6 – hydroxyl – 6 – pteridinyl) methylamino – 
benzoyl] – glutamic acid. (Reynold, 1993 and Budavari, 1989) 
(d) In BP: (2S) – 2 – [4 – [[(2–Amino – 4 – hydroxypteridin – 6 – yl) methyl] amino] 
benzamido] glutamic acid. 
 
1-1-3-3 Synthesis:  
Folic acid may be synthesized by the following method. When 2,3 
Dibromopropionaldehyde, dissolved in water-miscible organic solvent(alcohol, 
dioxane) is added to a solution of equal molecular quantities of 2,4,5 triamino – 6 – 
hydroxypyrimidine and p- aminobenzoy1 glutamic acid, maintaining a pH of about 4 by 
the controlled addition of alkali as reaction progresses (Remington's, 1975). 
 
 
 
 
 
 
 
 
 
 
 
 
                                            
                                  
 
                                       Fig (1-2): Synthesis of Folic Acid 
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1-1-3-4 Generic names: 
Acidum, cytofol, folsaver, folaain , foldine, folaemin, foliamin, folicet , folipac folicum, 
folmsyre, incafolic, nifolin, nifola acid, mallafol. 
1-1-3-5 Brand Names, Trade Names:  
Acfol ( Torlan, spain) , Folacid (Netherlands), Folaemin (Netherlands), Folasic (Nelson, 
Australia), Foldine folettes (Australia) , Folicid (usv, Asutralia), Folico (Ecobi, italy), 
folina (Tosi, italy) , Folsan (Kali-chemie- Germany), Lexpec (R.p. Drugs, united 
kingdom) , Vivofolacid (Novopham, Canada), Flilicine (India), Folmed (Syria ) , 
Cityfol (Citypharm –Sudan) . 
1-1-3-6 Combination preparations: Fefol – Ferrous sulfate USP and Folic acid     
(SKF, Philippines), Ferro – Folsan – Ferous sulfate succinic acid, Folic acid 
(Philippines), Iberrt –folic -500 iron, vitamin C, Ferfol, ferrous sulfate. Folic acid 
(Sigma-tau-Sudan). 
1-1-4 Physical properties: 
1-1-4-1 Appearance, color, odor:  
A yellowish to orange, crystalline powder, almost odorless, tasteless microcrystalline 
powder containing 5 to 8.5% of H2O. 
1-1-4-2 Solubility: 
Very slightly soluble in cold water (0.0016 mg/ml at 25°C) soluble to above 1% in 
boiling water, slightly soluble in methanol, appreciably less soluble in ethanol and 
butanol, Insoluble in acetone, chloroform, ether, and benzene, relatively soluble in 
acetic acid, phenol, pyridine, solutions of alkali hydroxides and carbonates (Merck, 
1983). It is soluble in hot diluted HCl and H2SO4 soluble in HCl and H2SO4 yielding 
very pale yellow solutions (USP, 1975). 
A solution in 0.1M NaOH is dextrorotatory (Martindale, 1982). Folic acid injection is a 
sterile solution of folic acid in water with the aid of sodium hydroxide or sodium 
carbonate to the injection result in formation of sodium folate which is the soluble 
sodium salt of folic acid (Drug Information, 1988). Commercially available folic acid 
injection is clear, yellow to orange in color.  
1-1-4-3 Stability:  
A solution of folic acid 1 mg/m1 , in a vehicle of  purified water preserved with 
hydroxyl benzoates and adjusted pH 8- 8.5 with NaOH, had little loss of potency when 
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stored at 25°C for 8 weeks (Martindale, 1982). Folic acid is labile to acid, 70-100% of 
the activity being destroyed on autoclaving at pH 1 (Daniel, 1947). It becomes 
progressively more stable as the pH increases, and is relatively stable to heat within the 
pH range 4 to 12. At pH 6.8, for instance, solutions can be sterilized by heating for 
thirty minutes without loss of potency. Folic acid is partially inactivated by lead and 
mercury salts and by treatment with sulfate. Aeration at pH 1 also causes partial 
inactivation. In pure solutions, it is rapidly inactivated by light with the formation of p-
aminobenzyoylglutamic acid and 2 – amino – 4 – hydroxyl – 6 – fomyl pteridine 
(Lowry, 1949). The later is converted first into the corresponding acid and then into 2 –
amino 4 – hydroxypteriine.  
1-1-4-4 Storage conditions:  
Preserve in well closed, light resistant containers for injection – preserve in single dose 
or multiple dose containers, preferably of glass type (USP, 1990). Store between 15 to 
30°C. Protect from freezing.  
1-1-4-5 pH:  
A suspension of 1g of folic acid in 10ml H2O has a pH of 4.0 – 4.8 Aqueous solutions 
prepared with sodium bicarbonate have a pH between 6.5 and 6.8 (Marck, 1983).  
1-1-4-6 Dissociation constant:- 
pKa 4.7, 6.8, 9.0 (30°C) (B.P.,1998). 
1-1-4-7 Determination of Folic Acid:  
Folic acid is reductively cleaved by zinc amalgam in acid solution to p- aminobenzoyl 
glutamic acid. Zinc amalgam is used for this reduction as stronger reducing agents such 
as Zn and hydrochloric acid, or TiCl3 may carry the reduction too far. See fig (1-3). 
 
 
 
 
 
 
 
 
 
 
 
 
   Fig (1-3): Reduction of p-aminobenzoylglumatic acid with zinc amalga 
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The primary aromatic amino group so produced is then diazotized in the normal 
manner, with precaution against the action of light, and coupled in acid solution with N- 
(1– naphthy) ethylenediamine hydrochloride. The colour has maximum absorption at 
550 nm and the extinction is compared with a calibration curve obtained from p–
aminobenzoylglutamic acid. 
To ensure that the measurements obtained refer solely to folic acid ,and that they do not 
include a contribution from a free primary aromatic amino group present in a 
decomposition product, a blank determination is carried out on unreduced solution and 
an appropriate correction is applied. The colour then corresponds to a definite quantity 
of p-amino benzoic acid which in turn corresponds, to a definite quantity of 
C19H19O6N7; the relationship being 1g p-amino benzoic acid is equivalent to 3.22g of 
C19H19O6N7  
1-1-5 Spectroscopic Characteristics:  
1-1-5-1 Ultraviolet spectrum (UV):-  
Ultraviolet spectrum of folic acid in 0.1N NaOH was scanned from 200 to 400 nm 
using LKB 4054 LKB UV/VIS spectrophotometer (Saleem, 1990). 
Fig (1-4) it exhibited the following UV data (Table).  
 
     ◙ Table (1-1): UV Characteristics of folic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               Fig (1-4): UV Spectrum of Folic Acid in 0.1 N NaOH 
 
   Table (1-1) 
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1-1-5-2 Infrared spectrum (IR):  
The IR spectrum of folic acid as KBr –disc was recorded on a Perkin Elmer 580 B 
infrared spectrophotometer to which an infrared data station is attached; Figure (1-5). 
The spectral band assignments are listed in table (1-2) (Clarke, 1975). 
 
            ◙ Table (1-2): values of infrared absorption.  
Frequency cm-1 Type of vibration Assignment 
3520 – 3200 NH –CONH Group  
3000 – 2500 CH –CH2 group  
1689 C=O –COOH group 
1600 C=O –CONH group  
1474 CH –CH2 group 
1330 CH –CH2 group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (1-5): IR Spectrum of Folic Acid as KBr disc 
 
 
1-1-5-3 Fluorescence spectrum: 
According to (Beckett and Stenlake, 1970) Fluorescence properties of folic acid at pH 7 
show excitation and fluorescence 365nm, and 450 nm respectively. 
1-1-5-4 Nuclear magnetic resonance spectrum: 
(a) PMR spectra: The PMR spectra of folic acid was recorded on a Varian T 60A, 
60MHZ NMR spectrometer using TMS as an internal reference. The spectra are shown 
in fig (1-6) and fig (1-7).  
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                                       Fig (1-6): PMR Spectrum of Folic Acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                
                                 Fig (1-7): PMR Spectrum of Folic Acid (D2O exchange) 
 
(b) 13C NMR spectra:  
The 13C NMR spectra of folic acid in DMSO –d6 was recorded on a Joel FX–100 NMR 
spectrometer and is presented in fig (1-8)  
 
 
 
 
 
 
 
 
 
 
 
                           Fig (1-8):  13 C-NMR Spectrum of Folic Acid in DMSO-d6 
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1-1-5-5 Mass spectrum and fragmentation:  
The measurements of secondary ion mass spectra of folic acid were performed by a 
modified leybold-Haraeus SIMS apparatus with a Blazer, quadrupled mass filter QMG 
1023. The dried samples were introduced into the vacuum chamber via a rod, passing 
through a lock system. For secondary ion emission the sample was bombarded by a 
scanned 3-KeVAr+ 10n beam with a current density of 10-2 A/0.1 cm2. For thermal 
investigations the Ag foils covered with the organic substances were introduced in to 
the mass spectrometer and directly heated by an electric current. The temperature was 
determined by a Ni – Cr – Ni element at the lower side of the 0.2mm Ag- foil. Before 
organic substances were deposited, the Ag foils were heated for 30 min at 400°C under 
atmospheric conditions. Some characteristic fragment 10ns, resulting from predictable 
bond cleavages is mentioned on the spectra, Fig (1-9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (1-9): Secondary ion mass spectrum of folic acid 
 
1-1-6 Methods of Analysis of folic acid: 
1-1-6-1 Elemental analysis: 
The elemental analysis of folic acid is as reported (Jacobsen, 1978). 
Element Composition Element Composition 
C 51.70 N 22.22 
H 4.34 O 21.75 
 
1-1-6-2 Identification:  
Folic acid was identified by dissolving 10.0mg in 0.1M sodium hydroxide and diluted 
to 100.0ml with the same solvent. 5.0ml of this solution was diluted to 50.0ml with 
0.1M sodium hydroxide. Then examined between 230nm and 380nm, the solution 
   9 
  
shows three absorption maxima, at 256 nm, 383 nm and 365nm. The specific 
absorbances at these maxima are about 590,575 and 206, respectively, calculated with 
reference to the anhydrous substance. The ratio of the specific absorbance at the 
maximum at 256nm to that at the maximum at 365nm is 2.8 to 3.0 (BP 88 and 98). 
1-1-6-3 Colorimetric Method:  
Folic acid, about (10 µg/ml) is determined colorimetrically after oxidation with KMnO4, 
diazotization with NaNO2, and coupling and color development at pH 1.8 to 2.0. The 
colour is compared at 550nm with that of a folic acid standard and a blank (3% K2HPO4 
solution) as used for diluting sample and standard, treated similarly. (Stoicescu, 1965). 
(Hutchings et at, 1947) was described, a chemical method of estimating folic acid, 
based on the observation that pterylglutamic acid and related compounds were cleaved 
by reduction with Zinc and acid giving a pteridine and an aromatic amine. The latter 
was estimated colorimetrically by reaction with N–naphthylendiamine.  
1-1-6-4 Spectrophotometer Method:  
Method is based on the reduction of folic acid with Zn dust and HCl, the mixture is 
filtered, and the filterate is treated with (i) ethanolic dimethyl amino cinnamaldehyde, 
(ii) NaOH, phenol and NaClO; the absorbance of the product is measured at 520,450 
and 610nm respectively (Viswanadhamc and Sastry, 1984).  
In this method the UV spectrum of folic acid solution in 0.1N NaOH exhibits 
characteristic extinction band, at 220, 256, 283 and 366mu. The extinction at 256 and 
283mu are analytically the most useful as their ration, which is nearly constant (1-2) for 
solution of the pure acid indicated the quantity of the sample (Marciszewsk1, 1964).  
1-1-6-5 Polargraphic method: 
Rozansk1. et al., (1978) was describes the method in which the finely powdered 
sample, containing > 1mg of folic acid was shaken for 30 minutes with 0.1M HCl 
(25m1) aqueous, 3% calcium lactate aqueous, 8% Na3PO4 (1:1) buffer (225m1) was 
added, and the mixture was heated at 50°C for one or (for slow release tablets) two 
hours and filtered. A 20ml portion of the filterate was adjusted to pH 6.8 to 7.5 with 
aqueous 10% ascorbic acid and after purging the solution with N2, a polarogram was 
recorded from -0.4V (VS. the S.C.E); 5ml of a standard folic acid solution was then 
added and a second folic acid was calculated from a given equation. The sensitivity of 
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the method was about 0.1 µg/ml for a diffusion current of 1nA, and accurate and 
reproducible results were obtained for 1.39 to 1.74 mg of folic acid. 
Folic acid in pharmaceutical preparations can also be determined polarographically, (by 
dissolving one tablet-containing 30- 60µg of folic acid, and usually Fe salts) in 10ml of 
0.15 – diethylene – triamine – NN – penta acetic acid (dissolve 60g of the acid in 
NaOH, adjust the pH to 8 and dilute to 1:1) and dilute to 5oml with 0.1M-acetate buffer 
of pH 5.5. De – aerate 20ml portion with N2, record on a.c. Polargram. (Use of a phase 
– sensitive a.c. polarograph improves the sensitivity substantially), measure the peak 
height, and determine the folic acid content by use of a calibration graph (rectilinear 
over the range 20 nm to 20 µm if a phase – sensitive a.c polarograph is used) or by the 
standard, addition method (Jacobsen and Bjoernsen, 1978). 
1-1-6-6 Fluorimetric Method: 
The flour metric determination of folic acid has been examined. On oxidation with 
KMnO4 it is converted in to 2–amino – 4– hydroxypteridine – 6 – carboxylic acid 
which fluorescence strongly at 470nm. When irradiated with light of wave-length 
365nm, the intensity of the fluorescence is proportional to the concentration. When 
interfering pigments are present, the oxidation product is isolated chromatographically 
(Allfrey and Teply, 1949). 
1-1-6-7 Thin Layer Chromatography (TLC):- 
The TLC system was used to separate folic by using several solvents with different 
plates. They are summarized in the table (1-3). 
◙ Table (1-3): Summary of conditions used for the TLC of folic acid: 
Reference Plate Developing Solvent Detection 
J.A. Blair & E. Dransfield 
(1969)  
Cellulose powder Butanol: acetic acid water (4 : 1 : 5) 254nm 
K.C. Guven & O.Pekin 
(1966) 
Silica gel G Propanol:10% ag.NH3 glycerol (4 : 1 
: 1) For 2 hour  
Green-yellow 
spot 
H.R.S. lyer & B.K Apte 
(1969) 
Silica gel G 
0.25mm 
Butanol: acetic acid ethanol: water 
(250 : 1 : 100 : 125)  
550nm 
Seiji Ishikawa & Goichiro 
Katsui (1964) 
Kiesel gel G Acetic acid : butanol : H2O (1 : 4 : 5) UV 
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1-1-6-8 High Performance Liquid Chromatography (HPLC): 
Different methods may be used for the determination of the content of folic acid by 
HPLC; for raw material folic acid, the method of analysis by HPLC. The 
chromatographic conditions include an ODS, 5µm, 150 × 4.6mm ID stationary phase, a 
mobile phase of (1: 3, V/V) mixture of methanol/0.1M phosphate buffer, pH 6.0, with a 
flow rate of 1ml/minute. The injection volume is of 20 micro liters, containing 0.5 ppm 
of both sample and standard concentration, with a detection wave length at 263nm UV. 
The retention time of folic acid will be 3.10 minutes (Wang and Hou, 1988). 
Tofallo and Dukes, (1981) was described the method of determination of folic acid in 
multivitamin - finished product by using HPLC, with a stationary phase of 30cm × 
4mm, C18, Bondapak. The mobile phase consists of Tetrabutylammonium hydroxide 
[7.5ml of aq. 40% solution] – KH2PO4 (2.04g) – H3PO4 (4ml. of 3N) – methanol 
(240ml) – H2O, with a pH of 7.0, with flow rate of 1.5ml/minute. The detection 
wavelength is 280nm.  
The official method for assay of folic acid as raw material or finished product by using 
HPLC in: (B.P98-B.P2004 and USP 2000). The chromatographic method may be 
carried out using (a) a stainless steel column (25cm × 4.6mm) packed with stationary 
phase C (5µm) (spherisorb ODS 1 is suitable), (b) as the mobile phase with a flow rate 
of 1ml/minute a mixture of 135 volumes of methanol and 800 volumes of a solution 
containing 0.938% w/v of sodium per chlorate adjusted to pH 7.2 with 0.1 potassium 
hydroxide and diluted to 1000 volumes with H2O. The drug is detected at 277nm 
(wavelength).             
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1-2 General Chemistry and Pharmacology of Iron:  
1-2-1 Introduction:  
Iron is an essential mineral in human nutrition. It is involved in the entire process of 
respiration, including oxygen transport and electron transport. The principal goal of 
respiration is the production of biologic energy. The function and synthesis of 
hemoglobin, which carries most of the oxygen in the blood, is dependent on iron. Basic 
to the electron transport reactions that produce energy in the mitochondria of cells is the 
combining of oxygen with hydrogen to form water. The reaction occurs by means of a 
flow of electrons, derived from the oxidation of foodstuffs, across electron-carrier 
proteins called cytochromes, and via the final combination of these electrons with 
oxygen to produce water (Fairbanks, 1999). 
Although iron is clearly essential for a wide range of vital biological processes, it is also 
a potentially toxic substance. The shift back and forth between its two oxidation states-
ferrous (II) and ferric (III)-via single electron-transfer reactions is the property that 
makes iron such an essential component of the cytochromes in the electron transport 
chain. However, this redox property also contributes to its potential toxicity. Redox 
cycling between ferrous (II) and ferric (III) can generate the highly reactive oxygen 
species hydroxyl radicals, which can damage lipids, DNA and proteins (Andrews, 1999 
and Smith, 1997).The symptoms of the iron overload disorder, hereditary 
haemochromatosis (HHC), are due to iron toxicity (Baer, 1996).  
Iron deficiency generally develops slowly, and may not be clinically apparent until iron 
stores are exhausted and the supply of iron to the tissues is compromised, resulting in 
iron-deficiency anemia. Groups that are vulnerable to iron deficiency include: infants 
over 6 months, toddlers, adolescents and pregnant women (due to high requirements); 
older people and people consuming foods high in iron absorption inhibitors (due poor 
absorption); menstruating women or individuals with pathological blood loss (due to 
high blood losses).     
Iron-deficiency, which can lead to microcytic, hypochromic anemia, is the most 
common nutritional disorder in the world. Approximately 25% of the world's 
population is iron-deficiency states which do not lead to anemia may have global 
effects on human health. On the other hand, iron overload disorders, which can lead to 
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cirrhosis, coronary heart disease and congestive heart failure, among other things, are 
also public health concern (WHO scientific group, 1968).  
Dietary sources rich in iron include liver, meat, beans, nuts, dried fruits, whole grains or 
enriched cereals, soybean flour and most dark green vegetables. Iron in foods occurs in 
two main forms: haem and non-haem. The major sources of haem iron in the diet are 
hemoglobin and myoglobin from meat, poultry and fish. Non-haem iron consists mainly 
of iron salts, derived from plant and dairy products. Most of the non-haem iron present 
as foods in the ferric form (Coma, 1991). 
The use of iron preparation in the treatment of certain anemias is well established. 
Ferrous salts are generally preferred for this purpose since it is widely accepted that 
ferrous iron is more readily absorbed from the gastro intestinal tract of man than is 
ferric iron (WHO scientific group, 1968).  
However, the treatment of anemia with inorganic salts of iron often results in 
gastrointestinal distress (not easily absorbed and destroys vitamin E as well); also the 
accidental ingestion of large doses of iron has caused a number of fatal and near - fatal 
cases of poisoning (Forbes, 1947 and Clark, 1954).                                     
The most common oral iron salts are ferrous sulfate, ferrous fumarate and ferrous 
gluconate, or ferrous succinate. Calculation of dosage for iron preparations it is always 
based on the amount of elemental iron to be administrated (Table 1-4). 
  ◙ Table (1-4). The amount of Iron salt and corresponding content of ferrous ion 
Iron salt Amount Content of ferrous 
iron 
(%) of elemental ion 
Ferrous fumarate  200 65.8 mg 32.9 
Ferrous gluconate  300 35 mg 11.66 
Ferrous succinate  100 35 mg 35 
Ferrous sulfate  300 60 mg 20 
Ferrous sulfate, dried  200 65 mg 35.5 
 
1-2-2 Trade names: 
Feostat (forest pharmaceuticals), Iron (Kenwood Therapeutic), Ferretts (pharmics), 
Hemocyte (U.S. pharmaceutical corp.), Nephro-Fer (R & D labs), (Bayer consumer), 
Feronate (Prime Marketing), Fe-40 (Bio-tech pharmacal), Ferro-caps (Nature's Bounty), 
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Ferro- Time (Time-Cap Labs), Vitedyn- Slo (Edyn Corp), Feosol (Smith Kline 
Beecham Consumer), Yieronia (R.I.D Inc), Fer-In-Sol (Mead Johnson), Ed-In-Sol 
(Edwards pharmaceutical), siderol (A.G. Marin pharmaceutical), Mol-Iron (Schering 
Plough Heathcare), Feratab (Upsher- Smith Labs), Ferrousal (Prime Marketing), Slow 
Fe (Novartis Consumer).      
 
1-2-3 Physico – chemical properties of ferrous fumarate:  
1-2-3-1 Chemical structure  
  (a) Structural formula:  
 
 
  
  (b) Molecular formula:  
  C4H2 FeO4  
  (c) Molecular weight:  
 169.90 
Preparation - Ferrous sulfate and sodium fumarate are metathesis in hot aqueous 
solution whereupon the sparingly soluble, anhydrous ferrous fumarate precipitates.     
  
 (d) Chemical name: 
  2-Butenedioic acid, (E) -, iron (2+) salt. 
1-2-3-2 Physical properties:-  
1-2-3-2-1 Description:  
Reddish orange to red-brown, odorless powder; may contain soft lumps that produce a 
yellow streak when crushed. 
1-2-3-2-2 Solubility:  
At 25°C, Ferrous Fumarate is soluble in water to the extent of 0.14 g per 100ml. And in 
alcohol to the extent of less than 0.01 g of 100ml, its solubility in acid is limited by the 
separation of free fumaric acid. Up to the point of this separation, approximately 0.45 g 
of C4H2 FeO4 can be dissolved in 100ml. of 1.0N HCl (Martindale, 1982) 
1-2-3-2-3 Compatibility:-  
Ferrous fumarate is ideally suited for use in formulation containing vitamins and can be 
incorporated in the commonly employed iron and vitamin dry preparation. In 
compatibility studies with the B vitamins, ferrous fumarate was found to compare 
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favorably with ferrous sulfate and ferrous gluconate. In the case of vitamin B12, it 
appeared to be definitely superior to the other two iron salts (Berk and Novich, 1962).  
1-2-3-2-4 The effect of pH change:  
Table (1-5) was illustrated the variations in iron solubility when pH was changed from 
2 to 6. Ferrous fumarate compared with other iron salt. It was found that at pH2 ferrous 
sulfate, Ferrochel and Na Fe EDTA were completely soluble and only 75% of iron from 
ferrous fumarate was soluble. When pH was raised to 6, iron from amino acid chelate 
and NaFeEDTA remained completely soluble while solubility from ferrous sulfate and 
ferrous fumarate decreased 64 and 74%, respectively compared to the amount of iron 
initially soluble at pH2.  
These results suggest that iron solubility from iron bis-glycine chelate Na Fe EDTA is 
not affected by pH changes within the ranges tested, probably because iron remained 
associated to the respective compounds (Garcia, 2001). 
◙Table (1-5). Iron solubility from ferrous sulfate, ferrous fumarate, NaFeEDTA and Ferrochel at pH 2 and 6       
pH Ferrous sulfate Ferrous fumarate Ferrochel Na Fe EDTA 
 mg % mg % mg % mg % 
2 6.22±0.2 100.0 3.83±0.1 100.0 5.71±0.3 100.0 5.41±0.1 100.0 
6 2.24±0.2 36.0 0.99±0.2 25.8 5.33±0.2 93.3 5.12±0.1 94.8 
 
1-2-3-2-5 Stability: 
Ferrous fumarate is substantially free of ferric iron and remains so upon handling 
without being specially protected from contact with air. It remains relatively free – 
flowing and shows little tendency to oxidize or hydrate even during several weeks 
exposure to a hot, humid atmosphere. Thus, ferrous fumarate exhibits improved 
stability as compared with ferrous sulfate or ferrous gluconate.  
Uncoated, compressed tablets containing approximately 200mg ferrous fumarate per 
tablet were stored for a ten - month period. At the end of this time, no significant loss in 
ferrous iron was found (Martindale, 1982). 
1-2-3-2-6 Storage conditions:-  
Store in an air tight container, protected from light, store at room temperature (between 
15 and 30°C) away from moisture and sun light. 
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1-2-3-3 Preparations and dosages: 
1-2-3-3-1 Uses: In the clinical management of iron-deficiency anemias, its efficacy is 
about the same as that of ferrous sulfate, but the untoward effects are somewhat less 
severe. The drug may sometimes be employed without difficulty in patients who cannot 
tolerate other preparations of iron. When side effects occur, they include anorexia, 
nausea, vomiting, cramping, and constipation or diarrhea. Like other iron preparations, 
ferrous fumarate may exacerbate gastrointestinal diseases, especially ulcerative ones. 
The effects generally subside as therapy is continued. The untoward effects are 
minimized if the dose is taken shortly after eating. 
1-2-3-3-2 Dose:  
Oral, adults, 200mg, once a day for prophylaxis and 3 times a day for treatment, except 
300mg/day for prophylaxis and 3 times a day for treatment with extended – release 
tablets; children, usually as the oral suspension, 3mg/kg once a day for prophylaxis and 
3 times a day for treatment. For treatment, doses may be gradually doubled, if 
necessary. 
1-2-3-3-3 Dosage Forms:  
Oral Suspension: 100mg (33mg Fe+2)/100ml, 45mg (15mg Fe+2)/0.6ml; Tablets: 
195,200,300,324,325 mg (64, 66, 99,106,107 mg Fe+2, respectively); chewable tablets: 
100mg (33mg Fe+2); Extended-Release Tablets: 324mg (106mg Fe+2).        
1-2-3-3-4 Official preparations:- 
(BP, 2004): Ferrous fumarate and folic acid tablets; ferrous fumarate oral suspension: 
Ferrous fumarate tablets. (USP 27): Ferrous fumarate and Docusate sodium Extended – 
release, ferrous fumarate tablets.  
 
1-2-4 Method of analysis of ferrous salts [Iron (II)]: 
1-2-4-1 Coulometric titration Method: 
In this method the oxidation of the Ce (III) - Ce (IV) coupled in sulphuric acid was 
+1.43 volt and was relatively closed to the potential at which water was oxidized at a 
platinum anode  
                                               (2H2O           O2 + 4H+ + 4e).                                (1) 
 
 
The Ce (IV) was generated in solution containing a high concentration of Ce (III), and  
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Consequently the generator anode was operated at a potential well below the standard 
potential. 40ml of the Ce (III) solution and 10ml of am sulphuric acid were placed in 
the titration cell, and 1.5M sulphuric acid in the isolated cathode compartment (The 
level must be above that of the ultimate level in the main cell). Nitrogen was passed for 
10minutes to remove dissolved air and maintained the stream of gas during the titration. 
5ml of ferrous salt solution was pipetted into the coulometric cell, and the level of the 
liquid was adjusted in the cathode compartment by adding 1.5M sulphuric acid with a 
dropper pipette. Then the solution was titrated coulometrically at about 50milliamp and 
followed the potential continuously with a digital voltmeter or a pH - meter (Bishop and 
Hitchcock, 1973). 
1-2-4-2 Titration Analysis Method: 
Ferrous salts iron (II) was determined by titrimetric analysis, after oxidation with (a) 
potassium permanganate (0.1N), which is a very powerful oxidizing agent, and is able 
quantitatively to oxidize Fe (II) to Fe (III) in acidic solution. 
                          MnO4- + 5Fe2+ + 8H+           Mn2+ + 5Fe3+ + 4H2O.               (2) 
 
The tested solution should be approximately 0.1M with respect to iron (II), and should 
contain about 10% (by volume) of diluted sulphuric acid to reduce the tendency for 
atmospheric oxidation of the iron solution. 
25ml of this solution was pipetted into a 250ml conical flask, 25ml of sulphuric acid 
(0.5M) was added, and titrated with the standard (0.1N) potassium permanganate 
solution until a faint permanent pink coloration was produced. 
(b) Potassium dichromate solution (0.1N), is used only in acid solution, and is reduced 
rapidly at the ordinary temperature to a green chromium (III) salt. 
 
                        Cr2O72- + 6Fe2+ + 14H+              2Cr3+ + 6Fe3+ + 7H2O              (3) 
 
The tested solution should be approximately 0.1M with respect to iron (II), and should 
contain diluted sulphuric acid to reduce the tendency for atmospheric oxidation. 25ml 
portion of this solution was titrated with the standard (0.1N) potassium dichromate 
solution, using either sodium diphenylamine sulphonate (I) or N–phenylanthranilic acid 
(II) as internal indicator. First, 0.4ml of the indicator (I) was used, 200ml of 2.5% 
sulphuric acid and 5ml of 85% phosphoric acid were added to solution, and titrated 
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slowly, with the standard dichromate until the solution assumes a bluish – green or 
grayish – blue tint near the end point. 
The dichromate solution was added drop wise, until the addition of 1 drop caused the 
formation of an intense purple or violet - blue. Coloration, it was unaffected on further 
addition of the dichromate solution. Second, 0.5ml of the indicator (II) was used, 200ml 
of M-sulphuric was added and then the system was titrated with 0.1N potassium 
dichromate until the color changed from green to violet – red (Wagner and Hull, 1971). 
1-2-4-3 Colorimetric and Spectrophotometer Method: 
1.10 – phenanthroline (C12H8N2, Ortho-phenanthroline or O-phen) is a tricyclic 
nitrogen heterocyclic compound that react, with metals such as iron, nickel, and silver 
to from strongly colored complexes. This property provides an excellent and sensitive 
method for determining these metal irons in aqueous solution. O-phen was reacted with 
ferrous iron the produce a deeply colored red complex, as shown below. 
  
                                                                                                                                      (4) 
 
            
 
 
 
 
 
 
  
 
 
 
 
 
 
The molar absorptivity (έ) of the ferrous complex, [(C12H8N2)3Fe] 2+, is 
11.100L/mol-cm at the wave length of maximum absorbance intensity, max = 510nm. 
This large value indicates the complex absorbs very strongly. The intensity of the color 
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is independent of pH in the range 2 to 9. The complex is very stable and the color 
intensity does not change appreciably in along period time. 
To determine the total iron in the sample, it must be completely in the ferrous state, and 
Fe2+ can readily be air-oxidized to the ferric state, Fe3+.O-phen will form a colored 
complex with Fe3+, but its spectrum is different from that of the ferrous complex and 
the color is not as intense. Thus, one could not determine the total iron present by 
making measurements at only one wavelength. Hence, a mild reducing agent is added 
before the color is developed in order to provide a measure of the total (Fe2+) present 
in solution. Hydroxylamine, as its hydrochloride salt, can be used. The reaction is:  
        2Fe3+ + 2NH2OH.HCl + 2OH-               2Fe2+ + N2 + 4H2O + H+ + Cl-       (5)         
The pH was adjusted to value between 6 and 9 by addition of an ammonia acetate 
buffer. The formed solution was allowed to stand for at least 10min before absorbance 
measurement (Vogel's, 1983). 
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1-3 Sustained Release Dosage forms: 
1-3-1 Overviews: 
With many drugs, the basic goal of therapy is to achieve a steady - state blood or tissue 
level that is therapeutically effective and nontoxic for an extended period of time. A 
basic objective in dosage form design is to: 
(1) Provide the minimum dose of drug to give a therapeutic effect at one or more 
specified sites when needed. 
(2) Optimize drug therapy by delivering drug to a site of action at a rate sufficient to 
satisfy the needs of the body for a specified period of time. This is usually 
accomplished by maximizing drug absorption; however, control of drug action through 
formulation also implies controlling bioavailability to reduce drug absorption rates 
(Ballard, 1978). 
Physicians can achieve several desirable therapeutic advantages by prescribing 
sustained release forms. Since the frequency of drug administration is reduced, patient 
compliance can be improved, and drug administration can be made more convenient as 
well. The blood level oscillation characteristic of multiple dosing of conventional 
dosage forms is reduced, because a more even blood level is maintained. A less obvious 
advantage, implicit in the design of sustained release forms, is that the total amount of 
drug administrated can be reduced, thus maximizing availability with a minimum dose. 
In addition, better control of drug absorption can be attained, since the high blood level 
peaks that may be observed after administration of a dose of a high availability drug can 
be reduce by formulation in extended action form (Urquhart, 1981).   
The safety margin of high – potency drugs can be increased, and the incidence of both 
local and systemic adverse side effects can be reduced insensitive patient. Overall, 
administration of sustained release forms enables increased reliability of therapy. Most 
drugs have a therapeutic window which is the drug plasma concentration range where a 
therapeutic effect is seen without unwanted toxic effects. So if a drug has a wide 
therapeutic index then the difference between the minimum effective (MEC) and toxic 
drug plasma concentration is large. Figure (1-10) Shows comparative blood level 
profiles obtained from administration of conventional, controlled, and sustained - 
release dosage form (Jantzen and Robinson, 1978).  
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The conventional tablet or capsule provides only a single and transient burst of drug. A 
pharmacological effect is seen as long as the amount of drug is within the therapeutic 
range. Problems occur when the peak concentration is above or below this range, 
especially for drugs with narrow therapeutic windows. The slow first - order release 
obtained by a sustained - release preparation is generally achieved by slowing the 
release of drug from a dosage form (Eriksen, 1970). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1-10): drug level versus time profile showing differences between zero order control 
release, slow first order sustained release, and release from conventional tablets or capsule. 
 
Sustained release, sustained action, prolonged action, controlled release extended 
action, timed release, depot, and repository dosage forms are terms used to identify 
drug delivery systems that are designed to achieve prolonged therapeutic effect by 
continuously releasing medication over an extended period of time after administration 
of a single dose. In the case of orally administrated forms, this period is measured in 
hours and critically depends on the residence time of dosage form in the gastrointestinal 
(GI) tract. The term “controlled release” has become associated with those systems 
from which therapeutic agents may be automatically delivered at predefined rates over 
long period of time. 
1-3-1-1 Advantages in using sustained or controlled Release Drug 
Delivery: 
1- Since the frequency of drug administration is reduced, patient compliance can be 
improved, in addition, drug administration can be made more convenient as well, 
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because the sustained or extended release products of drugs with short in-vivo half-life's 
can provide therapeutic plasma drug concentration without the necessity of frequent 
administration. 
2- The most usually stated advantage is that the “peak and valley” plasma 
concentrations seen following the repeated administration of conventional dosage units 
are not seen. Theoretically, the plasma drug concentration can be held at a steady level 
over a “long time period”. 
3- If the “peak and valley” functions are not seen then theoretically the patient should 
not be exposed to toxic or non-therapeutic plasma drug concentration, because a more 
even blood level is maintained. 
4- Overall, administration of sustained release forms enables increased reliability of 
therapy. 
A less obvious advantage, implicit in the design of sustained release forms, is that the 
total amount of drug administered can be reduced thus maximizing availability with a 
minimum dose. 
In addition, better control of drug absorption can be attained, since high blood level 
peaks that may be observed after administration of dose of a high availability drug can 
be reduced by formulation in an extended action form. 
The safety margin of high-potency drugs can b increased, and the incidence of both 
local and system in adverse side effects can be reduced in sensitive patients (Lee and 
Robinson, 1978). 
1-3-1-2 Disadvantages in using sustained or controlled Release Drug 
Delivery: 
1- Administration of sustained release medication does not permit the prompt 
termination of therapy. Immediate changes in drug need during therapy, such as might 
be encountered if significant adverse effects are noted, cannot be accommodated. 
2- The physician has less flexibility in adjusting dosage regimens. This is fixed by the 
dosage form design. 
3- Sustained release forms are deigned for the normal population, i.e. on the basis of 
average drug biologic half-lives. Consequently, disease states that alter drug 
disposition, significant patient variation, and so forth are not accommodated. 
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4- Economic factors must also be assessed, since more costly processes and equipment 
are involved in manufacturing many sustained release forms. 
5- The biological half-life of different drugs is a varying variable. If a drug has a long 
half-life then there is the chance of it accumulating in body tissue and this phenomenon 
could lead to toxic effects (Lee and Robinson, 1978). 
1-3-1-3 Biological Factors influencing oral sustained – Release Dosage 
form Design:  
1-3-1-3-1 Biological half - life: 
The usual good of an oral – release product is to maintain therapeutic blood levels over 
an extended period. To this, drug must enter the circulation at approximately the same 
rate at which it’s eliminated. The elimination rate is quantitatively described by the 
half-life (t ½). Each drug has its own characteristic elimination. This is the sum of all 
elimination process, including metabolism, urinary excretion, and all other processes 
that permanently remove drug from the blood stream. Therapeutic compounds with 
short half-life are candidates for sustained-release preparation, since this can reduce 
dosing frequency. However, this is limited in that drugs with very short half-lives may 
require excessively large amount of drug in each dosage unit to maintain sustained 
effects, forcing the dosage from itself to become limiting large. In general, drugs with 
half-lives short than 2 hr, are poor candidates for sustained-release preparation. 
Compounds with long half-lives, more than 8 hr, are also generally not used in 
sustaining forms, since their effect is already sustained. Furthermore, the transit time of 
most dosage forms in the gastrointestinal (GI) tract (i.e., mouth to ileocecal junction) is 
8-12 hr, making it difficult to increase the absorptive phase of administration beyond 
this time frame. Occasionally, absorption from the colon may allow continued drug 
delivery for up to 24 hr (Lee and Robinson, 1978).     
1-3-1-3-2 Absorption: 
The characteristic of absorption of a drug greatly affects it’s suitability as a sustained 
release product and is to place control on the delivery system, its necessary that the rate 
of release is much slower than the rate of absorption. If a drug it absorbed by active 
transport, or transport is limited to a specific region of the intestine, sustained-release 
preparation may have disadvantages to absorption. Absorption of ferrous salts, for 
example, is maximal in the upper jejunum and duodenum, and sustained-release 
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mechanism that do not release drug before passing out of this region are not beneficial 
one method to provide sustaining mechanisms of delivery for compounds such as these 
has been to try to maintain them within the stomach (Midleton and Morrison, 1966).  
This allows slow release of the drug. This then travels to the absorptive site. These 
methods have been developed as a consequence of the observation that co-
administration of food results in sustaining effect (Welling and Barbhaiya, 1982) 
 Although administration of food can create highly variable effects, there have been 
methods devised to circumvent this problem. One much attempt is to formulate low-
density pellets, capsules, these float on top of the gastric juice, delaying their transfer 
out of the stomach (Thanoo, 1991). Another approach is that of bioadhesive materials. 
The principle is to administer a device with adhesive polymers having an affinity for 
the gastric surface, most probably the mucin coat (Leung and Robinson, 1988) 
1-3-1-3-3 Metabolism:  
A drug that is significantly metabolized before absorption, either in the lumen or tissue 
of the intestine, can show decreased bioavailability from slower-releasing dosage 
forms. Most intestinal wall enzyme systems are saturated, as the drug is released at a 
slower rate to these regions, less total drug is presented to the enzymatic process during 
a specific period, allowing more complete conversion of the drug to its metabolite. For 
example, aloprenolol was more extensively metabolized in the intestinal wall when 
given as sustained - release preparation (Johansson and Sjogren, 1971).  
1-3-1-4 Factors influencing sustained-Release formulation: 
1-3-1-4-1 Physicochemical factors influencing oral sustained-Release 
Dosage-Form design:  
(a) Dose size:  
For orally administrated systems, there is an upper limit of the bulk size of the dose to 
be administrated. In general, a single dose of 0.5 – 1.09 g is considered maximal for a 
conventional dosage from, this also holds for sustained-release dosage forms (Lachman 
and Kanig, 1970).  
(b) Ionization, pka, and aqueous solubility: 
Most drugs are weak acids or bases. Since the unchanging form of a drug preferentially 
permeates across lipid membranes, it’s important to note the relationship between the 
pka of the compound and the absorptive environment. Delivering systems that are 
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dependent on diffusion or dissolution will likewise be dependent on the solubility of 
drug in the aqueous media. Considering that these dosage forms must function in an 
environment of changing pH, the stomach being acidic and the small intestine more 
neutral, the effect of pH on the release process must be defined. For many compounds, 
the site of maximum absorption will also be the area in which the drug is the least 
soluble. Compounds with very low solubility (less than 0.01 mg /m1) are inherently 
sustained, since their release over the time course of a dosage form in the GI- tract will 
be limited by dissolution of the drug. Examples of drugs that are limited in absorption 
by their dissolution rate are digoxin (Manninen and Reisell, 1972), and salicylamide 
(Bates and Jones, 1969). The solubility of the compound will limit the choice of 
mechanism to be employed in a sustained delivery system. Diffusion system will be a 
poor choice for slightly soluble drugs. Since the driving force for diffusion, which is the 
drug's concentration in solution, will be low (Fincher, 1968).    
(c) Partition Coefficient:-  
When a drug is administered to the GI tract, it must cross a variety of biological 
membranes to produce a therapeutic effect in another area of the body. It’s common to 
consider that these membranes are lipidic; therefore, the partition coefficient of oil-
soluble drugs becomes important in determining the effectiveness in membrane barrier 
penetration. Accordingly, compounds with a relatively high partition coefficient are 
predominantly lipid-soluble and, consequently, have low aqueous solubility. 
Furthermore, these compounds can usually persist in the body for long periods, because 
they can be localized in the lipid membranes of cells (Salzman and Brodie, 1978). 
(d) Stability:  
Orally administrated drugs can be subject to both acid-base hydrolysis and enzymatic 
degradation. Degradation will proceed at a reduced rate for drugs in the solid state; 
therefore, this is the preferred composition of delivery for problem case, for drugs that 
are unstable in the stomach, system that prolong delivery over the entire course of 
transit in the GI-tract are beneficial, likewise, for system that delay release until the 
dosage form reaches the small intestine may demonstrate decreased bioavailability 
when administrated from a sustaining dosage form. This is because more drugs is 
delivered in the small intestine and, hence, is subject to degradation. Examples of such 
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drugs are propantheline (Beerman - Helestorm and Rosen, 1972), and probanthine 
(Bachrach, 1958). 
1-3-1-4-2 Formulation factors influencing oral sustained-Release Dosage-
Form design:  
(a) Dissolution-Controlled Systems:  
Rate of solution (dissolution rate) and amount dissolved (solubility) are not the same 
and are not necessarily related, although in practice high drug solubility is usually 
linked to a high dissolution rate.   
In the dissolution of a solid, two stages occur. Firstly molecule of the solid must 
undergo a phase change to become a molecule of solute on the solvent in which the 
crystal is dissolving. The solution indirect contact with the solid will be saturated (in 
contact with undissolved solid). Thus, its concentration will be Cs (mg / ml). After this, 
the solute molecule must migrate through the boundary layers surrounding the crystal to 
the bulk of the solution at which its concentration will be C (mg / ml). As shown in fig 
(1-11). Drugs with slow dissolution rate will demonstrate sustaining properties, since 
the release of drug will be limited by the rate of dissolution. Sustained release 
preparations of drugs could be made by decreasing their dissolution. Dissolution-
controlled systems can be made to be sustaining in several different ways, by 
alternating layers of drug with rate, controlling cools. As shown in fig (1-12), a pulsed 
delivering can be achieved. If the outer layer is a quickly releasing bolus of drug, initial 
levels of drug in the body can be quickly established with pulsed intervals following. 
  
 
 
 
 
 
 
 
 
 
 
Figure (1-11): Representation of a matrix release system. Cs is the saturation concentration of drug 
controlling the concentration gradient over the distance h  
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Figure (1-12): representation of a reservoir diffusion device. Cm(0) and Cm(d) represent concentrations of 
drug at inside surfaces of the membrane and C(0) and C(d) represent concentrations in the adjacent 
regions.  
 
An alternative method is administering the drug as a group of beads that have coating of 
different thicknesses, their release will occur in progressive manner. Those with the 
thinnest layer will provide the initial dose. The maintenance of drug levels at later times 
will be achieved from those with thicker coatings. This dissolution process can be 
considered to be diffusion- layer controlled. This dissolution process at steady state is 
described by the Noyes-Whitney equation.  
dc  = Kd A (Cs – C) =   D   A (Cs – C)                (6) 
dt                                     h 
Where; dc / dt = dissolution rate, Kd = dissolution rate constant  
            D = diffusion coefficient, Cs = saturation solubility of the solid. 
            C= Concentration of solute in the bulk solution.  
Dissolution rate constant Kd is an equivalent of the diffusion coefficient divided by the 
thickness of the diffusion layer (D/h). The equation (1) predicts that the rate of release 
can be constant only if the following parameters are constant: (a) surface area, (b) 
diffusion coefficient, (c) diffusion layer thickness, and (d) concentration difference. 
When solute is removed from the dissolution medium at a faster rate than it enters into 
solution, then Cs – C approximates to Cs. In pharmaceutical terms, if the amount of 
drug dissolved in the dissolution medium does not exceed 10% of the saturation 
solubility of the solute, the drug is said to be dissolving under ''sink conditions'' then the 
equation may be simplified to:  
   dc = KACs                         (7) 
                               dt   
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Thus a plot of concentration of drug in bulk solution as a function of time should give a 
straight line and the gradient is equal to the second order rate constant.  
If a drug is allowed to accumulate in the dissolution medium to such an extent that the 
above approximation is no longer valid, i.e. when C > Cs/10, then “non-sink” 
conditions are said to be in operation. When C=Cs it is obvious from equation (2) that 
the overall dissolution rate will be zero because the dissolution medium is saturated 
with drug. If such a rate profile could be achieved, it would be ideal for an extended 
release product. Unfortunately, drug release is not often second order because of the 
difficulty in maintaining constant surface area of drug and / or a constant supply of 
undissolved drug.If a drug has a low aqueous solubility, then the chances are that, it 
will be good candidate for sustained or extended release, in that dissolution rate is likely 
to be slower than the rate of absorption through, i.e., the gastro-intestinal membrane. 
(b) Diffusion of drugs: 
The solute will spontaneously diffuse from a region of high concentration to one of low 
chemical potential, which is from a region of higher concentration to one of lower 
concentration, whilst the solvent molecules move in the reverse direction. The 
expression which relates the flow of material to the concentration gradient ⎟⎠
⎞⎜⎝
⎛
dx
dc  is 
referred to as Fick’s first law equation under conditions of steady state   
                                      ⎟⎠
⎞⎜⎝
⎛=
dx
dcDJ                                (8) 
 J = is the flux of a component across a plane of unit area ( 12−−lmmo )  
 D= is the diffusion coefficient (diffusivity). ( 12 −sm ) 
 (-) = negative sign indicates that the flux in the direction of decreasing 
concentration. 
 X = is the moving distance of a definite fraction of the molecules (m). 
 C= is the concentration of the solute ( 3−immo  ) 
 For this law to apply where are some assumptions: 
(a) The diffusion coefficient is invariant. 
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(b) Diffusion is unidirectional. 
(c) The diffusion properties of the medium are the same in all 
directions, i.e. isotropic. 
Fick’s first law has the variables J, C and X, (see earlier) but the J term is a 
multiple variable in that it contains 
dt
da  Where  a = amount. 
   t = time. 
Fick’s second law relates the accumulation of the diffusing substance in a 
specific volume to the net transfer rate of the diffusing substance through that volume: 
                   2dx
deD
t
c −=           (9) 
The diffusional properties of a drug have relevance in pharmaceutical systems in a 
consideration of such processes as the dissolution of the drug and its membrane 
transport, as shown in fig (1-13) 
 
 
 
 
 
 
 
 
     Fig (1-13): Schematic representation of a matrix release system 
(c) Hydrophilic Matrix Systems:  
These delivery systems are also called (swellable - soluble matrices). In general, they 
comprise a compressed mixture of drug and water - swellable hydrophilic polymer. The 
systems are capable of swelling, followed by gel formation, erosion and dissolution in 
aqueous media. Their behavior is in contrast to a true hydrogel, which swells on 
hydration but does not dissolve (Alderman, 1984).  
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(d) Principle of design of hydrophilic matrices:  
The system comprises a matrix of drug, hydrophilic polymer, any release modifiers and 
lubricant and glidant. On contact with water, the hydrophilic polymer components swell 
to form a hydrated matrix layer. This then controls further diffusion of water in to the 
matrix (Aulton, 1996).Diffusion of the drug through the hydrated matrix layer controls 
its rate of release. The outer hydrated matrix layer will erode as it becomes more dilute; 
the rate of erosion depends on the nature of the polymer. In hydrophilic matrices, 
swelling and erosion of the polymer occur simultaneously, and both of them contribute 
to the overall drug – release rate (Sujja, 1998). 
1-3-1-4-3 Types of hydrophilic matrix:  
(1) True gel matrix:  
These systems interact in the presence of water to form a cross-linked polymeric 
structure with a continuous phase trapped in the interstices of the gel network. The 
cross links can be chemical bonds or physical bonds, e.g. triple - helix formations in 
gelatin gels which are based on hydrogen bonds. The portions of the polymer chains 
between cross links can move, but the cross links restrict the overall movement of the 
chains (Figure (1-14)). 
(2) Viscous matrix:   
In the presence of water these systems from a matrix in which the increased viscosity 
occurs as a result of simple entanglement of adjacent polymer chains, but without 
proper cross linking. It is a dynamic structure. The chains are able to move relative to 
one another and the drug diffuses through the interstitial continuum, but the pathway is 
not fixed (Figure (1-15)). Examples are hydroxypropyl methyl cellulose and sodium 
alginate in water. 
 
 
 
 
 
 
                                    Fig (1-14): Presentation of 'true' gel matrix 
  
• The diffusion pathway is via the continuous 
phase in the interstices of the gel. 
• The cross links are more or less 'fixed' after the 
gel has formed. 
• The bulk viscosity of the gel is derived from 
the structure of the cross linked polymeric 
chains with a contribution from the continuous 
phase. 
• Bulk viscosity generally does not correlate 
well with diffusion. 
• Diffusion in the gel correlates with 'micro 
viscosity. 
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                      Fig (1-15): Presentation of ‘viscolized’ matrix 
  
1-3-1-4-4 Advantages of hydrophilic matrix delivery systems: 
Melia, (1991), was described some advantages, in the use of hydrophilic matrix system.  
• Simplicity of formulation. 
• Greater than 80% drug loading is possible in many cases. 
• Inexpensive. 
• Many polysaccharides available so that patents can be avoided and polysaccharide 
and drug can be matched.  
• Existing machinery and processes are used to produce the dosage form often as 
tablets. 
• HM systems are eroded as they pass through the g.i.tract. 
• Diffusion release occurs thus release does not depend on gastric motility. 
• Wide variety of routes of administration can be used. 
• Versatility: can formulate with or without initial burst of drug release. Can have 
systems that mimic multiparticulate systems or can have floating tablets. 
1-3-1-4-5 Disadvantages of hydrophilic matrix delivery systems: 
        (Aulton, 1996). 
• Release of the drug is dependent on two diffusion processes, penetration of the water 
through the hydrated matrix into the non-hydrated core, and diffusion of the 
dissolved drug through the hydrated matrix. 
• If the outer layer of the hydrated matrix erodes, this can complicate the release 
profile. 
• The diffusion pathway is via the continuous 
phase trapped between the adjacent polymeric 
chains. 
• There are no 'fixed' cross-links. 
• The bulk viscosity is related to the 
entanglement of adjacent polymer chains 
which are free to move within the continuous 
phase. 
• Bulk viscosity may correlate with diffusion. 
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• Requires batch-to-batch consistency in the matrix-forming materials, other 
components and process parameters. 
• Scale-up of manufacture can be a problem. 
• Need optimal rate-controlling polymers for different actives.   
1-3-1-4-6 Components of hydrophilic matrix delivery systems: 
     (Aulton, 1996). 
• Active drug. 
• Hydrophilic polymers. 
• (Matrix modifier). 
• Solubilizer and/or pH modifier). 
• Compression aid. 
• Lubricant. 
• (Glidant). 
 
1-3-1-4-7 Hydrophilic polymers: 
Hydrophilic polymers which, on contact with water, form a hydrated gel that remains 
sufficiently intact during passage through the gastrointestinal tract are suitable matrix-
forming agents for hydrophilic matrices. Examples of hydrophilic colloids include: 
• Hydroxypropyl methylcellulose (high-viscosity grades). 
• Sodium carboxymethyl cellulose. 
• Alginates. 
• Xanthan gum. 
• Xanthan gum/locust bean gum combinations. 
• Carbopol. 
These agents generally occupy 20-80% of the mass the actual amount will depend on 
the drug and the desired release characteristics. 
Hydration and swelling are the key factors in the functioning of a hydrophilic matrix, as 
has already been stated. 
1-3-1-4-8 Matrix modifier: 
These are materials that are incorporated into the matrix to modify the diffusion 
characteristics of the gel layer, very often to enhance drug diffusion and hence release 
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of the drug. Examples include sugars, polyols and soluble salts. The type of modifier 
will depend very much on the chemical nature of the hydrocolloid(s) used. They may 
also modify the rate and extent of hydration of the hydrophilic matrix material. Gel 
modifiers can have a number of other functions. For example, they may act: 
• To allow more complete, more uniform hydration of the gel matrix; 
• To allow more rapid hydration of the gel matrix; 
• To associate with the matrix molecules and thus to influence the interactions at a 
molecular level, e.g. cross linking; 
• To modify the environment in the interstices of the gel, either to speed up or slow 
down diffusion; 
• To suppress or promote the ionization of ionizable polymers. 
1-3-1-4-9 Solubilizers and pH modifiers for drugs in hydrophilic matrices: 
Many drugs will not dissolve sufficiently in gastrointestinal fluids to allow them to be 
released from a hydrophilic colloid matrix. Dissolution can be improved by the 
inclusion of solubilizing agents (e.g. PEGs, polyol, surfactants, etc.). The only 
restriction is that the formulation can be formed into a tablet and that the material is 
acceptable. Many drugs are ionizable. The inclusion of appropriate counter-ions can 
facilitate release from the system. Some materials can act as both dissolution enhancer 
and matrix modifier: the amount of excipient needed will be determined by the amount 
of drug. 
1-3-1-4-10 Lubricants for hydrophilic delivery systems: 
As with any tablet compacted on a tablet machine, a lubricant is necessary. Lubricants 
can have four functions; 
• Reduce interparticulate friction during compression and compaction. 
• Reduce die-wall friction; 
• Prevent sticking to the punches; 
• Improve flow of the formulation on to the machine and into the die. 
1-3-1-4-11 Drug release from hydrophilic matrices: 
The classic descriptions of the events following immersion of a matrix in aqueous 
media are as follows: 
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• Surface drug (if water soluble) dissolves and gives a 'burst effect'. 
• The hydrophilic polymer hydrates and an outer gel layer forms. 
• The gel layer becomes a barrier to uptake of further water and to the transfer of drug. 
• Drug (if soluble) release occurs by diffusion through the gel layer; insoluble drug is 
released by erosion followed by dissolution. 
• Following erosion the new surface becomes hydrated and forms a new gel layer. 
It may be anticipated that the relative importance of each release mechanism will 
depend on the physicochemical properties of the gel layer; the aqueous solubility of the 
drug; and the mechanical attrition of the matrix in the aqueous environment. 
When a drug/glassy polymer matrix is placed in an aqueous environment, the water 
penetrates the polymer network. As the amount of water, is increased by the presence of 
water and the temperature of the medium, the intake of solvent (water) induces stresses 
within the matrix polymer. Eventually the matrix polymer relaxes, and this manifests 
itself as swelling. It is possible to differentiate three 'fronts' during hydration: eroding, 
diffusing and swelling, (See fig (1-16)) (Conte et al, 1993).  
 
 
 
 
 
 
 
 
 
 
 
                      Fig (1-16): Moving front in a Hydro gel matrix 
 
Melia, (1991), was listed factors that may contribute to hydration behavior and drug 
release process in hydrophilic matrix devices: 
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1-3-1-4-12 The gel layer: 
• Water transport. 
• Polymer wetting. 
• Polymer hydration. 
• Polymer swelling and chain relaxation. 
• Enthalpic changes associated with above. 
• Effect of dissolved drugs and excipients on the above through changes in: 
• Water activity, ionic strength, pH modulation, ionic hydrogen bonding, or other 
interactions. 
• localized areas of the gel network with different diffusion characteristics or internal 
stress profiles , e.g. arising as a result of:  
• No homogeneity of water availability and solute distribution. 
• Restriction of available space for particle swelling. 
• Pore collapse as solute dissolve. 
• Presence of Insoluble excipients. 
• Entrapped air bubbles (e.g. from pores in tablet core) 
• Mechanical erosion at surface. 
• Surface disintegration. 
1-3-1-4-13 incorporated drugs and excipients: 
• Wetting. 
• Dissolution. 
• Interaction between different species. 
• Interaction with the polymer network. 
• Diffusibility through gel network. 
• Enthalplic changes associated with above. 
1-3-1-4-14 Matrix diffusion system: 
In general the matrix device system consists of a drug dispersed homogenously through 
a polymer matrix as represented in fig (1-17). Drug in the outside layer of the matrix 
exposed to the bathing solution is dissolved first and then diffuses out of the matrix. 
   36 
  
This process continues with the interface between the bathing solution and the solid 
drug moving toward the interior. 
Obviously, for this system to be diffusion – controlled, the rate of dissolution of drug 
particles within the matrix must be much faster than diffusion rate of dissolved drug 
leaving the matrix (Flynn - Yalkowsky and Roseman, 1974). 
 
 
 
 
 
 
 
 
 
Fig (1-17): Matrix diffusion system before drug release (time= 0) and after partial drug 
release (time = t) 
1-3-1-4-15 Swellable matrices:  
Swellable matrices have found favor as pharma ceutical formulation is in that the dose 
form looses its integrity as it passes through the body. Swellable matrices for oral 
delivery are generally hydrogels; they are water - swollen networks (i.e. cross - linked 
structures) of hydrophilic polymers. Matrix system or swelling controlled can provide 
zero order drug release under specific conditions. As initially solvent free glassy 
polymers containing drugs, the presence of a thermodynamically compatible dissolution 
medium or penetrant induces swelling, the glass transition temperature of the polymer 
is lowered in the swollen region and a moving rubbery / glass boundary is produced 
allowing the ‘dispersed’ drug to diffuse out words. Theoretically, zero order kinetics 
would result when the velocity of the movement of the swelling interface is much 
smaller than the diffusion coefficient of the drug. In effect, drug release is controlled by 
the swelling process and not the drug diffusion through the swollen gel (Korsmeyer’s 
and Peppas, 1983). 
An equation used to characterize the drug release from a swelling system is:  
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Mt 
 M∞ 
Mt 
 M∞ 
 
                      =   Ks ta               (10) 
Where:  
 Mt = is the a mount of drug released at time t, 
 M∞ = is the mount of drug released at infinite time. 
   Ks & a are constants, characteristics of the polymer /drug/ solvent system.  
The equation is only valid when  
    
      ≤ 0.6                                                                (11) 
◙ Table (1-6). The numerical value of (a) indicates the mechanism of drug release.  
Value of a Drug release mechanism 
Time dependence of 
release 
0.5 fickian t-1/2 
0.5<a<1.0 Non fickian (anomalous transport) ta-1 
1.0 Case II transport Independent, i.e. zero order 
a > 1.0 Super case II transport ta-1 
 
1-3-1-4-16 Release mechanism from matrices:   
Release from Hydro gel matrices: is a combination of two processes: 
         (a) Swelling of the polymer, 
         (b) Dissolution of the polymer, 
The result will be erosion of the system combined with drug diffusion and dissolution. 
In effect, rate and direction of the front, kinetics and mathematical model to describe 
this system involves the following assumptions:  A pseudo – steady state is maintained 
during drug release. The diameter of the drug particles is less than the average distance 
of drug diffusion through the matrix. The bathing solution provides sink conditions at 
all times, the diffusion coefficient of drug in the matrix remains constant (i.e. no change 
occurs in the characteristics of the polymer matrix). According to the rate of release of 
the drugs dispersed in an inert matrix system, have been derived by Higuchi, (1961):-  
 
Cs 
2    38 
  
Dm Cs 
h 
P 
T 
          = CoDh -              (12) 
 
Where;  
Dm = change in the amount of drug released per unit area. 
Dh = change in the thickness of the zone of matrix that has depleted. 
Co = total amount of drug in a unit volume of the matrix. 
Cs = saturated concentration of the drug within the matrix. 
 
From diffusion theory,  
  
    Dm =                       dt                 (13)  
     
Where; Dm = the diffusion coefficient in the matrix. 
Equating Eqs (6) & (7), integrating, and solving for h gives  
 
    M    = [Cs Dm (2Co – Cs]1/2                        (14) 
 
When the amount of drug is in excess of the saturation concentration that is, Co >> Cs 
    M    = (2CsDm Cot)1/2 = KH   t                  (15) 
 
Which indicates that the amount of drug released is a function of the square root of 
time. In a similar manner, the drug release from a porous or granular matrix can be 
described by  
 
    M   = [ DsCa       (2Co – pCa)t ]1/2                       (16)      
 
Where;  
P = porosity of the matrix. 
T = tortuosity. 
Ca = solubility of the drug in the release medium. 
Ds = diffusion coefficient in the release medium. 
Dm 
 
Dh 
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Equ. (9) Or (10) can be reduced to:  
 
  M   = KHt1/2                              (17) 
 
Where, KH is a constant, so that a plot of amount of drug released versus the square root 
of time will be linear, if the release of drug from the matrix is diffusion – controlled. By 
the Higuchi model, (1966) the release of drug from a homogeneous matrix system, can 
be controlled by varying the following parameters: 
• Initial concentration of drug in the matrix, 
• Porosity, 
• Torotuosity, 
• Polymer system forming the matrix, and  
• Solubility of the drug. 
 
1-3-2 Guidelines for Dissolution in Vitro Release Testing: 
It is not possible to simulate in a single in vitro test system the range of variables that 
affects drug release during the passage of sustained release medication through the G1- 
tract. Properly designed in vitro tests for drug release serve two important functions. 
First, data from such tests are required as a guide to formulation during the 
development stage, prior to clinical testing. Second, in-vitro testing is necessary to 
ensure batch to batch uniformity in the production of a proven dosage form. Different 
methods are usually required by these two distinctly different testing situations. 
Although attempts to correlate in vitro release profiles with clinical performance are 
useful once sufficient clinical testing has been completed, in vitro / in vivo correlation 
must not be assumed as in-vitro studies are not sufficient to establish the efficacy of a 
new preparation. 
Dissolution in USP: (< 700 > Dissolution). Selection of the dissolution testing apparatus 
(USP Apparatus I or II) during drug development should be based on a comparison of 
in vitro dissolution an in vivo pharmacokinetic data available for the product. The USP 
apparatus I (basket method) is generally preferred for capsules and products that tend to 
float, and USP apparatus II (Paddle method) is generally preferred for tablets. 
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In many instances in which USP test procedures are followed, upper and lower limits 
are specified for drug release in simulated gastric and / or intestinal fluid measurements 
are made at specific time intervals appropriate to the specific product. At present, there 
are no specific USP specifications for sustained release   dosage form. Procedures are 
determined by nature of the dosage form.  
The recommendations for dissolution media should be consistent with those in the FDA 
Guidance for industry: Waiver of in vivo Bioavailability and Bioequivalence studies for 
immediate-Release solid oral Dosage forms Based on a Biopharmaceutics classification 
system (page 11, section IIID in vitro studies). That document recommends the 
following media: (I) 0.1N HCl or simulated Gastric fluid USP without enzymes; (II) a 
pH 4.5 buffer; and (III) a pH 6.8 buffer or simulated intestinal USP without enzymes 
(FDA Guiding, 1997).  
1-3-3 Developing Dissolution Tests for Modified Release Dosage Forms: 
1-3-3-1General Consideration: 
The FDA, but also realizes the need for initializing the method and a case by case basis 
leaving the justification of a given methodology up to the scientist. 
Therefore, the individual scientist is challenged to design an appropriate test based on 
the objectives to be accomplished, e.g. quality control, in-vitro – in vivo correlations, 
showing bioequivalence, etc. below are physical chemical parameter and physiological 
conditions to consider when designing a dissolution test for modified release delivery 
systems (Guidance-Oral Extended, 1996) and (Guidance-For Industry, 1997).  
1-3-3-2 Physiological Conditions that Effect Drug Release: 
Intestinal transit, gastric Emptying and variable pH, the effect of gastric emptying on 
drug release delivery system generally occurs when the dosage form is non-
disintegrating and can result in variability in the Cmax and Tmax of the plasma profile. 
This is due to the variability of retention times in the stomach usually between the fed 
and fasted states but can occur within each condition as well. For example, if the patient 
is in the fasted state, gastric emptying generally occurs within two hours. However, in 
the fed state, a non-disintegrating delivery system will remain in the stomach, either 
floating on top of the stomach contents or sinking to the bottom depending on the 
density. When this occurs, gastric emptying rather than the dosage form control drug 
release. In addition, if the dosage form has a delayed release component, the drug may 
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not be sufficiently protected residence times at pH 1.2 > 2 hours, low pH may also alter 
the performance by causing chemical reaction of the materials used in the dosage for 
modifying the release of drug. Therefore, while the final dissolution test may only 
require a 1-2 hour presoak at gastric pH, the dosage form should be thoroughly 
evaluated at gastric pH if there is potential for long gastric residence times (Crison and 
Siersma, 1996). 
Recently, gastric emptying and duodenal transit of a magnetically marked capsule, 16.1 
mm long and 5.7 mm in diameter, were measured using biomagnetic measuring 
equipment called magnetic marker monitoring in the fasted state. Gastric emptying of 
the capsule ranged from 14 minutes, 5 seconds to 140 minutes. For these transit times, a 
dissolution test that includes 2 hours in simulated gastric fluid, pH 1.2, should be 
sufficient; however, duodenal transit times ranged from 7 seconds to 245 seconds with 
the proximal duodenum ranging from 3 to 17 seconds and the distal duodenum ranging 
from 4 to 235 seconds. If the goal of the dosage form is to release the drug in the 
duodenum, e.g. target transport through tight junctions, then the dissolution should 
reflect the possibility of a short residence time. This is especially true if the mechanism 
for targeting the release is enteric coating, since 7 seconds may not be enough time for 
the enteric coating to dissolve and the drug to release. Further hampering of drug 
release can occur if the enteric coating erodes at pH 6.5, since the pH at the proximal 
duodenum is closer to 5.5 than 6. Therefore, an appropriate dissolution test for sensitive 
release mechanism such as enteric-coated dosage forms may require several pHs 
simultaneously taking into consideration the potential in vivo residence time at each 
pH. (Weitschies-Kotiz, 1997 and Weischies - Cordin, 1998). 
Coated particles / beads currently used in both, extended release and delayed release 
and delivery systems can (a) disperse throughout the GI tract; (b) have multiple types of 
coatings that achieve a variety of release profiles, and (c) in most cases show dose 
proportionality. Gastric emptying of coated particles differs from the large non-
disintegrating dosage forms in that they will empty from the stomach at a constant rate, 
provided the diameter and density are of the appropriate size. For example, Teflon 
beads that have a diameter of 1.6 mm and a density of 1 gm / cm3 empty from the 
stomach, in the fed state at a rate of approximately 30%/hours. Depending on the design 
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of the delivery system, dissolution tests for bead formulations may consist of 2-3 hours 
in simulated gastric fluid at pH 1.2, followed by 15-3 minutes in simulated intestinal 
fluid at pH 5.5, and they simulated intestinal fluid at pH 6.8 or pH 8.0 (Amidom and 
Lennernas, 1995). 
The extent of food effect on the performance of a dosage form is very difficult to 
establish; and in many cases, just as difficult to mimic with a dissolution test, food can 
affect gastric emptying, but may also alter the release of the drug from dosage form, the 
solubilization of the drug, and the transport of the drug across the intestinal wall. For 
lipophilic, water-insoluble drugs, fatty meals can do one, or both of two things: 
First, a fatty meal can increase gastric residence time therefore increasing the time 
available for solubilization. Second, fatty meals may enhance the solubilization of the 
drug by the lipids contained in the meal, or by increasing the amount of bile salt 
released into the intestine, or both. Dissolution media for water insoluble drugs 
generally contain a surfactant to aid in the dissolution; previous dissolution tests 
consisted of hydroalcoholic mixtures, however this combination was abandoned for the 
more physiologically relevant surfactants (Crison – Weiner and Amidon, 1997). 
Formulas of dissolution media with mixed micelles designed to mimic the fed state are 
available, but can be very costly due the bile salts and lecithin, these formulas generally 
consist of mixtures of sodium taurocholate and egg lecithin. One study in particular 
showed that a 4:1 ratio of bile salt to lecithin could be used as a dissolution medium for 
water insoluble drugs. The same authors compared the effect of bile salt concentrated 
and lecithin / bile mixtures on the dissolution of several poorly soluble drug salts and 
developed a correlation between the logs of the octanol: water partition coefficient and 
the solubility of several poorly soluble steroids in 15mM sodium taurocholate. Also 
important from this work was the finding that no significant increase in solubility was 
observed at “fasted”, concentration of the bile salt (Mithani and Bakatselou, 1996). 
The use of oil/water emulsions as dissolution media to mimic a fatty meal has also been 
considered; however, these systems can be difficult to work with. Agitation and 
elevated temperatures, i.e. 37°C, can affect stability of the emulsion thus limiting the 
length of time available for dissolution. In addition, extraction of the drug from the oil 
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phase may require several steps, thereby lengthening the analytical time and cost of 
operation (Crison and Leesman, 1991).  
1-3-4 Literature Review:  
Jabber and Naser, (2004), compared the release rate of the conventional lithium 
carbonate tablets with sustained release matrix tablets containing 450 mg lithium 
carbonate which were developed by using different types and ratios of hydrophilic 
polymers including carbopol (CP), Na carbomethyl cellulose (Na-CMC) and Hydroxyl 
Propyl Methyl Cellulose (HPMC). The matrix tablets were prepared by either direct 
compression or wet granulation. In vitro and in vivo, newly formulated sustained – 
release LC tablets were compared with sustained – release commercial tablet (Eskalth 
CR ®). Result the matrix tablets containing 15% CP exhibited suitable release kinetics 
and uniform absorption characteristics comparable to that of Eskalith CR. In vivo, this 
formulation produced a smooth and extended absorption phase very much similar to 
that of Eskalith CR with identical elimination half - life and extends of absorption. 
Hosseninali, (2003), studied preparation of sustained - release matrix tablets of Aspirin 
with ethylcellose (EC), Eudragit RS 100 and Eudragit 5100 and studying the release 
profile and their sensitivity to tablets hardness. In this study, matrix aspirin (acetyl 
salicylic acid) tablets were prepared by direct compression. The release behavior was 
studied in two counterpart series of tablets with hardness difference of three kp units, 
and compared by non-linear regression analysis. The release pattern for both the 
Eudragit S100 containing RS100- containing formulations fitted best in Higuchi model, 
and proper equations were suggested. In the EC – containing formulation, Higuchi and 
also zero-order models were probable models for the release. In the Eudragit S100 
containing formulation, the release profile was completely sensitive to the hardness 
change. In Eudragit RS100 containing, the slope of the release graph did not change 
due to the hardness decrease, but the y- intercept 0 the lag time in release was 
decreased. In EC-containing matrix tablets, both the slopes & the y- intercept did not 
change by the decrease in hardness. EC with an amount as little as 10% in formulation 
could make sustained- release aspirin tablets in which the release profile is not sensitive 
to moderate changes in hardness. 
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Patel and Bariya, (2002), investigated the impact of formulation factors on the 
properties of a 12h modified- release formulation of Verapamil - HCl. In this study, a 23 
full factorial design was employed to investigate the influence of amount of  Eudragit 
RSPO/ Eudragit RLPO (x, a matrix agent), HPMC K4M (X2, an auxiliary agent cum 
binder) and PEG 4000 (X3, channeling agent cum plasticizer ). The tablets were 
prepared by direct compression and they were evaluated for in vitro dissolution studies 
in 0.1N HCl. The time require for 90% of the drug release (t 90) was calculated by using 
an appropriate kinetic model for each batch. The method of Bamba et al, was adopted 
to determine the kinetic of drug release from different batches. The dissolution data 
were fitted to zero – order, Higuchi, Hixson-Crowell, Korsomeyer- Peppas, and 
Weibull models. Swelling and fluid penetration studies were carried out in 0.1N HCl. 
The required release pattern was shown by batches containing a low level of Eudragit 
RSPO/RLPO (30%w/w), low level of HPMC K4M (10%w/w), and high level of PEG 
4000 (15%w/w). These formulations showed slower drug release in alkaline medium 
(pH7.2). 
Claudio, (2002), developed uncoated HPMC matrix tablets, evaluating the relationship 
and influence of different content levels of microcrystalline cellulose starch, and lactose 
in order to achieve a zero – order release of Diclofenac sodium. He found there was no 
significant difference in drug release between the hydrophilic matrices when the HPMC 
concentration was modified in low percentage. The USP paddle method was selected to 
perform the dissolution profiles carried out in 900 ml 0.1N HCl and phosphate buffer 
(pH: 6.8).The formulations were not affected when subjected to different stability 
conditions. The release profile remained unchanged after three months storage of 
tablets. The best –fit release kinetic was achieved with the zero –order plot, flowed by 
the Higuchi and first order equation. 
Kiettisak, (2000), formulated Pentoxifylline water soluble drug, with Hydroxyethyl 
cellulose (HEC) WP40, QP52000, MV90000, and Hydroxy propyl methyl cellulose 
(HPMC) E4M and F4M as the rate controlling polymers in sustained release matrix 
tablet formulations. Poly vinyl pyrrolidone (PVP) K15, K25 and K30 were added into 
the formulations as the release modifier. The tablets were prepared by wet granulation 
method and compressed into oblong – shaped tablets. The effect of water or ethanol 
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which used as granulating liquid and various types of the polymers on dissolution rate 
of the drug in simulated gastric fluid and simulated intestinal fluid were investigated. 
The effects of water and ethanol, used in wet granulating step, on the release profiles 
which were studied in simulated gastric fluid and simulated intestinal fluid, were not 
different. The results showed that the quantity of drug release followed a Higuchi 
square root time kinetic. HPMC E4M found to be a suitable polymer for sustaining the 
release of the drug. The release of the drug from the pentoxifylline sustained release 
tablet was increased by adding any types of PVP used in this study. However, PVP K30 
has affected on the releases profiles of drug similar to that of PVP K25. At the 
concentration 5 and 10% of PVP K25 were added into the formulations gave no 
different. 
Raghuram, (2003), studied the different tablets formulations of Nicorandil, prepared by 
wet granulation technique as once daily sustained release matrix tablets. Ethanol 
solutions of ethyl cellulose (EC), Eudragit RL-100, Eudragit RS100, and 
polyvinylpyrrolidone was used as granulating agents along with hydrophilic matrix 
materials like hydroxyl propyl methylcellulose (HPMC), sodium carboxymethyl 
cellulose, and sodium alignate. The produce granules from all formulations were 
evaluated for angle of repose, bulk density, compressibility index, total porosity, and 
drug content. The tablets were subjected to thickness, diameters, weight, variation test, 
drug content, hardness, friability, and in vitro release studies. All the tablet formulations 
showed acceptable pharmacotechnical properties and complied with in- house 
specifications for tested parameters. According to the theoretical release profile 
calculation, a once- daily sustained – release formulation should release 5.92mg of 
Nicorandil in 1 hour, like conventional tablets, and 3.21mg per hour up to 24 hours. The 
results of dissolution studies indicated that formulation no. (1) (drug: HPMC, 1:4; 
ethanol as granulation development agent), could extend the drug release up to 24 
hours. The further formulation development process, formulation no. (9) (drug : 
HPMC,1:4; EC 4% wt/vol. as granulating agent), the most successful formulation of the 
study, exhibited satisfactory drug release in the initial hours, and the total release               
pattern was very close to the theoretical release profile. All formulations except number 
(1), the last one exhibited diffusion – dominated drug release. The mechanism of drug 
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release from formulation no. (9), was diffusion coupled with erosion, in conclusion the 
hydrophilic matrix of HPMC alone could not control the Nicorandil release effectively 
for 24 hours. It is evident from the results that a matrix tablet prepared with HPMC and 
a granulating agent of a hydrophilic polymer (EC, 4% wt/vol.) is a better system for 
once –daily sustained release of a highly water-soluble drug like Nicorandil. 
Hecules, (1997), evaluated water soluble polymers as sustained release binder, in a 
Phenylpropanolamine tablet formulations. The objective of this study was to compare 
the sustained release (SR) properties of water-soluble polymers high viscosity like 
Hydroxypropylcellulose HPC, and Hydroxyethylcellulose (HEC). This study was 
conducted using the polymers at 30% use levels. The batches were manufactured using 
allow shear wet granulation technique. The results allowed direct compression of these 
polymers. The tablets produced were evaluated based on tablet physical properties and 
drug dissolution release. Dissolution testing was conducted on all tablets which were 
compressed at 15KN hardness, using USP apparatus type II at 100rpm. The dissolution 
medium was DI water (500ml), maintained at 37°C. The dissolution results are reported 
as time to release 80% (T80) and 90% (T90) of Phenylpropanolamine. HPC extended the 
T90 dissolution results to more than eight hours release which was the longest release of 
all the polymers studied. Guar demonstrated a T90 of ore than hours HEC gave some 
sustained release properties in this PPA model formulation, with a T80 value of 2 hours 
and a T90 value > 3hours. Although Carrageenan closely followed the HEC T80 test 
results.  The Carrageenan T90 results indicate that it did not provide as effective 
sustained release performance properties as HEC. In this PPA model formulation, the 
polymer ranking, based on release profile, is HPC > guar > HEC > Carrageenan > CMC 
> Pectin. All polymers produced acceptable tablets with respect to hardness and 
friability. The best tablet performance results were seen when hydroxyl propyl cellulose 
(HPC) was the sustained release matrix – forming polymer. This polymer gave the best 
tablet hardness and friability at the lowest compression forces. The performance of 
Carrageenan tablets rank closely with HPC tablets except its performance was not as 
good at lower compression forces (SKN). Guar gum was a polymer that also showed 
good performance once the compression forces were above SKN. Hydroxyethyl 
cellulose (HEC), Sodium carboxymethylcellulose (CMC), and pectin all had similar 
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compression characteristics. The over all ranking of these polymers in this PPA model 
formulation, based on tablet properties, is HPC > Carrageenan > Guar > HEC = Pectin 
> CMC. 
Sandip, (2003), formulated the Tramadol hydrochloride using hydrophilic and 
hydrophobic matrix system. The effect of concentration of hydrophilic (hydroxyl propyl 
methyl cellulose (HPMC) and hydrophobic polymers (Hydrogenated Castrol Oil 
(HCO), ethyl cellulose) on the release rate of Tramadol was studied. Hydrophilic matrix 
tablets were prepared by wet granulation technique, while hydrophobic (wax) matrix 
tablets were prepared by melt granulation technique and in vitro dissolution studies 
were performed using USP – pharmacopeia’s apparatus type II. Hydrophobic matrix 
tablets resulted in sustained in vitro drug release (> 20 hours) as compared with 
hydrophilic matrix tablets (< 14 hours). The presence of ethyl cellulose in either of the 
matrix systems prolonged the release rate the drug. Tablets prepared by combination of 
hydrophilic polymers failed to prolong the release beyond 12hours. Hydrophobic matrix 
tablets prepared using HCO were found to be best suited for modulating the delivery of 
the highly water – soluble drug, Tramadol hydrochloride. For hydrophilic matrix 
tablets, the tablets were prepared by wet granulation technique. Drug and other 
excipients were granulated with PVP-K-90 using IPA as granulating agent the dried 
Granules were lubricated and compressed into tablets; each tablet contained 200ml of 
Tramadol hydrochloride.  
Qiuy, (1997), developed a hydrophilic matrix system oral delivery of Zileution, and was 
studied the effects of certain formulation, processing, and dissolution variable on in 
vitro drug release. Tablet formulation with 60 – 70% drug and varying release rates 
were prepared by wet granulation using low and medium viscosity grades of hydroxyl 
propylethocellulose. In vitro drug release was evaluated using USP apparatus, the in 
vitro drug release from all formulations. Followed zero Order kinetics and was 
independent of compression force. In general, the release rate decreased with increasing 
drug load and higher polymer concentration or viscosity high. Shear graduation also 
resulted in lower release rate. Accelerated release was observed with increased as well 
as in the dissolution media with higher surfactant concentration and / or ionic strength. 
No stereo selective release from the matrix system was observed. The hydrophilic 
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matrix system effectively controlled the in vitro release of Zileution. Matrix Tablets 
with release rates can be prepared by adjusting various formulations and processing. 
The matrix system also has the advantage of simple processing and relatively low cost.  
Minarrom and Garcia, (2001), studied the formulation parameters in hydrophilic 
matrices and metoprolol tortrate by used 23 factorial design. They compared the 
dissolution profiles of two hydrophilic polymers (hydroxyl propyl methyl cellulose and 
hydroxyethylcellulose) at high and low concentrations and in the presence or absence of 
on insoluble excipient (calcium hydrogen phosphate dehydrate) the results that the 
presence of on insoluble excipient influenced almost all of the dissolution parameters.  
Siepmann and Peppas, (2000), improved a mathematical model to predict the resulting 
drug release kinetics (The sequential lager model) of the hydrophilic matrices. The aims 
of this study were (i) elucidate the transport mechanisms involved in drug release from 
hydrophilic matrices and (ii) To develop a mathematical model allowing quantitative of 
the resulting release kinetics.  
Methods: Our previously presented model has been substantially modified by adding: 
(i) in homogeneous swelling, (ii) poorly water soluble drugs: and (iii) high initial drug 
loadings. The validity of the improved model has been tested experimentally using 
hydroxypropyl methylcellose (MPMC). Matrices containing either a poorly water 
soluble (theophylline or chlorpheniramine maleate) at various initial loadings in 
phosphate buffer pH7.4 and 0.1NHCl, respectively. Results: its by overcoming the 
assumption of homogeneous swelling we show that the agreement between theory and 
experiment could be significantly improved among others .the model could describe 
quantitatively even complex effect on the resulting relative release rate ( first slowing 
down then accede rating drug release ) observed when increasing the initial loading and 
poorly water soluble drugs. Conclusion: the practical benefit of this work is improved 
design models that can be predict accurately the required composition and dimensions 
of drug loaded hydrophilic matrices in order to achieve desired release profiles, thus 
facilitating the development of new pharmaceutical products.  
Sunda, (1995), studied the influence of formulation change on drug release kinetics 
from hydroxylpropymethylcellulose matrix tablets examination was mode of the 
Indomethacin from hydroxylpropymethyl cellulose (HPMC) matrices and the results 
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were found to usually follow first order release kinetics the release mechanism changed 
with formulation. HPMC content was the predominant controlling factor. As the HPMC 
content increased drug release rate decreased and the release mechanism gradually 
changed from higuchi diffusion release to case 11 transport additives increased the 
release rate and enhanced fickian diffusion. As drug content increased release rate 
calculated from my release data increased. When Indomethacin content was lower, drug 
release was diffusion controlled and when high non fickian transport or case 11 
transports was apparent Additive effects were also examined. Starch was found to most 
effectively maintain case 11 releases. Complex additives containing starch were 
superior to any additive itself a multiple regression model was used to determine the 
relationship between response (release rate) and factors (content of HPMC and diluents) 
and on the basis of this mode a formulation was established and found valid by 
agreement with data from the regression mallet.  
Reza - Quadir and Haider , (2003), investigated the effect of plastic , hydrophilic and 
hydrophobic types of polymers and their content level on the release profile of drug 
from matrix systems as the physicochemical nature of the ingredients influence the drug 
retarding ability of these polymers three different drugs were used to evaluate their 
comparative release characteristics in similar matrices  METHODS :Matrix tablets of 
theophylline Diclofenac sodium and Diltiazem HCl using Kollidon SR , Carnuba wax 
and Hydroxypropyl methylcellulose (HPMC. 15cps ) were prepared separately by direct 
compression process the USP Basket method was selected to perform  the dissolution 
test carried out in 250ml 0.1N HCl for first two hours and 1000 ml phosphate buffer of 
pH 6.8 for ten hours .  
Results: statistically significant differences were found among the drug release profile 
from different classes of polymeric matrices the release kinetics was found to be 
governed by the type and content of polymer in the matrix system. Higher polymeric 
content (75%) in the matrix decreased the release rate of drug because of increased 
tortuosity and decreased porosity. At lower polymeric level (25%) the rate and extent of 
drug release was elevated carnauba wax was found to cause the strongest retardation of 
drug on the other hand highest drug release was from HPMC matrices while Kollidon 
SR gave an intermediate release profile between these two polymers. Release rate was 
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also found to be the function of physicochemical nature of drug molecule theophylline 
and Diltiazem HCl being soluble in nature released faster than Diclofenac sodium from 
all matrix systems the release mechanism was explored and explained with bi-
exponential equation. Release profile showed a tendency to follow zero order kinetics 
from HPMC matrix systems where Fickian (case 1) transport was predominant 
mechanism of drug release from kollidon SR matrix system. The mean dissolution time 
(MDT) was calculated for all the formulation and the highest MDT value was obtained 
with carnauba wax for all the drugs under investigation conclusions: the results 
generated in study showed that the profile and kinetics of drug release were functions 
and polymer type, polymer level, and physicochemical nature of drug. A controlled 
plasma level profile of drug can obtain by judicious combination of polymers and 
modulation of polymer content in the matrix system. At present all the polymers being 
studied are used extensively in pharmaceuticals to control the release up drug. the 
approach of the present study was to make a comparative  evaluation among these 
polymers and to assess the effect of physico-chemical nature of the active ingredient on 
drug release profile the study reveals that the release of water soluble drugs was higher 
than the drugs with lower solubility and the mechanism of release was changed with the 
nature and content of polymer in the matrix the type of  polymers used a conspicuous 
effect on release mechanism the data  generated in this study also shows that the drug 
release from plastic and hydrophobic matrix was less than hydrophilic polymer again 
the release pattern of drug from hydrophilic matrices was matrices . However , number 
of critical parameters such as granulation process tab letting conditions hardness and 
porosity of the tablet and compression pressure will markedly affect drug release 
pattern formulation design the wide range of  polymers available from controlling the 
release of drug from dosage form endows the formulator with higher degree of 
flexibility and the present study clearly manifests the necessity of combining different 
classes of polymers to get an acceptable pharmacokinetic profile in the fluctuating in 
vivo environment .  
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1-4 The Objectives of this study: 
Introduction: 
Most pharmaceutical companies in Sudan were established around the mid 1970s 
totaling up to a number of 15 factories. All these factories operate on the same range of 
products with certain limitations in technology due to the higher expenses. 
This study is an academic work attempting at covering the aspects of sustained release 
formulations tablets and the manufacturing tools used to produce them which might add 
knowledge to all those involved in the pharmaceutical field. 
The product selected is a ferrous fumarate plus folic acid film coated tablet as sustained 
release. Although both these elements are obtained from diet, their absorption is 
increased significantly in anemic patients, during pregnancy and after, whilst mothers 
are lactating. Therefore, it is necessary to increase their concentration as iron is required 
for hemoglobin whilst folic acid is essential for various metabolic processes including 
DNA synthesis. 
Aims and Objectives: 
1. Develop and optimize sustained release hydrophilic matrix tablets for two poorly 
water soluble drugs (ferrous fumarate 200mg plus folic acid 0.5mg) film coated 
tablets SR to aid metabolic processes in the body. 
2. Try to use a certain processing procedure that controls the release of iron over a 
period of several hours that in turn minimizes the problem of gastro-intestinal 
disturbances and at the same time doesn’t affect the release of folic acid. 
3. Determine the effect of the different dissolution media with its different pH an iron 
release profiles, when using different combinations of excipients and polymers to 
produce different matrices. 
4. Evaluate the relationships and influences of the different content levels of 
excipients in drug release kinetics and mechanism. 
5. Study the influence of the drug (ferrous fumarate) phyiso-chemical nature on the 
retarding ability of polymers. 
6. To investigate various factors such as, effect of different ratios of drug with 
polymer, excipients, different granules particle size. 
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7. To establish which matrix system gives the best controlled drug release, then after 
coating the matrix compare controlled drug release with that of conventional 
tablets and that of pellets of capsules available on the market.   
8. To compare the effects for when matrix tablets are coated with a hydrophobic 
polymer such as ethyl cellulose base. 
9. Evaluate the stability of the hydrophilic matrix tablets and that of conventional 
tablets then compare this with the stability pellets of capsules available on the 
market using accelerated stability test for a period of three months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   53 
  
 
 
 
CHAPTER TWO 
Experimental 
 
 
 
 
 
 
 
 
 
 
 
  
 
2-1 Materials and Equipments:   
2-1-1 Raw materials and Exicipents: 
Ferrous fumarate BP, Eagle chemical works – India, Lot No: FE-05/04-05. Folic acid 
BP, Sri Krishna Drug Ltd – India, Lot No: FB022/05M. Metolose 90SH 15000, HPMC 
15000 CPS, Shin – ETSU - Japan, Lot No: 30795. Microcrystalline Cellulose pH 101, 
JRS pharma GMBH & Co. KG – Germany, Lot No: 5610130914. Maize Starch BP, 
Robert E.M.Tilge - Germany, Lot No: 1215/01R5431. Polyvinylpyrrolidone-PVP 
K30ISP, Bulk Medicines & Pharmaceuticals – Germany, Lot No: 20050312.Spray 
dried lactose monohydrate- Flowlac 100- Molkerei meggle wasserburg Gmbit & Co. 
KG-Germany, Lot No: 507085. Di-calcium phosphate 2H2O, Lot No: 3834/02R41330. 
Talcum Powder pharma, Robert E.M.Tilge - Germany, Lot No: 4170R5731. 
Magnesium Stearate BP, Robert E.M.Tilge - Germany, Lot No: 3111R5731.Tabcoat 
TC, PL-22 Purple Code No 04FD304-India.  
2-1-2 Chemical Reagents and Solutions: 
Dipotassium hydrogen orthophosphate, Applichem, Code No: A3620, 1000. Methanol, 
Applichem,Code No: A1635,2500. Potassium hydroxide, Merck, Code No: B746721. 
Sodium perchlorate, Merck, A997964841. Potassium iodide, Merck, Code No: 
618.B687543. Sodium thiosulphate, Scharlau, Code No: So0727, Hydrochloric acid, 
Applichem, Code No: A0659.2500. Ammonium cerium (IV) sulphate,Merck, Code No 
CR02714. Sulphuric acid, Merck, Code No: K24457331. Sodium carbonate, BDH 
Chemicals, Code No: 30121. Dipotassium hydrogen phosphate, Applichem, Code No: 
A3620.1000. Nitric acid, Applichem, Code No: A3622101. Ammonium thiocyanate, 
BDH Chemical, Code No: 27206. Ammonium acetate, BDH Laboratory, and Code No: 
prod 271424C. Hydroxyl amine hydrochloride, Applichem, Code No: A4925.0500. 
Ferrous ammonium sulfate hexahydrate, BDH Laboratery, Code No: 27166, Sodium 
acetate, Applichem, Code No: A3621.1000. 1, 10 Phenanthroline monohydrate, Merck, 
Code No: K91012025. Purified water, (Amipharma Laboratories); 
Ami05/129,134,157,177,183,206. 
2-1-3 Dosage forms: 
Ferro-Fol Caps (iron with folic acid), Egyptian int. Pharmaceutical industries 
Co.E.1.pCo-Egypt, BNo: 057615. Fefol; Caps (iron with folic acid), Galaxosmithkline 
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Pharmaceutical Ltd - India, BNo: FA5047. Ferfol SR Caps (iron with folic acid), Sigma 
– Tau Ltd, Sudan, BNo: 0518119. 
2-1-4 Equipment:  
Analytical Balance, model Va/wa, 5KG, Oertling-Germany. Rapid mixer granulator 
model Lab GMP, Sr.No:1146, India. Alliance fluid bed drier, model TR5E, Sr.No:572-
India. SMT double cone blender, model Lab GMP, Sr.No: L85. Manesty tablet machine 
type D3B, Sr.No: L86-England. SMT multimill machine model Lab GMP, Sr.No: L237-
India. Particle size tester, model: JEL 200-Germany. Tablet hardness tester, Model; 
TBH30, Erweka, Germany. Friability tester, Model: Ta, Erweka, Germany.  
Disintegration tester, Model: ZY3-3, Erweka, Germany. SMT Coating pan Model: Lab 
GMP12, Sr.No: 84, India. Analytical balance + printer, Model: CP224S, Sartorius, 
Germany. Dissolution tester - six vessels: Model DT6, Erweka, Germany. Bulk density 
tester, Model: Sym, Erweka, Germany. PH-meter, Model: pH522WTW, Germany. 
Certrifuge 80-2, Model: Sr.No.47, Shanghai. S.U. In factory. Magnetic stirrers, Model: 
ES5, Lka-werk, England. Water bath (thermostatic) with shaker, Model: D3006, G.F.L. 
Ultra sonic bath, Model: FS3006, Decon. High performance liquid chromatography 
(HPLC), Model: LC250B, Perkin-Elmer, USA. Spectrometer single beam, hellos 
gamma, Model: S.no.uvg85024, Spectronic Unicam, Germany. Spectrophotometer 
UV/VIS double beam, Model: Lambda12, Perkin Elmer - USA. Atomic Absorption 
Flame emission spectrophotometer, model AA-6200, SHIMADZU- Japan. Stability 
chamber, Model: D-72336, Balinger - Germany. 
2-2 Application of the HPLC method in the analysis of folic acid: 
Procedure: (B.P., 2003). The following solutions were used:  
Mobile phase: 120 volumes of methanol were mixed with 880 volumes of a solution 
containing 11.16 g/L potassium dihydrogen phosphate and 5.50 g/L of dipotassium 
hydrogen phosphate solution. 
Solution (1) 0.100g of folic acid (CRS) was dissolved in 5ml of a 28.6 g/L solution of 
sodium carbonate and diluted to 100 ml with mobile phase. 2.0 ml of this solution was 
diluted to 10 ml with mobile phase. Solution (2) 0.100 g of sample (folic acid) was 
dissolved in 5 ml of a 28.6 g/l solution of sodium carbonate and diluted to 100 ml with 
the mobile phase, and then 2.0 ml of this solution was diluted to 10 ml mobile phase. 
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                     Corrected burette reading × 0.01699 × Molarity factor 
Wt. Of sample taken 
The chromatographic procedure: 
(a) A stainless steel column (25mm × 4.0mm) packed with stationary phase: spherical 
octylsilyl silica gel for chromatography R (5 µm) with a carbon loading of 12.5 percent, 
a specific surface of 350m2/g and a pore size of 10 nm. 
(b) Flow rate: 1 ml/min, injection volume: 5 µl, run time: 3 minutes. 
(c) A detection wavelength of 280 nm. 
Calculate the content of C19H19N7O6 using the declared content of C19H19N7O6 in folic 
acid (CRS). 
 (d) The resultant peaks represented standard solution and sample solution are shown in      
[Fig (3-1)].    
2-3 Assay of Ferrous fumarate:  
1) Preparation of Ferroin solution:  
0.7g of iron (II) sulphate and 1.76g of phenanthroline hydrochloride were dissolved in 
70ml of water, and diluted with water to 100ml. 
2) Assay Procedure. (BP-2003) 
0.150 gm of the sample was weighed, and dissolved with slight heating in 7.5 ml of 
dilute sulphuric acid and cooled. 25 ml of water and 0.1 ml of ferroin R were added.  
This was titrated immediately with 0.1M ammonium and cerium sulphate until the color 
changed from orange to light bluish-green. 
1ml of ammonium and cerium sulphate is equivalent to 16.99 of C4H2 FeO4. 
Analytical test results data:- 
   ○ Weight of sample taken = 0.1500 g. 
   ○ Titrated against, 0.1M Cerium Sulphate. 
   ○ Volume consumed = 8.8 ml.  
Calculation:- 
    Content of ferrous furmarate =  
                           ×     100 
   
 Loss on drying = 0.3% 
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2-4 Preparation of Conventional (Ferrous Fumarate + Folic Acid tablets): 
                                                                NO of Tabs: 1000 tabs 
  (1)Table (2-1): Manufacturing Formula;  
NO Ingredients mg / tabs (g) / Batch % / tabs 
1. Ferrous Fumarate  200.00 400.0 54.645 
2. Folic Acid  0.50     1.0 0.137 
3. Dicalcium Phosphate  60.00 120.0 16.393 
4. Starch 20.30   40.6 5.546 
5. Starch ( For Paste ) 25.00   50.0 6.831 
6. P.V.P-K-30 13.00   26.0 3.552 
7. Dried Starch 8.00   16.0 2.186 
8. Microcrystalline Cellulose 33.20   66.4 9.071 
9. Talc Purified  4.00     8.4 1.093 
10. Magnesium Stearate  2.00     4.0 0.546 
11. Purified Water  - 200.0 - 
                    TOTAL 366 mg 732.0 g 100.00 % 
 
 (2) Manufacturing Process: 
The following materials were sifted through their respective mesh sizes using 
vibratory sifter. 
 1. Ferrous fumarate   (20 mesh)   = 400.00 g. 
 2. Dicalcium Phosphate          (100 mesh)            =  120.00 g. 
 3. Starch (maize)            (100 mesh)              =    40.60 g. 
 4.  P.V.P-K-30   (40 mesh)  =   26.00 g. 
The materials were put into a Kenwood mixer and mixed at low speed for 10 
minutes. A starch paste was prepared by dispensing 50.0g of starch in 50.0g of 
purified water, to be used as a binder. 130.0g of purified water was heated up to 
boiling point and then transferred to the starch paste. The mixture was heated until a 
homogenous starch paste was formed and was then left to cool to 50°C. Starch paste 
was then added to the dry materials mixture, and mixed together until a homogenous 
wet mass was formed. The wet mass was then passed through a 2mn diameter screen 
size multimill M/C in order to produce wet granules. The wet granules were thedried 
in a fluid bed drier at a temperature of about 70°C and then passed through the 
multimill. The moisture content of the granules was calculated to be 2.26 %.   
The following materials were sifted through their respective mesh size and mixed with 
dry granules produced for 10 minutes. 
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1. Dried starch     (80 mesh)   = 16.0 g. 
2. Folic Acid    (20 mesh)  =   1.0 g. 
3. Microcrystalline Cellulose           (40 mesh)   = 66.4 g. 
4. Talcum purified    (80mesh)  =   8.0 g. 
5. Magnesium stearate           (100 mesh)           =   4.0 g.     
The granules were then compressed in clit -16 rotary machines using a 9 mm round 
standard concave punch which was plain on both sides. 
The following was analyzed;  
■Av. Wt. Tab: 366 mg ± 3%                          ■ Wt. Variation: Av. Wt. ±5% 
■ Thickness: 4.00 ± 0.3mm                            ■ Friability: ≤ 1.0% 
■ Disintegration time: ≤ 8 minutes                 ■ Hardness: ≥ 5 kg 
Manufacturing process of the conventional ferrous fumarate + folic acid tablets is 
illustrated in figure (2-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      
 
 
                   
                       Figure (2-1): Process flow diagram for preparation conventional tablets 
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2-5 Preparation and Characterization of Matrix Tablets: 
2-5-1 Design of Experiments and Orthogonal Arrays (OAs): 
In this study, optimization design techniques are used to find either the best possible 
quantitative formula for a product or the best possible set of experimental conditions 
(input values) needed to run the experiments.   
Different matrix tablets formulations (given in table 2-3) were prepared by wet 
granulation technique. 
 
◙ Table (2-2):L9 - Taguchi Orthogonal Array (OAs) – Experimental Design Layouts, 
for different formulations of HPMC hydrophilic matrix, using four factors each at three 
levels.  
Formulations
No / Run A B C D 
TSR01 +1 -1 +1 -1 
TSR02 0 0 +1 -1 
TSR03 -1        +1 +1 -1 
TSR04 +1 -1 -1 +1 
TSR05 0 0 -1 +1 
TSR06 -1 +1 -1 +1 
TSR07 +1 -1 0 0 
TSR08 0 0 0 0 
TSR09 -1 +1 0 0 
 
 
 
 
• Independent Variables: Levels (-1) (0) (+1) 
A: Hydroxypropyl methylcellulose (HPMC) 3 20% 25.00% 30.00% 
B: Microcrystalline cellulose           (MCC) 3 0 05.00% 10.00% 
C: Maize starch                                (MZS) 3 0 05.46% 10.93% 
D: Lactose monohydrate                  (LMH) 3 0 05.46% 10.93% 
 
●This optimization design allow for granting the balance needed, e.g.: average weight   
of tablets because the other additives are the same for all formulations.  
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◙    Table (2-3): Composition (in mg/ Tablet) of (iron + folic Acid) hydrophilic Matrix tablets for  
       different combinations.  
Formulation 
Code No 
Ferrous 
Fumarate 
mg 
Folic 
Acid 
mg 
HPMC 
 
mg 
MCC 
 
mg 
Starch
 
mg 
Lactose
 
mg 
P.V.P 
 
mg 
Et OH 
(95%) 
ml 
Talc 
 
mg 
Mgst
 
mg 
AV. Wt 
of 
Tablet 
In mg. 
TSR01 200 0.5 109.80 0 40 0 10.30 120 3.20 2.20 366 
            
TSR02 200 0.5 91.50 18.30 40 0 10.30 120 3.20 2.20 366 
            
TSR03 200 0.5 73.20 36.60 40 0 10.30 120 3.20 2.20 366 
            
TSR04 200 0.5 109.80 0 0 40 10.30 120 3.20 2.20 366 
            
TSR05 200 0.5 91.50 18.30 0 40 10.30 120 3.20 2.20 366 
            
TSR06 200 0.5 73.20 36.60 0 40 10.30 120 3.20 2.20 366 
            
TSR07 200 0.5 109.80 0 20 20 10.30 120 3.20 2.20 366 
            
TSR08 200 0.5 91.50 18.30 20 20 10.30 120 3.20 2.20 366 
            
TSR09 200 0.5 73.20 36.60 20 20 10.30 120 3.20 2.20 366 
 
 
All the powders were passed through 80 mesh screen. Required quantities of active 
material (ferrous fumarate), polymer (HPMC), and different quantities of 
microcrystalline cellulose (MCC) starch, and lactose, were mixed in a planetary 
Kenwood mixer for 10 minutes with low speed. There after, the dry mix powders were 
granulated with 10% w/v PVP/EtOH Ethanolic solution. After enough cohesiveness 
was obtained, the wet mass was passed through a 22/44 mesh screen. The wet granules 
were dried in a hot air oven at 40° C for 3 hours. 
The dry granules were sieved using 40 meshes. Finally, second active material (folic 
acid) talc and magnesium stearate were added as glidant and lubricant. Prior to the 
compression, the produced granules were evaluated for several tests. Then, tablets were 
compressed using rotary tableting machine (low speeds) Clit - 16 - India, with shallow 
concave punches of 10 mm diameter. Manufacturing process of the matrix tablets are 
illustrated in figure (2-2) 
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 Figure (2-2) Process flow diagram for preparation hydrophilic matrix tablet 
2-6 Evaluation of Granules (HPMC): 
2-6-1 Angle of Repose: - 
The angle of repose of granules was determined by the funnel method. The accurately 
weighed granules were taken in a funnel. The height of the funnel was adjusted in such 
a way that the tip of the funnel just touched the apex of the heap of the granules. The 
granules were allowed to flow through the funnel freely on to the surface. 
The diameter of the powder cone was measured and angle of repose was calculated 
using the following equation [11]. 
    Tan θ = h/r         (18) 
 Where; h & r are the height and radius of the powder cone. See Table (3-1)
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2-6-2 Bulk Density: - 
Both loose bulk density (LBD) and tapped bulk density (TBD) were determined. A quantity of 
10g of powder from each formula, previously lightly shaken to break any agglomerates formed, 
was introduced into a 50ml measuring cylinder. After the initial volume was observed, the 
cylinder was allowed to fall under its own weight onto a hard surface from the height of 2.5 cm 
at 2-second intervals. The tapping was continued until no further change in volume was noted. 
LBD and TBD were calculated using the following formulas: See Table (3-2) 
 LBD = weight of the powder / volume of the packing     (19) 
          TBD = weight of the powder / tapped volume of the packing   (20) 
2-6-3 Compressibility Index:  
The compressibility index of the granules was determined by Carr’s Compressibility index: See 
Table (3-2) 
  Carr’s index (%) = [(TBD – LBD)] / TBD     (21) 
2-6-4 Total Porosity:  
Total porosity was determined by measuring the volume occupied by a selected weight of 
powder (Vbulk) and the true volume of granules (the space occupied by the powder exclusive of 
space greater than the intermolecular space, V). See Table (3-2)   
  Porosity (%) =         (Vbluk - V)    × 100                (22) 
                   Vbluk 
2-6-5 Sieve analysis: 
The formulated granules, final mix of compression were sieved using electromagnetic sieve 
shaker. Different sieve mesh sizes were used, i.e. 425µ, 250 µ, 150 µ, 75 µ. All the formulations 
were shook for 10 minutes and the differences were calculated. The results were tabulated. See 
Table (3-3) 
2-7 Physical Parameters of Un-Coated Conventional and Biopolymeric Matrix 
tablets:  
Thickness, diameter, hardness, friability, disintegration time and weight variation were tested. 
The test of thickness, diameter and hardness were carried out with 10 tablets, using the hardness 
tester (model: TBH30, Erweka, Germany). Friability of 20 tablets was carried out using the 
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friability tester (model: TAO51, Erweka – Germany). Disintegration time was carried out with 
6 tablets using water as the medium of dispersion at 37° ± 2°C by DT apparatus (model: ZT3-3, 
Erweka, Germany). Weight variation of the tablets was carried out in an analytical balance, 
(model: CP124S, Germany) with 20 tablets by weighting them individually. See Table (3-4) 
2-7-1 Swelling Study of Matrix Tablets  
2-7-1-1 Axial Swelling Study: 
The method of, Sujja and Areevath et al, (1998), a tablet was placed on a glass slide (70 mm in 
length, 24 mm in width) and then  the slide was put in a Petri dish (67 mm in diameter and 15 
mm in height) containing 45 ml of 0.1 N HCl (37 ± 0.5°C, pH 1.2). The Petri dish was then 
covered. The lateral edge of the tablet was observed with a vertical moving microscope. The 
observations were taken at 60 min time intervals up to 540 min. The axial swelling in (mm) was 
measured by using a calibrated eye piece. The results are shown in table (3-5). 
2-7-1-2 Radial Swelling Study: 
The method of, Sujja and Areevath et al, (1998), was adopted. The Petri dish was kept under the 
microscope equipped with a calibrated eye piece. Measurements of the diameter (mm) were 
taken at 60 min time intervals up to 540 min. The results are shown in table (3-6). 
2-8 Chemical Analysis of Un-Coated Conventional and Biopolymeric Matrix 
tablets: -   
2-8-1 Assay of Folic acid: HPLC method 
Mobile phase – A solution of 0.938% w/v of sodium perchlorate and 0.075% w/v of 
potassium dihydrogen orthophosphate was adjusted to pH 7.5 with 0.1M potassium hydroxide, 
and transferred to a 1-liter volumetric flask. 135ml of methanol was added, and the total was 
diluted with water to volume 
 
 
Standard Preparation: 
0.0006% w/v of folic acid (RS) solution was mixed with a 0.57% w/v solution of dipotassium 
hydrogen orthophosphate in 100ml volumetric flask. 
Assay preparation: 
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20 tablets from each formulation were weighed and finely powdered. A portion of powder 
equivalent to 0.3mg of folic acid was transferred to 50ml volumetric flask, and mixed with 
25ml of a 0.57% w/v solution of dipotassium hydrogen orthophosphate for 30 minutes with the 
aid of ultrasound, and the supernatant liquid were centrifuged and decanted to 50ml volumetric 
flask. The residue was shaken with 10ml of the solvent for 15minutes with a further 10ml of 
solvent, and the supernatant liquids were combined and diluted to 50ml and filtered. 
Chromatographic system: The liquid chromatograph was equipped with a 277nm detector and 
(25 cm × 4.6 mm) stainless steel column, packed with stationary phase C (5µm) (spherisorb 
ODS 1). The flow rate was about 1ml/min. 
Procedure: Separately, equal volumes of 25µl of standard stock and the assay preparation 
samples were injected into the chromatograph system. The chromatograms were recorded and 
the responses for the major peaks (peak height area) were measured. The quantity in percentage 
of folic acid in the portion of tablets taken, were calculated by the application of the formula:  
                   Content of folic acid % =                 x 100 
                    PSAMP: peak response from the assay preparation. 
   PSTD: peak response from standard preparation. 
The resultant peaks from samples and standards, their retention times in minutes, peak heights 
and areas are shown in the table beside each chromatogram. 
2-8-2 Analysis of ferrous fumarate in conventional and matrix tablets. 
2-8-2-1 Assay of Ferrous Fumarate: By Titration (B.P, 2004) 
From each formulation, 20 tablets were weighed and finely powdered. A quantity of the powder 
equivalent to 0.3g of ferrous fumarate was dissolved in 7.5ml of 1M Sulphuric acid with gentle 
heating. The mixture was then cooled, and 25ml of water was added to it. The resultant mixture 
was titrated immediately with 0.1M ammonium cerium (IV) sulphate VS. and ferroin solution 
was used as indicator. The color changed from orange to colorless at end point. See Table (3-3) 
Calculation:- 
       Assay (%) =            Burette reading × 0.01699 × Morality factor × 100 
                                                        Weight of sample  
 
 
PSAMP 
PSTD 
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2-8-2-2 Molecular absorption spectroscopy method: 
Preparation of standard iron solution: A quantity of ferrous fumarate (0.02g) was weighed, and 
transferred accurately into 100.ml volumetric flask. About 60ml of water was added and mixed 
well for 60 minutes with the aid of ultrasonic bath, to dissolve all the solid salt. Then the 
volume was completed to the mark with water to give a solution having a known concentration 
of iron (Fe+2) in (µg/ml) (65.8µg/ml). The solution was then filtered and aliquots of the filtrate 
equal to 2ml, 4ml, 6ml, 8ml, and 10ml respectively, were transferred into 5 separate volumetric 
flasks to serve as the "blank" (zero iron concentration). 1ml of the hydroxylamine hydrochloride 
solution, 1ml of the 1M ammonium acetate, and 10ml of  the 0.3% 1,10-phenanthroline solution 
were added to  each one of the 6 flasks respectively, and the volumes were completed to the 
mark with water to give solutions of different concentrations of iron (Fe+2) ( 5.264, 10.528, 
15.792. 21.056 and 26.32 µg/ml  respectively). The absorbance of each solution was then 
measured at 510nm. The absorbance of the iron solutions were plotted versus micrograms of 
iron. Microsoft Excel program was used to determine the slope and linear regression of straight 
line. 
Preparation of the sample solution: Twenty tablets of ferrous fumarate + folic acid tablets from 
each formulations (TFF0 - TSR1-9) were weighed, powdered, and an amount equivalent to 
0.0366g was weighed from each one and transferred into 10 separate volumetric flasks (100ml), 
dissolved in a portion of water (about 60ml) with the aid of ultrasonic bath, and then the 
volumes were completed to the mark with water. The solutions were then filtered and aliquots 
of the filtrate equal to 5ml were pipetted from each one of the ten formulations and transferred 
into 10 separate volumetric flasks (25-ml). 1ml of the hydroxylamine hydrochloride solution, 
1ml of the 1M ammonium acetate solution, and 10ml of the 0.3% 1, 10-phenanthroline solution 
were pipetted in order to each flask. Each flask was swirled to mix the contents, and then the 
volumes were completed to the mark with water. The solutions were allowed to stand for 10 
minutes until the color developed. The absorbance of each solution was measured at 510 nm 
using spectrophotometer UV/VIS double beam. The calculated concentrations and 
corresponding absorbances are shown in table (2-4).     
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◙ Table (2-4). Iron standard calibration solutions, concentrations in (ppm) & absorbance’s: 
Samples of Fe+2 standard solutions ( 
volumes pipette) 
(ml) 
Concentration of Fe+2 (µg/ml) Corresponding absorbance’s 
(ABS) 
0 ml 0.000 0.000 
2 ml 5.264 0.867 
4 ml 10.528 1.711 
6 ml 15.792 2.467 
8 ml 21.056 3.267 
10 ml 26.320 4.067 
 
R2 = 0.9996
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     Figure (2-3). Calibration curve of standard (Fe+2) solution using U.V. analytical method 
 
Plot of absorbance’s vs. concentration give straight line having linear equation (Y= ax + b), 
linear constant values (a= 0.15355514), (b= 0.4238095) and linear regression R2= 0.99955179.  
Therefore calculation formula: x (in µg/ml) = (y-b/a). (Dilution factor)  
2-8-2-3 Atomic absorption spectrophotometer method (USP): 
Preparation of 6N hydrochloric acid: 5ml of hydrochloric acid was added slowly to 5ml of 
water, and mixed. 
Preparation of diluting solution: 1ml of 6N hydrochloric acid was added to 59ml of water, and 
mixed. 
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Preparation of phosphoric acid solution: 20ml of phosphoric acid was diluted with diluting 
solution 200ml, and mixed. 
Preparation of iron stock solution: 350mg of ferrous ammonium sulfate hexa hydrate was 
weighed accurately and transferred into 1000ml volumetric flask, dissolved in diluting solution, 
and diluted with diluting solution to volume, and finally mixed to obtain a solution having a 
known (50mg/ml) concentration. 
Preparation of standard iron solution: 2.0, 4.0, 6.0, 8.0, and 10.0ml of iron stock solutions were 
transferred into 5 separate volumetric flasks (100ml), then 6ml of phosphoric acid solution was 
added to each flask and the volume was completed to the mark with diluting solution to give 
solution of different concentration of iron (Fe+2) (1.0, 2.0, 3.0, 4.0, and 5.0mg/ml respectively). 
Preparation of blank solution: 6.0ml of phosphoric acid solution was transferred into 100ml 
volumetric flask and diluted with diluting solution to volume. 
Assay preparation: 20 tablets from each prepared formulations (TFF0 -TSR1-9) were weighed, 
powdered and an accurately weighed portion from each, equivalent to about 1.5g to ferrous 
fumarate were transferred in 10 separate volumetric flasks (1000-ml). 110ml of 6N hydrochloric 
acid was added to each flask and boiled for 30 minutes, then cooled and diluted with water to 
volume, after filtered. 5ml from each solution were transferred into 10 separate volumetric 
flasks (50-ml), and each one was diluted with diluting solution to volume. 8 ml from each of the 
above solutions were transferred into 10 separate volumetric flasks (100-ml), and 6ml of 
phosphoric acid solution were added to each one. Finally the contents of each flask were diluted 
with diluting solution to volume, to give solutions of known concentrations of iron (about 
4mg/ml) of each. 
Procedure: The absorbance of the standard iron solutions and the assay preparation solutions 
were determined concomitantly at the iron emission line at 248.3 nm using atomic absorption 
flame emission spectrophotometer. The spectrophotometer was equipped with an iron hollow - 
cathode lamp and an air - acetylene flame, using the blank solution as the "blank", with the 
following measurement parameters:- 
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Order  : First  
Zero intercept : No 
Conc. Unit : ppm 
Repetition sequence : SM – M – M . . .  
Pre- spray time (sec) : 3 
Integration time (sec) : 5 
Response time : 3 
 
The plot of the absorbance of the standard preparations versus their concentrations, in mg/ml of 
iron was represented in the Figure below. The different concentrations, in mg/ml of iron in the 
assay preparations (UNK) were obtained from the graph in use the UNK average absorbance, 
(see table 2-13). The average quantity, in mg, of ferrous fumarate in each sample (TFF0 – 
TSR01-9) were calculated by applying the below formula, see table (2-13)  
     Q = (TC) (169.90)       (23) 
     D      55.85     
Where:  
T = the labeled quantity, in mg, of ferrous fumarate in each tablet; C = the concentration in 
mg/ml, of iron in the assay preparation; D = the concentration, in mg/ml, of ferrous fumarate in 
the assay preparation; 169.90 and 55.85 are the molecular weight of ferrous fumarate and 
atomic weight of iron, respectively. 
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Therefore: 
         C = Abs – 0.03656/0.1082                         (24) 
 
2-9 In Vitro drug solution studies of (Fe+2): 
2-9-1 Apparatus: In vitro drug release studies for all the prepared formulations, 
conventional and matrix tablets (TFF0 - TSR1-9) were conducted for a period of 16 hours, 
using a dissolution test apparatus (Dissolutest-6-stations, model DT6 Erweka- Germany). 
The USP paddle method was selected to perform the dissolution studies. Analysis of the 
dissolution samples was achieved by using the analytical method of spectrophotometry. 
2-9-2 Spectrophotometer determination of iron (II) in dissolution samples:  
a) Preparation of standard iron solution:  
0.20g of pure dry ferrous fumarate was weighed accurately into a small plastic weighing 
boat and transferred quantitatively into a 1-L volumetric flask. The weighing boat and the 
neck of the flask were close together to ensure an accurate transfer of 400ml of deionized 
water. This was mixed well for 15 minutes with the aid of ultrasound to dissolve all the solid 
salt. The ferrous salt solution was diluted to volume with deionized water, mixed well again, 
and the concentration of this stock solution was calculated in ppm of iron. 
Concentration of 0.200g ferrous fumarate in 1 liter deionized water = 200mg/L, therefore 
concentration of (Fe+2) = 65.8mg/L; in 1 ml = 0.0658mg/ml. 
b) Iron standard calibration solutions:  
2, 4, 6, 8 and 10ml of the standard iron solution were pipetted into each of five 25ml 
volumetric flask, respectively. About 10ml of deionized water was put into a sixth 25ml 
volumetric flask to act as the “blank” (i.e. zero iron concentration). 1ml of hydroxylamine 
hydrochloride solution, 1ml of 1M ammonium acetate, and 10ml of 0.3% 1,10-
phenanthroline solution were added to each flask, and all samples in each flask were diluted 
to the mark with deionized water, mixed well, and allowed to stand for at least 10 minutes 
before absorbance measurements, were taken. 
c) Preparation of the sample solutions:  
From each solution that was withdrawn and filtered previously from dissolution stages at the 
end of each hour, 5ml was pippetted into 25ml volumetric flasks. 1ml of the hydroxylamine 
hydrochloride solution, 1ml of the 1M ammonium acetate solution, and 10ml of 0.3% 1, 10-
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phenanthroline solution were pippetted into each flask. Each flask was swirled to mix the 
contents, and then each solution was diluted to the 25ml mark with deionized water 
carefully, and mixed thoroughly. The solutions were allowed to stand for 10 minutes, until 
the color had developed. 
d) Absorbance measurements: - 
By using spectrometer UV/VIS double beam the absorbance of each solution was measured 
at a 510nm. The cuvettes were rinsed several times with the next solution to be measured 
before measurement. 
e) Calculations (calibration curve):-  
For the standard solutions: the concentration of (Fe+2) in each of the concentrations was 
determined, according to this relationship: 
Concentration of (Fe+2) in (µg/ml) of STD solutions =  
                   Concentration in mg/ml X volume taken of STD solution X1000 
                                   Dilution volume 
The calculated concentrations and corresponding absorbance of the standard solutions were 
summarized, as shown in table (2-14). The absorbance of the iron standards were plotted 
versus concentrations of iron in µg/ml. Microsoft excel was used to determine the slope and 
intercept (and their standard deviations) by the method of least squares, to obtained linear 
correlation coefficient.R2.The linearly of the calibration curve, is illustrated in figure (2-5). 
 
 
Table (2-5).  Iron standard calibration solutions, concentrations in (ppm). And absorbance: 
Samples of Fe+2 standard 
solutions ( volumes pipetted) / 
ml 
Concentration of Fe+2 
(µg/ml) 
Corresponding 
absorbance (ABS) 
0 ml 0.000 0.000 
2 ml 5.264 0.429 
4 ml 10.528 0.818 
6 ml 15.792 1.245 
8 ml 21.056 1.659 
10 ml 26.320 2.078 
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R2 = 0.9999
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                      Fig (2-4): calibration curve of iron standard solution 
 
2-9-3 Dissolution media: 
Several dissolution media were used in order to cover the influence of using different 
solutions, different pH and also, the effect of adding different types of surfactants on the 
drug release. 
 
2-9-3-1 Dissolution medium (1): 0.1N HCl, and then D.M water: 
 In this method the in vitro dissolution study of all prepared tablets (TFF0&TSR01-9) were 
carried out in 1000ml 0.1N hydrochloric acid to simulate a pH of 1.2 to give a likeness of 
gastric fluid, for the first hour. For the remainder of the time the tablets were immersed in 
D.M water to simulate a pH of 6 like that of intestinal fluid. 
Note that the TFF0 tablets completely dissolved in the hydrochloric acid within the first 5 
minutes so could not be tested with D.M water. For this reason TFF0 in 0.1N HCl samples 
were taken at time intervals of 0.25hr 0.50hr and 1hr.  
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These solutions were maintained at 37°C ± 0.5°C., with the rate of stirring being 100 ± 2 
rpm. The first sample (5ml) was removed after 1 hour and filtered. Then, the tablets were 
immersed into deionized water, and filtered; the samples (5ml) were taken at selected, 
intervals 2,4,6,8,10,12,14 and 16 hours, and were monitored for progress of the dissolution. 
An equal volume of fresh dissolution medium, (D.M water) maintained at the same 
temperature, was added after each sample was taken, to maintain the volume (1000ml). 
Amount of drug release (Fe+2) was then determined by analyzing the filtered samples using 
the spectrophotometer. Finally, the percentage of drug (Fe+2) release at different, time 
intervals was calculated by using an equation generated from the calibration curve 
constructed from a reference, or by applying the below formula: 
                     Cu = Au - intercept X (volume of sample) 
                                   Slope 
■The slope and intercept of the straight line provide a relationship between absorbance and       concentration: A = 
SlopeC + Intercept. 
■The absorbance of the unknown solution, Au, is then used with the slope and intercept to calculate the concentration 
of the unknown solution, Cu. 
The calculated percentages of drug release (Fe+2) are represented in [tables 3-10, 3-11, 3-12, 
and 3-13]. The figures (3-2) and (3-3), shows the drug (Fe+2) release percentages plotted 
against time (hours). 
 
2-9-3-2 Dissolution medium (2): D.M water at pH=6:  
 In this method deionized water at (pH=6.0) without surfactants was used as dissolution 
medium. The prepared tablets (TFF0&TSR01-9) were placed in 1000ml of D.M water and 
maintained at 37° ± 0.5°C under 100rpm paddle speed. At predetermined time intervals (after 
1hr, 2hr, 4hr, 6hr, 8hr, 10hr, 12hr, 14hr, 16 hr); 5ml samples were taken and filtered through 
filter paper. The dissolution medium was then replaced by 5ml of fresh dissolution fluid stored 
at the same temperature to maintain a constant volume, after withdrawing each sample. The 
filtrated samples were analyzed by using spectrophotometer analytical method. The amounts of 
drug (Fe+2) present in the sample was calculated by using the equation generated from the 
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calibration curve constructed from the reference standard. Calculated results of drug release 
percentages are given in [tables 3-14, 3-15, 3-16, and 3-17]. Drug (Fe+2) release at selected time 
periods above was plotted as percent release versus time (hours) curves as shown in figures (3-
4) and (3-5).  
2-9-3-3 Dissolution medium (3): phosphate buffer at pH=4.5: 
Preparation of dissolution media: 6.80g of potassium dihydrogen orthophosphate was 
dissolved in 1000ml of D.M water, to produce a dissolution medium of pH 4.5. 
The in vitro dissolution study of prepared tablets (TFF0& TSR01-9) in the simulated duodenal 
contents, when the stomach is in the fed state (pH=3.5), was carried out by using 1000ml of the 
prepared solution as dissolution medium maintained at 37° ± 0.5°C throughout dissolution run, 
at paddle rotation speed of 100rpm. At time 1, 3, 5,7,9,11,13 and 15hr, 5ml of samples were 
withdrawn. An equal volume of fresh medium stored at the same temperature was added to 
maintain the constant volume after withdrawing each sample. Samples were filtered through 
filter paper. The drug release at different time intervals was measured by a UV 
spectrophotometer analytical method. The amounts of drug (Fe+2) percent in the samples was 
calculated with the aid of the equation generated from the calibration curve constructed from 
the reference standard [tables 3-18, 3-19, 3-20, and 3-21]. Drug (Fe+2) dissolved at specified 
time period, was plotted as percentage release versus time (hours), figures (3-6) and (3-7).  
 
2-9-3-4 Dissolution medium (4): phosphate buffer at pH=6.8: 
Preparation of dissolution medium: 6.805g of potassium dihydrogen orthophosphate was 
dissolved in 1000ml of deionized water and then 0.896g of sodium hydroxide was added to 
above solution to produce a pH of 6.8, like that of intestinal fluid according to (USP25-
SIFSP). 
The in vitro dissolution study of prepared tablets (TFF0& TSR01-9) in this simulated intestinal 
fluid (prepared phosphate buffer pH6.8) was carried out by using 1000ml of the solution as the 
dissolution medium and the temperature was maintained at 37° ± 0.5°C throughout dissolution 
run, at paddle rotation speed of 100rpm. At time 1, 3, 5,7,9,11,13 and 15 hr, 5ml of samples 
were withdrawn, filtered through filter paper and an equal volume of fresh dissolution media 
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(37° ± 0.5°C) was added to maintain the volume constant after withdrawing each sample. The 
filtered samples were analyzed spectrophotometrically (analytical method 2-9-2). The amount 
of drug (Fe+2) present in the samples were calculated by using the equation generated from the 
calibration curve constructed from reference standard [tables 3-22, 3-23, 3-24, and 3-25]. Drug 
(Fe+2) dissolved at selected time period was plotted as percent release versus time (hours), 
figures (3-8) and (3-9).  
 
2-10 Kinetic Analysis of Dissolution Results: 
2-10-1 Application of Kinetic Equation:- 
According to Colombo and Peppas, (2000), different kinetic equations shown in table (2-31) 
below, were applied to interpret the release rate from formulations (TFF0 – TSR01-9). the 
different drug release data which was obtained from dissolution medium(1): 0.1N HCl from 1st 
hr, and then D.M water at pH6, dissolution media(2): D.M water at pH6, dissolution 
medium(3): phosphate buffer at pH 4.5, and dissolution medium(4): simulated intestinal fluid at 
pH 6.8 phosphate buffer, were fitted to the following kinetic equations. 
◙Table (2-6). Expressions useful for estimating the release kinetics parameters. 
 
Kinetic Equation Kinetic Parameters 
• Zero – order model 
    Q = Q0 – K0t             
                                  (25) 
( cumulative amount of drug release vs. time) 
Where:- 
Q= the amount of drug release at time t, and K0 is the release rate 
• First – order model  
  Log C = log C0 – kt/2.303 
                                  (26)  
( log cumulative %age of drug remaining vs. time) 
Where:- 
Q= the amount of the drug release at time t, and k is the release rate 
constant) 
• Higuchis model  
    Q = kt1/2 
                                   (27) 
( cumulative %age of drug release vs. square root of time ) 
Where:- 
Q= the amount of drug release at time t, and k is the diffusion rate 
constant 
 
2-10-2 The best straight line fitting: 
 For calculating these kinetic parameters, a simple mathematical calculation method (the best 
straight line fitting theory – Gauss, 1855) was utilized for calculation of kinetic values from 
different plots of formulations. The method of least square (Gauss – theory) described that " 
sum of the squares of errors = minimum value ". 
• Assume we have the given points below with no linear plot ( see plot ): 
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X X0 X1 X2 X3 …………… Xn 
y Y0 Y1 Y2 Y3 …………… yn 
  
• Straight line equation : y = ax + b 
We want a,b that give the best straight line. 
• From Gauss theory: 
(Error at xi, yi) = (yi – axi – b) 
M= minimum value = Σ ( yi – axi – b )2 
 
 
dm = 0        Σ 2( yi – axi – b ) ( - xi ) = 0  
da  
dm = 0        Σ 2( yi – axi – b ) ( -1 ) = 0  
db         
Generated two equations in two variables xi , yi and 2 unknown constants a, cb  
  Σ xi yi – a Σ xi2 – b Σ xi = 0              (1) 
Σ yi – a Σ xi – b Σ1 = 0                         (2)  
The given points, to find the numerical values of, Σ xi, Σyi, Σxi2 and Σ xi yi according to the 
table below. 
Xi X1 X2 X3 ……………. Xn Σ xi 
yi Y1 Y2 Y3 …………….  yn Σ yi 
Xi2 X12 X22 X32 …………….Xn2 Σ xi2 
Xi yi X1 y1 X2 y2 X3 y3 …………Xn yn Σ xi yi 
 
Substitute these values in equations (1) and (2) to find the values of constants a,b that give the 
best straight line.  
A scientific graphic calculator program (CFX 9850 GB. plus) was used for this calculations. 
The application of, the 4 kinetic equations according to the Gauss theory are shown in [Figures 
(2-5) to (2-16)]. The calculated results of different values of regression coefficient (R2) are 
summarized in (tables 3-26, 3-27, 3-28 and 3-29).  
y= ax + b 
y 
x 
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2-10-3 Kinetic Models Analysis and Statistics: 
2-10-3-1 Application of Zero – Order model: 
  (a) Dissolution medium (1): 
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Fig (2-5): Zero – Order curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9), in 
dissolution media (1), 0.1N HCl for the first hr and then D.M water at pH 6.  (n=3) 
 
(b) Dissolution medium (2): 
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Fig (2-6): Zero – Order curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison to the conventional tablets (TFF0), in dissolution media (2), D.M water at pH 6.  (n=3) 
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(c) Dissolution medium (3): 
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Fig (2-7): Zero – Order curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison to the conventional tablets (TFF0), in dissolution media (3), phosphate buffer at pH 4.5. 
(n=3) 
(d) Dissolution medium (4): 
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Fig (2-8): Zero – Order curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison to the conventional tablets (TFF0), in dissolution media (4), Simulated Intestinal Fluid 
phosphate buffer pH 6.8. (n=3) 
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2-10-3-2 Application of First – Order model: 
(a) Dissolution medium (1): 
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Fig (2-9): First – Order curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9), in 
dissolution media (1), 0.1N HCl for the first hr and then D.M water at pH 6.  (n=3) 
 
(b) Dissolution medium (2): 
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Fig (2-10): First – Order curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison, to the conventional tablets (TFF0), in dissolution media (2), D.M water at pH 6.  (n=3) 
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(c) Dissolution medium (3): 
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Fig (2-11): First – Order curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison to the conventional tablets (TFF0), in dissolution media (3), phosphate buffer at pH 4.5. 
(n=3) 
(d) Dissolution medium (4): 
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Fig (2-12): First – Order curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison to the conventional tablets (TFF0), in dissolution media (4), Simulated Intestinal Fluid 
phosphate buffer pH 6.8. (n=3) 
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2-10-3-3 Application of Higuchi’s model: 
(a) Dissolution medium (1): 
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Fig (2-13): Higuchi’s model curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9), in 
dissolution media (1), 0.1N HCl for the first hr and then D.M water at pH 6.  (n=3) 
(b) Dissolution medium (2): 
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Fig (2-14): Higuchi’s model curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison to the conventional tablets (TFF0), in dissolution media (2), D.M water at pH 6.  (n=3) 
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 (c) Dissolution medium (3): 
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Fig (2-15): Higuchi’s model curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison to the conventional tablets (TFF0), in dissolution media (3), phosphate buffer at pH 4.5. 
(n=3) 
(d) Dissolution medium (4): 
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Fig (2-16): Higuchi’s model curve of drug (Fe+2) release from hydrophilic matrix tablets (TSR01-9) in 
comparison to the conventional tablets (TFF0), in dissolution media (4), Simulated Intestinal Fluid 
phosphate buffer pH 6.8. (n=3) 
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2-10-3-4 Application of Korsmeyer’s model: 
 
The dissolution data was also fitted to the exponential equation (Korsmeyer’s equation), which 
derived from the linear line of log cumulative percentage versus log time, to describe the drug 
release behavior from polymeric systems (Korsmeyer, 1983). 
The values of release exponent (n) and kinetic rate constant (k) were calculated from     Eqn          
Mt   =   ktn                                                                                     (28) 
                      M∞  
Eqn (28) was written in a linear from (y = ax + b), by taking logarithms of both sides, to give:- 
       Log    Mt  =  n log t + log k                                  (29) 
                    M∞ 
Eqn (29) represents that log Mt   is a linear. Function of (slope = n, intercept = log k) 
          M∞ 
Therefore, the values of n and k of different intercept and slope of the plots below: 
 
 
(y = log Mt) against (x = log t),  
      M∞ 
 
 
 
 
 
 
Where 
 Mt corresponds to the amount of drug released in time t, M∞ is the total amount of drug 
released after an infinite time; k is a constant related to the properties of the drug delivery 
system and n is the diffusional exponent indicative of the mechanism of drug release. 
When the value of n < 0.50, the drug is released from the polymeric matrix with a Fickian (case 
І) diffusion mechanism, for 0.5 < n < 1, non – Fickian (anomalous) release drug diffusion 
n= yi   =slope 
xi
Log Mt = Y 
       M∞ 
yi
xi 
b= Log k 
Log t = x 
l pe 
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occurs and when n > 1, non – Fickian (super case II) or zero order release kinetics. Case II 
generally refers to the erosion of the polymeric chain and anomalous transport (non – Fickian) 
refers to a combination of both diffusion and erosion controlled drug release (Peppas, 1985).  
Mean dissolution time (MDT) was considered as a basis for comparison of the dissolution rates. 
Therefore, to characterize the drug release rate in different experimental conditions (MDT) was 
calculated from dissolution data according to Mockel and Lippold, (1993), using the following 
equation (30):  
  MDT = (    n    ). K-1/n       (30) 
                  n + 1         
 
The application of different drug release data from different dissolution media 1,2,3 and 4 in 
Eqn (29) are illustrated in tables (2-7, 2-8, 2-9,and 2-10) The calculated results of R2 n,k and 
MDT are summarized in (tables 3-30, 3-31, 3-32, and 3-33). 
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Table (2-7): Application of Korsmeyer et al model: log cumulative percentage of drug release vs. Log time. (Log 
(Mt/ M∞) = n log t + log k) for dissolution media (1) 0.1N HCl for first hour, and then D.M Water at pH6. 
Time/min t 60 120 240 360 480 600 720 840 960 
 Log t 1.778 2.078 2.380 2.556 2.681 2.778 2.857 2.924 2.982 
           
Log 
Cum 
% 
         
TFFO 
  
• n=                    Log k=                      k=                           R2=                           MDT= 
Log 
Cum 
% 
1.7831 1.8308 1.8771 1.9328 2.0293 2.1523 2.2544 2.341 2.4165 
TSR 01 
 
• n= 0.52             Log k= 0.747           k= 5.58                   R2= 0.8182               MDT= 0.0125 
Log 
Cum 
% 
1.5887 1.6179 1.6611 1.7372 1.8759 2.0364 2.1631 2.2704 2.3618 
TSR 02 
 
• n= 0.64             Log k= 0.285           k= 1.93                   R2= 0.7941               MDT= 0.1397 
Log 
Cum 
% 
1.6675 1.7038 1.741 1.8245 1.9635 2.1312 2.2602 2.3636 2.4496 
TSR 03 
 
• n= 0.65            Log k= 0.3390          k= 2.18                   R2= 0.7924               MDT= 0.1188 
Log 
Cum 
% 
1.6088 1.6098 1.6107 1.6129 1.6639 1.7662 1.8709 1.9707 2.0689 
TSR 04 
 
• n= 0.33            Log k= 0.898            k= 7.91                   R2= 0.5905               MDT= 4.71X 10-4 
Log 
Cum 
% 
1.6357 1.6701 1.6762 1.6798 1.7151 1.8976 2.0352 2.1554 2.2537 
TSR 05 
 
• n= 0.46            Log k= 0.681            k= 4.79                   R2= 0.6349               MDT= 0.011 
Log 
Cum 
% 
1.6501 1.6648 1.6701 1.7611 1.9406 2.0977 2.2232 2.3284 2.1478 
TSR 06 
 
• n= 0.65            Log k= 0.297            k= 1.98                   R2= 0.7658               MDT= 0.138 
Log 
Cum 
% 
1.225 1.3228 1.4658 1.6647 1.8743 2.06 2.1998 2.3132 2.4108 
TSR 07 
 
• n= 1.02            Log k= -0.78             k= 0.17                   R2=  0.9059              MDT= 2.87 
Log 
Cum 
% 
1.4438 1.5016 1.6107 1.8175 2.0064 2.1842 2.3155 2.4197 2.5055 
TSR 08 
 
• n= 0.94            Log k= -0.423           k= 0.38                   R2= 0.8913               MDT= 1.36 
Log 
Cum 
% 
1.4316 1.4673 1.5765 1.7953 2.0081 2.1880 2.3207 2.4245 2.5099 
TSR 09 
 
• n= 0.96            Log k= -0.489           k= 0.324                 R2= 0.8846               MDT= 1.58 
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Table (2-8): Application of Korsmeyer et al model: log cumulative percentage of drug release vs. Log time. (Log 
(Mt/ M∞) = n log t + log k) For dissolution media (2) – D.M Water at pH 6   
Time/min t 60 120 240 360 480 600 720 840 960 
 Log t 1.778 2.079 2.380 2.556 2.681 2.778 2.857 2.924 2.982 
           
Log 
Cum 
% 
1.3047 1.7776 2.1462 2.3924 2.549 2.6638 2.7546 2.8294 2.8934 
TFFO 
  
• n= 1.31            Log k= -0.98             k= 0.11                   R2= 0.9973               MDT= 3.06 
Log 
Cum 
% 
-0.552 0.2355 1.1852 1.5884 1.8174 2.0697 2.2553 2.4263 2.5576 
TSR 01 
 
• n= 2.58            Log k= -5.09             k= 8.13X10-6          R2= 0.9964               MDT= 67.70  
Log 
Cum 
% 
-0.113 0.5403 1.1801 1.6268 1.9045 2.1497 2.3345 2.4798 2.600 
TSR 02 
 
• n= 2.28            Log k= -4.20             k= 6.31X10-5          R2= 0.9994              MDT= 48.32 
Log 
Cum 
% 
0.1271 0.7466 1.3533 1.7394 1.9939 2.1915 2.3780 2.5185 2.6370 
TSR 03 
 
• n= 2.09            Log k= -3.61             k= 2.45X10-4          R2= 0.9997              MDT= 36.13 
Log 
Cum 
% 
-0.017 0.7395 1.3552 1.7348 2.019 2.2483 2.4302 2.508 2.5823 
TSR 04 
 
• n= 2.18            Log k= -3.85             k= 1.41X10-4          R2= 0.9977              MDT= 40.04 
Log 
Cum 
% 
-0.327 0.3783 1.3457 1.7309 1.9327 2.1895 2.3864 2.5295 2.6438 
TSR 05 
 
• n= 2.49            Log k= -4.73             k= 1.86X10-5          R2= 0.9953              MDT= 56.65  
Log 
Cum 
% 
0.3263 0.6739 1.2787 1.6755 1.9496 2.1998 2.3838 2.5304 2.6439 
TSR 06 
 
• n= 2.01            Log k= -3.41             k= 3.89X10-4          R2= 0.9891              MDT= 33.20 
Log 
Cum 
% 
-0.241 0.5518 1.2629 1.6628 1.9386 2.1422 2.3247 2.4617 2.5840 
TSR 07 
 
• n= 2.33            Log k= -4.33             k= 4.68X10-5          R2= 0.9987              MDT= 50.49  
Log 
Cum 
% 
0.2833 0.6821 1.2629 1.6499 1.9357 2.1523 2.3358 2.4815 2.5928 
TSR 08 
 
• n= 1.99            Log k= -3.39             k= 4.07X10-4          R2= 0.9928              MDT= 33.64 
Log 
Cum 
% 
0.0606 0.7895 1.4435 1.8332 2.0977 2.3116 2.4849 2.6163 2.7123 
TSR 09 
 
• n= 2.21            Log k= -3.83             k= 1.48X10-4          R2= 0.9993              MDT= 37.22 
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Table (2-9): Application of Korsmeyer et al model: log cumulative percentage of drug release vs. Log time. (Log 
(Mt/ M∞) = n log t + log k), for dissolution media (3) – phosphate buffer pH 4.5.   
Time/min t 60 180 300 420 540 660 780 900  
 Log t 1.7781 2.2552 2.4771 2.6232 2.7323 2.7781 2.8920 2.9542  
           
Log 
Cum 
% 
0.7902 1.6188 1.8664 2.0089 2.0916 2.1567 2.2151 2.2622 
 
TFFO 
 
• n= 1.23            Log k= -1.27             k= 0.054                 R2= 0.9668              MDT= 5.92 
Log 
Cum 
% 
0.0253 0.5634 1.1176 1.5381 1.8006 1.9747 2.104 2.2159 
 
TSR 01 
 
• n= 1.99            Log k= -3.68             k= 2.09X10-4           R2= 0.9729              MDT= 47.03 
Log 
Cum 
% 
0.1271 0.5263 1.151 1.5194 1.7610 1.9332 2.0686 2.1877 
 
TSR 02 
 
• n= 1.89            Log k= -3.44             k= 3.63X10-4           R2= 0.9588              MDT= 43.22 
Log 
Cum 
% 
0.3636 0.7759 1.4041 1.7545 2.0014 2.1645 2.2863 2.3874 
 
TSR 03 
 
• n= 1.86            Log k= -3.14             k= 7.24X10-4           R2= 0.9653              MDT= 31.73 
Log 
Cum 
% 
0.3969 0.8976 1.3926 1.7478 1.9635 2.1157 2.2349 2.3378 
 
TSR 04 
 
• n= 1.75            Log k= -2.85             k= 1.41X10-3           R2= 0.9789              MDT= 27.08 
Log 
Cum 
% 
0.3979 0.8750 1.3304 1.6601 1.8691 2.0246 2.1558 2.2673 
 
TSR 05 
 
• n= 1.67            Log k= -2.71             k= 1.95X10-3           R2= 0.9774              MDT= 26.24 
Log 
Cum 
% 
0.1271 0.8095 1.3769 1.6727 1.8294 1.9514 2.0347 2.1006 
 
TSR 06 
 
• n= 1.76           Log k= -3.04              k= 9.12X10-4           R2= 0.9888              MDT= 34.03 
Log 
Cum 
% 
0.0969 0.7315 1.2464 1.5949 1.7829 1.9122 1.9980 2.0718 
 
TSR 07 
 
• n= 1.75            Log k= -3.06             k= 8.71X10-4           R2= 0.9873              MDT= 35.67 
Log 
Cum 
% 
0.1583 0.6821 1.0445 1.3974 1.5819 1.7223 1.8078 1.8760 
 
TSR 08 
 
• n= 1.55            Log k= -2.70             k= 2.00X10-3           R2= 0.9835              MDT= 33.50 
Log 
Cum 
% 
0.1875 0.617 1.0595 1.4073 1.6374 1.7965 1.9307 2.061 
 
TSR 09 
 
• n= 1.68            Log k= -2.96             k= 1.10X10-3           R2= 0.9678              MDT= 36.16 
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Table (2-10): Application of Korsmeyer et al model: log cumulative percentage of drug release vs. Log time. (Log 
(Mt/ M∞) = n log t + log k), for dissolution media (4) – Simulated intestinal fluid, phosphate buffer at pH 6.8. 
Time/min t 60 180 300 420 540 660 780 900  
 Log t 1.7781 2.2552 2.4771 2.6232 2.7323 2.7781 2.8920 2.9542  
           
Log 
Cum 
% 
-0.420 -0.318 -0.236 -0.232 0.0277 0.2137 0.3972 0.5835 
 
TFFO 
 
• n= 0.79            Log k= -2.02             k= 9.55X10-3          R2= 0.7213               MDT= 159.12 
Log 
Cum 
% 
-0.728 -0.557 -0.333 -0.256 0.0877 0.3188 0.5345 0.6958 
 
TSR 01 
 
• n= 1.09            Log k= -2.90             k= 1.26X10-3          R2= 0.7785               MDT= 238.50 
Log 
Cum 
% 
-1.00 -0.721 -0.707 -0.115 0.1571 0.3794 0.5497 0.6977 
 
TSR 02 
 
• n= 1.53            Log k= -4.03             k= 9.33X10-5           R2= 0.8523              MDT= 260.40 
Log 
Cum 
% 
-1.00 -0.721 -0.055 0.2405 0.4885 0.673 0.8215 0.937 
 
TSR 03 
 
• n= 1.79            Log k= -4.41             k= 3.89X10-5           R2= 0.9455              MDT= 186.62 
Log 
Cum 
% 
-2.221 -1.795 -1.585 -0.157 0.1920 0.4765 0.6652 0.8079 
 
TSR 04 
 
• n= 2.91            Log k= -7.93             k= 1.17X10-8           R2= 0.8659              MDT= 395.75 
Log 
Cum 
% 
-1.045 -0.744 -0.552 -0.119 0.2355 0.5132 0.6893 0.8331 
 
TSR 05 
 
• n= 1.69            Log k= -4.37             k= 4.27X10-5           R2= 0.8863              MDT= 241.92 
Log 
Cum 
% 
-1.045 -0.244 -0.119 0.1238 0.3598 0.5490 0.7134 0.8388 
 
TSR 06 
 
• n= 1.56            Log k= -3.87             k= 1.35X10-4           R2= 0.9801              MDT= 184.26 
Log 
Cum 
% 
-0.721 -0.707 -0.543 -0.176 0.1258 0.2801 0.4418 0.5827 
 
TSR 07 
 
• n= 1.19            Log k= -3.15             k= 7.08X10-4           R2= 0.8033              MDT= 241.06 
Log 
Cum 
% 
-1.045 -0.431 -0.124 0.0899 0.2552 0.3926 0.5477 0.6748 
 
TSR 08 
 
• n= 1.45            Log k= -3.69             k= 2.04X10-4           R2= 0.9944              MDT= 207.63 
Log 
Cum 
% 
-1.045 -0.431 -0.187 -0.031 0.1492 0.3180 0.4683 0.6117 
 
TSR 09 
 
• n= 1.37           Log k= -3.54             k= 2.88X10-4            R2= 0.9863              MDT= 222.12 
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2-11 The effect of addition various surfactants to simulated intestinal fluid pH 6.8 
on drug release characteristics: 
(TFF0 & TSR01-9) tablets were all tested with different surfactants added to dissolution 
medium (4), to see what effect they have on drug release, as initially they all gave a minimal 
drug release profile. This was only observed with dissolution medium (4).   
The dissolution studies of all prepared tablets (TFF0 & TSR01-9) were performed using USP 
apparatus (2). All studies were carried out in 1000ml of phosphate buffer at pH6.8 (SIF), 
with addition of different types of surfactants: 
       ◙ Anionic surfactant:   (0.5% w/v Sodium Lauryl Sulfate). 
       ◙ Nonionic surfactant: (0.5% w/v Tween 80). 
       ◙ Cationic surfactant:   (0.5% w/v Certrimide Agar). 
All dissolution media were maintained at 37° ± 0.5°C throughout the dissolution run, at 
paddle rotation speed of 100rpm. Each media was tested independently, and samples (5ml) 
were taken at 1, 3, 5,7,9,11,13 and 15hrs intervals. An equal volume of fresh medium stored 
at the same temperature was added to maintain the dissolution volume constant after 
withdrawing each sample. Samples were filtered through filter paper, and analyzed by the 
UV spectrophotometer (analytical method). The amounts of drug (Fe+2) release in each 
media (a, b, c) at selected intervals was calculated using the calibration curve equation of 
(Fe+2) standards. The percentages (%) of (Fe+2) release from each tablet was plotted against 
the different time intervals as shown in figures (3-10) to (3-19). The dissolution profiles of 
different tablet formulation, due to different types of surfactants used, was compared 
visually. 
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CHAPTER THREE 
Results & Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
  
3.1 Results: 
3.1.1 Analysis of Active material: 
(a) Folic acid: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The folic acid ingredient was analyzed by HPLC, B.P (2003). Liquid chromatography technique 
was used for separation. A mixed solution of 120 volumes of methanol with 880 volumes of a 
solution containing potassium dihydrogen phosphate and dipotassium hydrogen phosphate 
solution were used as mobile phase. A stainless steel column packed with spherical octylsilyl 
silica gel for chromatography (5µm) with a carbon loading of 12.5%, a specific surface of 
350m2/g and a pore size of 10 nm, were used as stationary phase, and detection was carried out 
at 280 nm. Retention time of folic acid observed was about 3 minutes. 
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Calculation:-  
             Wt. Taken of STD = 0.1000g  
   Wt. Taken of SAMP = 0.1000g 
   STD peak height = 289.601 
   SAMP peak height = 292.143  
                         Content (%age) =      292.143 X 93.5 X 100        = 99.90 % 
                                                             289.601X (100- 5.6) 
          
The content of folic acid found was more when 99%. This result complied with that specified 
by the B.P (2003) (96-102%).  
(b) Ferrous fumarate: 
The assay of ferrous fumarate raw material was carried out as per B.P 2003. The potentiometric 
titration method was employed; the titration was carried out using 0.1M ammonium and cerium 
sulphate solution. 
  ● Analytical test results data: 
      Weight of sample taken = 0.1500 g.    
      Titrated against, 0.1M Cerium Sulphate. 
      Volume consumed = 8.8 ml.  
  ● Calculation:   Content of ferrous furmarate = 
      Corrected burette reading X 0.01699 X Molarity factor   X 100                            
Wt. Of sample taken 
    Loss on drying = 0.3                                                                                          
Content =       8.8 X 0.01699 X100 X 100 =           99.97%                         
0.1500 X (100-0.3) 
The assay content observed was more than 99% which is within the acceptable criteria as per 
BP (2003) (97-102%). 
 
3.1.2 Formulation of TFF0 – conventional and TSRs – matrix tablets. 
The tablets were manufactured in Amipharma Laboraories Ltd as per the manufacturing 
formula of table (2-1). Chapter-2. Conventional tablets (ferrous fumarate + folic acid) were 
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prepared according to the processing procedure which was illustrated in process flow diagram, 
figure (2-2) 
The other Matrix tablets were prepared by wet granulation technique. L9-Taguchi-Orthogonal 
Array-Experimental design method was used, using 4 factors each at 3 levels, table (2-2). The 
manufacturing process of the hydrophilic matrix tablets were illustrated in process flow diagram 
(2-3) 
3.1.3 Evaluation of Dry granules: 
The granules in both the above formulations (Conventional and matrix Tablets) were evaluated. 
The angle of repose, bulk density, moisture content compressibility index, total porosity, and 
sieve analysis tests were conducted. The results of angle of repose ranged from 18.41 to 22.93, 
table (3-1). The results of LBD, TBD and compressibility index (%) ranged from 0.455 g/ml to 
0.714 g/ml, 0.500 g/ml to 0.910 g/ml and 4.80 to 21.54%, respectively. The results of 
percentage of the total porosity of a round ranged from 4.76% ratio 21.43%. The moisture 
content (%) of the dry granules of all formulations ranged from 2.114 to 4.150, table (3-2). The 
results of sieve analysis of the formulated granules (TFF0 & TSR1-9) was found as follow: 
Retained on; (i) 425µ mesh size ranged from 0.25 to 18.99%, (ii) 250µ mesh size ranged from 
1.10 to 26.75%, (iii) 150µ mesh size ranged from 0.45 to 32.0%, (iv) 75µ mesh size ranged 
from 21.25 to 73.48%, and reached Bottom 0µ ranged from 4.18 to 21.72%, table (3-3). 
    ◙   Table (3-1): Result of the angle of repose of the granules (TFF0-TSR01-9) 
Formulation 
Code NO 
h: height of the 
powder cone 
r: radius of the 
powder cone 
Angle of repose (°) 
TFF0 1.30 2.75 19.07 
TSR01 1.60 3.15 18.41 
TSR02 2.10 3.15 20.49 
TSR03 2.20 3.15 20.81 
TSR04 2.10 3.20 20.17 
TSR05 1.70 3.10 19.20 
TSR06 2.00 3.20 19.82 
TSR07 2.00 3.25 19.52 
TSR08 2.00 3.05 20.80 
TSR09 2.30 2.90 22.93 
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◙    Table (3-2): Evaluations of Lubricated Granules 
Formulation 
Code NO 
Moisture 
Content (%) 
Loose Bulk 
Density (g/ml)
Topped Bulk 
Density (g/ml)
Compressibility 
Index (%) 
Total Porosity 
TFF 0 3.530 0.714 0.910 21.54 21.43 
TSR01 2.114 0.625 0.667 06.29 06.25 
TSR02 3.946 0.500 0.556 10.07 10.00 
TSR03 3.723 0.500 0.526 04.94 05.00 
TSR04 2.472 0.476 0.500 04.80 04.76 
TSR05 2.242 0.476 0.526 09.51 09.52 
TSR06 3.085 0.500 0.556 10.07 10.00 
TSR07 3.368 0.455 0.500 09.00 09.10 
TSR08 2.871 0.556 0.588 05.44 05.55 
TSR09 4.150 0.588 0.625 05.92 05.88 
 
 
◙   Table (3-3): Result of sieve analysis of the formulations (TFF0-TSR01-9). 
Mesh size No Formulation 
Code No 425 µ         (%) 250 µ         (%) 150 µ         (%) 75 µ           (%) Bottom     (%) 
TFF0 14.00 26.75 32.00 21.25 6.00 
TSR01 00.25 01.10 03.54 73.48 21.72 
TSR02 00.53 03.43 17.41 68.07 10.82 
TSR03 04.68 14.29 22.41 51.23 07.39 
TSR04 03.11 17.11 26.67 47.78 05.56 
TSR05 09.00 24.50 25.52 37.02 04.18 
TSR06 07.06 19.70 24.20 43.47 05.57 
TSR07 05.10 18.20 23.70 47.90 05.30 
TSR08 18.93 24.50 18.93 33.53 04.52 
TSR09 18.99 24.05 20.90 31.43 04.64 
 
3.1.4 Physical parameters of un-coated (TFF0 & TSR01-9) tablets: 
The thickness of the tablet ranged from 4.10 to 4.44 (mm). The hardness and percentage 
friability of the tables ranged from 127.80 to 281.80 N and 0.008 to 0.045%, respectively. TFF0 
tablets disintegrated in 13 minutes and 38 second; while, TSR01-9 tablets swell at different rates, 
table (3-4).  
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◙ Table (3-4): Physical Properties of Uncoated Conventional and Hydrophilic matrix Tablets: 
Tablets 
Code NO 
Average 
weight 
)variation (g 
Diameter 
(mm) 
Friability  
 )(% 
Hardness 
(N) 
Thickness 
(mm) 
Disintegration 
(Time) (min) 
TFF0 0.3673 9.00 0.016 127.80 4.10 13min  38sec 
TSR01 0.3683 9.00 0.033 257.60 4.34 Swell 
TSR02 0.3692 9.00 0.008 203.20 4.44 Swell 
TSR03 0.3707 9.00 0.014 228.20 4.39 Swell 
TSR04 0.3695 9.00 0.041 271.00 4.25 Swell 
TSR05 0.3687 9.00 0.024 224.00 4.36 Swell 
TSR06 0.3714 9.00 0.019 264.60 4.42 Swell 
TSR07 0.3688 9.00 0.045 281.80 4.39 Swell 
TSR08 0.3657 9.00 0.027 263.80 4.39 Swell 
TSR09 0.3668 9.00 0.028 255.40 4.32 Swell 
 
The results of average axial and radial swelling rate (mm/sec) ranged from 2.08x10-4 to 
2.88x10-4 and 2.59x10-4 to 3.10x10-4 respectively, see [Tables (3-5) & (3-6)]. 
◙ Table (3-5): Result of axial swelling of the matrix tablets. 
 
Rate of increase in tablet Diameter(mm/hr) 
 Tablets code NO 
0hr 1hr 3hr 5hr 6hr 7hr 
Average Axial Swelling rate 
 (mm/sec)    ×  10-4 
TSR01 9.00 10.61 12.40 14.31 14.95 15.38 2.53 
TSR02 9.00 10.60 13.04 14.42 14.69 15.82 2.71 
TSR03 9.00 10.62 13.10 14.28 15.11 16.26 2.88 
TSR04 9.00 10.58 12.04 13.22 13.82 14.24 2.08 
TSR05 9.00 10.69 12.02 13.68 14.20 15.07 2.41 
TSR06 9.00 10.61 12.20 13.84 14.00 15.03 2.41 
TSR07 9.00 10.85 12.78 14.85 15.31 15.91 2.40 
TSR08 9.00 10.06 12.03 14.52 15.11 15.84 2.71 
TSR09 9.00 10.97 12.86 13.92 14.25 15.77 2.65 
 
◙ Table (3-6): Result of radial swelling of the matrix tablets.  
Rate of increase in tablet thickness (mm/hr) 
 Tablets code NO 
0hr 1hr 3hr 5hr 6hr 7hr 
Average Radial Swelling  rate 
(mm/sec)×  10-4 
TSR01 4.31 6.77 7.58 9.02 10.42 10.85 2.59 
TSR02 4.40 6.59 8.79 10.17 10.81 11.91 2.98 
TSR03 4.38 6.75 8.50 10.58 11.05 12.15 3.10 
TSR04 4.42 6.62 8.63 9.79 10.47 11.27 2.71 
TSR05 4.45 6.61 8.41 9.87 10.23 11.33 2.73 
TSR06 4.46 6.08 8.26 9.81 10.52 11.25 2.71 
TSR07 4.38 6.89 8.82 10.28 11.33 12.40 3.20 
TSR08 4.45 7.12 8.93 10.41 11.10 12.10 3.03 
TSR09 4.36 6.75 8.54 9.91 11.01 12.06 3.05 
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4.1.5 Chemical analysis of un–coated conventional and matrix tablets: 
(a) Folic acid was determined by HPLC method, B.P (2004), using spherisorb ODS 1, HPLC 
column and a detection wavelength of 277nm. Determination of folic acid content in (TFF0 & 
TSR01-9) tablets showed results ranging from 96.77 to 99.13%, see the below HPLC 
chromatograms. 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
1 STD 6.833 10.579 163.4255 
2 STD 10.933 9.697 10.1470 161.0290 162.2273 
3 TFF0 15.116 9.822 161.5920 
4 TFF0 19.233 9.887 9.855 159.1040 160.348 
 
 
 
= 98.84 % 
 
 
 
 
 
 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation
5 TSR01 23.838 9.774 160.3840 
6 TSR01 27.466 9.947 9.861 164.0780 162.231 
 
= 97.81 % 
 
 
 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
7 TSR02 31.566 9.921 164.0860 
8 TSR02 35.666 9.992 9.9565 163.2470 163.6665 
 
= 98.12 % 
 
 
 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
9 TSR03 39.766 9.783 160.9504 
10 TSR03 43.850 9.856 9.8195 163.0109 161.9807 
 
= 96.77 % 
   94 
  
 
 
 
 
 
 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
1 STD 6.433 10.021 161.3207 
2 STD 10.350 9.881 9.951 161.0988 161.2098 
3 TSR04 14.283 9.799 160.9765 
4 TSR04 17.900 9.931 162.0233 
5 TSR04 21.683 9.863 
9.864 
160.8039 
161.2679 
 
 
 
 
= 99.13 % 
 
 
 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
6 TSR05 25.333 9.805 161.4548 
7 TSR05 29.066 9.634 162.0225 
8 TSR05 32.733 9.841 
9.760 
160.3732 
161.2835 
 
 
= 98.08 % 
 
 
 
 
 
 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
1 STD 6.533 10.133 160.2423 
2 STD 10.383 9.957 10.045 160.9305 160.5864 
3 TSR06 14.116 9.994 160.6543 
4 TSR06 17.816 9.847 9.921 160.6874 160.6709 
 
 
 
= 98.77 % 
 
 
 
 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
5 TSR07 21.500 9.939 161.5608 
6 TSR07 25.200 9.891 9.915 160.7849 161.1729 
 
= 98.71 % 
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Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
7 TSR08 28.966 9.685 162.2369 
8 TSR08 33.083 9.856 9.771 160.4512 161.3441 
 
= 97.27 % 
 
 
 
 
 
 
 
 
Peak Heights Peak Area No Component Retention 
Time Value Average Value Average 
Assay: 
Calculation 
9 TSR09 36.400 9.785 161.3651 
10 TSR09 40.000 9.827 9.806 160.8994 161.1323 
 
= 97.62 % 
 
 
These results complied with that specified by the B.P (2004) (90.0 to 115.0%). The HPLC 
chromatograms showed two forms of peaks. For example in HPLC chromatogram of TFF0, the 
first 2 peaks (retention time 6.833 and 10.933 min respectively), correspond to the standard 
sample (STD), the fourth and sixth peaks (Retention time: 10.116 and 19.233 min, respectively) 
correspond to the sample (TFF0). The third and fifth peaks (retention time about 13.50 and 
17.30 min respectively) were thought to be due to the second drug and excipients used in 
formulations of the (TFF0 & TSR01-9). 
(b) Ferrous fumarate of conventional and matrix tablets (TFF0 & TSR01-9) was determined by 
using (i) potentiometric titration method (B.P-2004), and (ii) by spectrophotometric method (2-
8-2-2). The two results were compared by using; (iii) Atomic absorption spectrophotometer 
methods (USP-2004), e.g. TFF0 tablets gave an assay result of 100.88% by potentiometric 
titration method and 102.52% by UV-Spectrophotometer method. Using Atomic absorption 
spectrophometer the result was 103.76%. Tables [(3-7), (3-8), and (3-9)]. 
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◙ Table (3-7): Results for Assay of Ferrous Fumarate of the Conventional and Matrix Tablets      
Tablets 
Code No 
Average weight of 
Tablets (g) 
Weight 
taken (g) 
Volume Consumed 
Burette Reading (ml) 
Assay: Calculation %
TFF0 0.3669 0.5561 18.00 100.88 
TSR01 0.3704 0.5561 17.20 97.32 
TSR02 0.3658 0.5509 17.60 99.28 
TSR03 0.3649 0.5592 17.60 97.56 
TSR04 0.3681 0.5500 17.30 98.36 
TSR05 0.3659 0.5566 17.80 99.40 
TSR06 0.3698 0.5500 17.00 97.10 
TSR07 0.3677 0.5516 17.30 97.97 
TSR08 0.3726 0.5521 17.10 98.04 
TSR09 0.3648 0.5561 17.50 97.52 
 
 
 
 
 
◙ Table (3-8). Results of: U.V analysis of (Fe+2), in the prepared formulations (TFF0 & TSR01-9). 
Formulation 
code No 
Reading absorbance 
(ABS) 
Calculated 
concentration of 
(Fe+2) in (µg/ml) 
% age of (Fe+2) per labeled 
content 
TFF0 2.114 67.455 102.52 
TSR01 2.020 64.394 97.86 
TSR02 2.060 65.697 99.84 
TSR03 2.061 65.729 99.89 
TSR04 2.107 67.227 102.16 
TSR05 2.107 67.227 102.16 
TSR06 2.114 67.455 102.52 
TSR07 2.113 67.423 102.47 
TSR08 2.116 67.520 102.61 
TSR09 2.111 67.358 102.36 
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◙ Table (3-9): Atomic absorption spectrophotometer analysis results of ferrous fumarate in     
conventional and matrix tablets.                                                                                                          
UNK – Average Formulation 
code No 
Absorbance Actual Concentn
Concentn of 
(Fe+2) Eqn (17) 
(%) 
Concentn of ferrous 
fumarate Eqn (16) 
(%) 
TFF0 0.479 4.093 102.33 103.76 
TSR01 0.467   3.9808   99.52 100.92 
TSR02 0.482 4.117 102.93 104.37 
TSR03 0.460 3.920   98.00   99.73 
TSR04 0.472 4.020 100.50 101.91 
TSR05 0.465 3.960   99.00 100.39 
TSR06 0.459 3.910   97.75   99.12 
TSR07 0.469 4.001 100.03 101.43 
TSR08 0.464 3.950   98.75 100.14 
TSR09 0.471 4.012 100.03 101.71 
 
All the above 3-method are comparable, also the contents of ferrous fumarate by applying these 
3- methods were observed within the acceptable limits B.P (90 –105%) and USP (95- 110%) 
 
3.1.6 In vitro Dissolution Studies: 
The dissolution study of the formulations (TFF0 & TSR01-9) was carried out in four different 
dissolution media (a) medium (1) 0.1N HCl for first hour, followed by D.M water at pH 6, (b) 
medium (2) D.M water at pH 6, (c) medium (3) phosphate buffer pH 4.5, and (d) medium (4) 
phosphate buffer pH 6.8 without surfactant. 
The averages of the drug (Fe+2) release (%) of (n = 3 tablets) from each formulations were 
summarized in the below tables, and the corresponding release profiles are shown in the figures 
attached for it. 
 
◙ Table (3-10). Results of dissolution studies of (TFF0) in dissolution medium: 
0.1N HCl for the first hour 
 TFF0 
Time (hrs) Absorbance (ABS) Concentration (µg/ml) Drug Release (%) 
0.25 0.979 62.04 94.29 
0.50 1.074 68.08 103.46 
1 1.087 68.90 104.71 
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Fig (3-2): The in vitro release profile of drug (Fe+2) from (TFF0) conventional tablet, in 0.1N HCl   at pH 
1.2 for 1hr. (n=3) 
 
In dissolution medium (1): Conventional tablets TFF0 released 104.71% of (Fe+2) by the end 
of the first hour. Matrix tablets TSR0I, TSR02, and TSR03 released 60.7%, 38.79%, and 
46.51% of the drug (Fe+2) by the end of the first hour; and 41.65%, 43.69% and 50.56% by the 
end of the 16th hours, respectively. Matrix tablets TSR04, TSR05, and TSR06 released 40.63%, 
43.23% and 44.68% of the drug (Fe+2) by the end of the first hour, and 23.72%, 36.30%, and 
48.68% at the end of the 16th hours, respectively. Matrix tablet, TSR07, TSR08, and TSR09 
released 16.79%, 27.79% and 27.02% of iron (Fe+2) by the end of first hour; and 51.86%, 
57.44% and 57.79% by the end of the 16th hours, respectively. 
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◙ Table (3-11). Results of dissolution studies of SR- Tablets (TSR01, TSR02, & TSR03),   
dissolution medium: 0.1N HCl for the first hour, and then D.M water pH                          
 TSR01 TSR02 TSR03 
Time 
(hrs)  (ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
1 0.631 39.94 60.70 0.404 25.53 38.79 0.484 30.61 46.51 
2 0.075 4.63 7.04 0.030 1.77 2.70 0.044 2.66 4.05 
4 0.081 5.01 7.62 0.047 2.85 4.34 0.049 2.98 4.53 
6 0.109 6.79 10.32 0.093 5.77 8.78 0.123 7.68 11.67 
8 0.223 14.03 21.32 0.215 13.52 20.55 0.263 16.57 25.18 
10 0.365 23.05 35.03 0.350 22.10 33.59 0.451 28.51 43.33 
12 0.392 24.76 37.63 0.384 24.26 36.86 0.487 30.80 46.80 
14 0.413 26.10 39.64 0.426 26.84 40.79 0.510 32.23 48.97 
16 0.434 27.41 41.65 0.455 28.75 43.69 0.529 33.27 50.56 
 
◙ Table (3-12). Results of dissolution studies of SR- Tablets (TSR04, TSR05, & TSR06), 
dissolution medium: 0.1N HCl for the first hour, and then D.M water pH6  
 TSR04 TSR05 TSR06 
Time 
(hrs)  (ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
1 0.423 26.73 40.63 4.450 28.45 43.23 0.465 29.40 44.68 
2 0.003 0.06 0.09 0.039 2.35 3.56 0.018 1.01 1.54 
4 0.001 0.06 0.09 0.012 0.63 0.96 0.008 0.38 0.57 
6 0.027 0.135 0.21 0.001 0.06 0.1 0.115 7.17 10.90 
8 0.055 3.36 5.11 0.044 2.66 4.05 0.308 19.43 29.53 
10 0.129 8.06 12.25 0.283 17.84 27.11 0.396 25.02 38.02 
12 0.167 10.47 15.92 0.307 19.37 29.44 0.437 27.62 41.98 
14 0.202 12.60 19.18 0.361 22.76 34.60 0.478 30.20 45.83 
16 0.249 15.60 23.72 0.378 23.90 36.30 0.508 32.03 48.68 
 
◙ Table (3-13). Results of dissolution studies of SR- Tablets (TSR07, TSR08, & TSR09), 
dissolution medium: 0.1N HCl for the first hour, and then D.M water pH6                          
 TSR07 TSR08 TSR09 
Time 
(hrs)  (ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
1 0.176 11.05 16.79 0.290 18.29 27.79 0.282 17.78 27.02 
2 0.046 2.79 4.24 0.043 2.60 3.95 0.026 1.52 2.31 
4 0.087 5.39 8.20 0.096 5.96 9.07 0.089 5.52 8.39 
6 0.178 11.17 16.98 0.260 16.38 24.89 0.258 16.25 24.70 
8 0.299 18.86 28.66 0.373 23.56 35.80 0.411 25.97 39.47 
10 0.416 26.29 39.95 0.534 33.78 51.34 0.544 34.42 52.31 
12 0.454 28.70 43.62 0.561 35.50 53.95 0.573 36.26 55.10 
14 0.493 31.00 47.26 0.584 36.90 56.10 0.589 37.18 56.50 
16 0.540 34.09 51.86 0.598 37.83 57.44 0.602 38.03 57.79 
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Fig (3-3): The in vitro release profiles of drug (Fe+2) from (TSR01-9) matrix tablets, in 
dissolution media (1), 0.1N HCl for the first hr and then D.M water at pH 6.  (n=3)    
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In dissolution medium (2): The in vitro drug release characteristics were studied in D.M 
Water at pH 6 for a period of 16 hours. It was observed that in the first hour the conventional 
tablets (TFF0) released 20.27%, after 6 hours, the drug release was maximum (106.84%). At 
the end of 16th hours of study, the results of (Fe+2) release of the matrix tablets (TSR01 to 
TSR09) in D.M water by the end of the first hour ranged from 0.28% to 2.1%. At the end of the 
16th hours the drug release (%) was observed differently in different TSR-formulation. The 
tables and figures below show the results and drug release profiles:  
◙ Table (3-14).Results of dissolution studies of (TFF0) dissolution medium: D.M water pH 6     
 TFF0 
Time (hrs) Absorbance (ABS) Concentration (µg/ml) Drug Release (%) 
1 0.211 13.26 20.17 
2 0.414 26.16 39.76 
4 0.832 52.71 80.10 
6 1.109 70.30 106.84 
8 1.112 70.49 107.13 
10 1.112 70.49 107.13 
12 1.113 70.55 107.22 
14 1.110 70.36 106.93 
16 1.112 70.49 107.13 
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Fig (3-4): The in vitro release profile of drug (Fe+2) from (TFF0) conventional tablet in D.M water at pH 6 
for 16 hrs. (n=3)                                                                                                                                   
102 
  
 
◙ Table (3-15). Results of dissolution studies of SR- Tablets (TSR01, TSR02, & TSR03) dissolution 
medium: D.M water pH 6.                                                                                            
 TSR02 TSR02 TSR03 
Time 
(hrs)  (ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
1 0.005 0.19 0.28 0.010 0.50 0.77 0.016 0.88 1.34 
2 0.017 0.95 1.44 0.030 1.77 2.70 0.046 2.79 4.24 
4 0.143 8.95 13.60 0.123 7.68 11.67 0.178 11.17 16.98 
6 0.245 15.43 23.45 0.284 17.90 27.21 0.337 21.27 32.33 
8 0.281 17.71 26.92 0.395 24.95 37.92 0.455 28.76 43.72 
10 0.538 34.04 51.73 0.633 40.07 60.90 0.591 37.40 56.84 
12 0.651 41.21 62.63 0.778 49.28 74.89 0.866 54.87 83.38 
14 0.902 57.15 86.86 0.891 56.45 85.80 0.947 60.01 91.20 
16 0.978 61.98 94.19 1.000 63.38 96.32 1.075 68.14 103.55 
 
 
◙ Table (3-16). Results of dissolution studies of SR- Tablets (TSR04, TSR05, & TSR06) dissolution 
medium:  D.M water pH 6.                                                                                             
 TSR04 TSR05 TSR06 
Time 
(hrs)  (ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
1 0.012 0.63 0.96 0.007 0.313 0.47 0.024 1.39 2.12 
2 0.049 2.98 4.53 0.022 1.27 1.92 0.029 1.71 2.60 
4 0.180 11.30 17.17 0.207 13.01 19.78 0.150 9.39 14.28 
6 0.330 20.83 31.65 0.330 20.83 31.65 0.296 18.67 28.37 
8 0.522 33.02 50.18 0.332 20.95 31.84 0.434 27.43 41.69 
10 0.755 47.82 72.67 0.718 45.46 69.10 0.721 45.66 69.39 
12 0.957 60.65 92.17 0.921 58.36 88.69 0.868 54.99 83.58 
14 0.549 34.73 52.79 0.987 62.55 95.06 1.009 63.65 97.19 
16 0.625 39.65 60.12 1.058 67.06 101.91 1.051 66.62 101.24 
 
 
◙ Table (3-17). Results of dissolution studies of SR- Tablets (TSR07, TSR08, & TSR09)          
dissolution medium: D.M water pH 6.                                                                                            
 TSR07 TSR08 TSR09 
Time 
(hrs)  (ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
(ABS) (µg/ml) 
Drug 
Release 
(%) 
1 0.008 0.38 0.573 0.22 1.27 1.92 0.014 0.76 1.15 
2 0.033 1.96 2.99 0.32 1.90 2.89 0.054 3.30 5.01 
4 0.155 9.71 14.76 .0142 8.89 13.51 0.226 14.22 21.61 
6 0.289 18.22 27.69 0.275 17.33 26.34 0.420 26.54 40.34 
8 0.425 26.86 40.82 0.433 27.37 41.59 0.594 37.59 57.13 
10 0.540 34.16 51.92 0.580 36.70 55.78 0.828 52.45 79.72 
12 0.753 47.69 72.48 0.776 49.15 74.69 1.043 66.11 100.47 
14 0.814 51.56 78.36 0.897 56.83 86.38 1.121 71.06 102.30 
16 0.978 61.98 94.19 0.919 58.23 88.50 1.062 67.31 107.30 
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Fig (3-5): The in vitro release profiles of drug (Fe+2) from (TSR01-9) matrix tablets, in          
dissolution media (2), in D.M water at pH 6.  (n=3)                                                                     
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In dissolution medium (3): conventional tablets (TFF0), released 6.17% of iron (Fe+2) at the 
end of the first hour. After 3 hours the release was maximum (35.41%), and after that the 
release decreased gradually. At the end of 15 hours the drug release was 18.81%. 
 
◙ Table (3-18). Results of dissolution studies of (TFF0) in dissolution medium (3): phosphate buffer at 
pH=4.5: 
 TFF0 
Time (hrs) Absorbance (ABS) Concentration (µg/ml) Drug Release (%) 
1  0.066 4.06 6.17 
3 0.369 23.30 35.41 
5 0.333 21.02 31.94 
7 0.298 18.79 28.56 
9 0.224 14.09 21.42 
11 0.209 13.14 19.97 
13 0.216 13.59 20.65 
15 0.197 13.38 18.81 
 
0
5
10
15
20
25
30
35
40
0 100 200 300 400 500 600 700 800 900 1000
Time (min)
D
ru
g 
(F
e+
2 )
 R
el
ea
se
 (%
)
TFF0
Fig (3-6): The in vitro release profile of drug (Fe+2) from (TFF0) conventional tablet in 
dissolution media (3), phosphate buffer at pH 4.5. (n=3) 
 
 In this medium at the end of the first hour, the results of drug (Fe+2) release of the matrix tablet 
ranged from 1.06% to 2.50%. After that the matrix tablet, slowly released the drug (Fe+2), and 
after 15 hours the results of drug (Fe+2) release ranged from 10.90% to 50.66%, the tables and 
figure below show the results and drug release profiles:  
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◙ Table (3-19). Results of dissolution studies of SR- Tablets (TSR01, TSR02, & TSR03)         
dissolution medium: phosphate buffer pH 4.5    
 TSR01 TSR02 TSR03 
Time 
(hrs) (ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release  
(%) 
1 0.013 0.69 1.06 0.016 0.88 1.34 0.026 1.52 2.31 
3 0.029 1.7 2.60 0.023 1.33 2.02 0.040 2.41 3.66 
5 0.100 6.22 9.45 0.098 6.09 9.26 0.203 12.76 19.39 
7 0.224 14.09 21.42 0.214 13.46 20.45 0.328 20.70 31.46 
9 0.299 18.86 28.66 0.257 16.19 24.61 0.453 28.64 43.52 
11 0.325 20.51 31.17 0.293 18.48 28.08 0.476 30.10 45.75 
13 0.341 21.52 32.71 0.237 20.64 31.36 0.492 31.11 47.29 
15 0.389 24.57 37.35 0.385 24.32 36.96 0.527 33.34 50.66 
 
 
◙Table (3-20): Results of dissolution studies of SR- Tablets (TSR04, TSR05, & TSR06)    
dissolution medium: phosphate buffer pH 4.5 
 TSR04 TSR05 TSR06 
Time 
(hrs) (ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS)  (µg/ml) 
Drug 
Release 
 (%) 
1 0.028 1.65 2.50 0.028 1.65 2.50 0.016 0.88 1.34 
3 0.058 3.55 5.40 0.054 3.30 5.01 0.055 3.36 5.11 
5 0.202 12.70 19.30 0.146 9.14 13.89 0.182 11.43 17.37 
7 0.326 20.57 31.26 0.254 16.00 24.32 0.243 15.30 23.25 
9 0.375 23.68 35.99 0.295 18.60 28.27 0.214 13.46 20.45 
11 0.402 25.40 38.60 0.332 20.95 31.84 0.229 14.41 21.90 
13 0.429 27.11 41.21 0.389 24.57 37.35 0.198 12.44 18.91 
15 0.478 30.23 45.94 0.436 27.56 41.88 0.180 11.68 17.75 
 
 
◙ Table (3-21). Results of dissolution studies of SR-Tablets (TSR07, TSR08, & TSR09)     
dissolution medium: phosphate buffer pH 4.5 
 TSR07 TSR08 TSR09 
Time 
(hrs) (ABS)  (µg/ml) 
Drug 
Release 
(%) 
(ABS)  (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release 
 (%) 
1 0.015 0.82 1.35 0.017 0.95 1.44 0.018 1.01 1.54 
3 0.045 2. 73 4.14 0.037 2.22 3.37 0.029 1.71 2.60 
5 0.129 8.06 12.25 0.067 4.12 6.27 0.078 4.82 7.33 
7 0.227 14.28 21.71 0.146 9.14 13.89 0.148 9.27 14.08 
9 0.223 14.03 21.32 0.139 8.70 13.22 0.187 11.74 17.85 
11 0.220 13.84 21.03 0.153 9.59 14.57 0.201 12.63 19.20 
13 0.187 11.74 17.85 0.121 7.55 11.48 0.237 14.92 22.67 
15 0.193 12.13 18.43 0.115 7.17 10.90 0.311 19.62 29.82 
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Fig 
(3-7): The in vitro release profiles of drug (Fe+2) from (TSR01-9) matrix tablets, in dissolution 
media (3), phosphate buffer at pH 4.5. (n=3) 
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In dissolution medium (4): Both conventional (TFF0) and matrix tablets, (TSR01-9) were 
tested for dissolution in the above media. In the case of conventional tablets the results of drug 
(Fe+2) release at end of the first hour was 0.39%. After 15 hours the drug release reached 1.34%. 
◙ Table (3-22). Results of dissolution studies of (TFF0) dissolution medium: Simulated 
Intestinal Fluid phosphate buffer pH 6.8 
 TFF0 
Time (hrs) Absorbance (ABS) Concentration (µg/ml) Drug Release (%) 
1 0.006 0.25 0.39 
3 0.001 0.07 0.10 
5 0.001 0.07 0.10 
7 0.002 0.004 0.006 
9 0.007 0.31 0.48 
11 0.008 0.37 0.57 
13 0.011 0.57 0.86 
15 0.016 0.88 1.34 
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Fig (3-8): The in vitro release profile of drug (Fe+2) from (TFF0) Conventional tablet in 
dissolution media (4), Simulated Intestinal Fluid phosphate buffer pH 6.8. (n=3)   
                   
In the case of the matrix tablets the results of drug (Fe+2) release, at the end of the first hour 
ranged from 0.006% to 0.19%. After 15 hours the results of drug release (%) ranged from 
1.06% to 2.02%, the tables and figures below show the results and drug release profiles: 
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◙ Table (3-23). Results of dissolution studies of SR- Tablets (TSR01, TSR02, & TSR03) 
dissolution medium: Simulated Intestinal Fluid phosphate buffer pH 6.8                          
 TSR01 TSR02 TSR03 
Time 
(hrs) (ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release  
(%) 
1 0.004 0.12 0.187 0.001 0.07 0.1 0.001 0.02 0.10 
3 0.003 0.059 0.09 0.003 0.059 0.09 0.003 0.059 0.09 
5 0.004 0.12 0.187 0.002 0 .004 0.0006 0.009 0.44 0.67 
7 0.003 0.059 0.09 0.008 0.37 0.57 0.011 0.57 0.86 
9 0.009 0.44 0.067 0.009 0.49 0.67 0.016 0.88 1.34 
11 0.011 0.57 0.86 0.012 0.63 0.96 0.019 1.08 1.63 
13 0.016 0.88 1.34 0.014 0.76 1.15 0.022 1.27 1.92 
15 0.018 1.01 1.54 0.017 0.95 1.44 0.23 1.33 2.02 
 
◙ Table (3-24). Results of dissolution studies of SR- Tablets (TSR04, TSR05, & TSR06) 
dissolution medium: Simulated Intestinal Fluid phosphate buffer pH 6.8                          
 TSR04 TSR05 TSR06 
Time 
(hrs) (ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release  
(%) 
1 0.002 0.004 0.006 0.003 0.059 0.09 0.003 0.059 0.09 
3 0.001 0.068 0.01 0.003 0.059 0.09 0.007 0.31 0.48 
5 0.001 0.068 0.01 0.001 0.068 0.10 0.004 0.124 0.19 
7 0.009 0.44 0.67 0.007 0.31 0.48 0.008 0.38 0.57 
9 0.011 0.57 0.86 0.012 0.63 0.96 0.012 0.63 0.96 
11 0.017 0.95 1.44 0.018 1.01 1.54 0.015 0.82 1.25 
13 0.019 1.07 1.63 0.019 1.07 1.63 0.019 1.08 1.63 
15 0.021 1.20 1.83 0.022 1.27 1.92 0.020 1.14 1.73 
 
◙ Table (3-25). Results of dissolution studies of SR- Tablets (TSR07, TSR08, & TSR09) 
dissolution medium: Simulated Intestinal Fluid phosphate buffer pH 6.8                          
 TSR07 TSR08 TSR09 
Time 
(hrs) (ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release 
 (%) 
(ABS) (µg/ml) 
Drug 
Release  
(%) 
1 0.004 0.12 0.19 0.003 0.059 0.09 0.003 0.059 0.09 
3 0.002 0.004 0.006 0.005 0.19 0.28 0.005 0.19 0.28 
5 0.003 0.059 0.09 0.006 0.25 0.38 0.005 0.19 0.28 
7 0.006 0.25 0.38 0.007 0.31 0.48 0.005 0.19 0.28 
9 0.009 0.44 0.62 0.008 0.38 0.57 0.007 0.31 0.48 
11 0.008 0.38 0.57 0.009 0.44 0.67 0.009 0.44 0.67 
13 0.011 0.57 0.86 0.013 0.69 1.06 0.011 0.57 0.86 
15 0.013 0.69 1.06 0.015 0.82 1.20 0.014 0.76 1.15 
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    Fig (3-9): The in vitro release profiles of drug (Fe+2) from (TSR01-9) matrix tablets, in dissolution 
media (4), Simulated Intestinal Fluid phosphate buffer pH 6.8.  (n=3)                                                 
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3.1.7 Kinetic analysis of Dissolution Results:  
4 kinetic equations  (zero order model, first order model, Higuchi’s model, and Kortsmeyer et al 
model) were applied to the dissolution results obtained from different types of tablets, (TFF0 
and TSR01-9) which were tried in different dissolution media,  as summarized in[tables (3-26), 
(3-27), (3-28),and (3-29)].                                                         
                                               
◙ Table (3-26): Summary of kinetic values (R2) when the drug (Fe+2) release data of the 
formulations (TFF0 & TSR1-9) were plotted according to (Zero-order, First-order, Higuchi’s, and 
Korsmeyerۥ s equations), in dissolution medium (1). 
kinetic Zero-order 
plots 
First-order 
plots 
Higuchi's 
plots 
     Korsmeyer's 
     plots  
Tablets 
code No 
Regression 
coefficient 
(R2) 
Regression 
coefficient 
(R2) 
Regression 
coefficient 
(R2) 
 
Slope 
(n) 
Regression 
Coefficient 
(R2) 
TFF0 -  - - - - 
TSR01 0.9375 0.7681 0.8394 0.52 0.8182 
TSR02 0.9157 0.7989 0.8065 0.64 0.7941 
TSR03 0.9199 0.7736 0.8122 0.65 0.7924 
TSR04 0.8254 0.8190 0.6930 0.33 0.5905 
TSR05 0.8342 0.8017 0.7059 0.46 0.6349 
TSR06 0.9153 0.7767 0.8044 0.65 0.7658 
TSR07 0.9421 0.8160 0.8441 1.02 0.9059 
TSR08 0.9492 0.7836 0.8548 0.94 0.8913 
TSR09 0.9485 0.7759 0.8533 0.96 0.8846 
 
 
◙ Table (3-27): Summary of kinetic values (R2) when the drug (Fe+2) release data of the 
formulations (TFF0 & TSR1-9) were plotted according to (Zero-order, First-order, Higuchi's, and 
Korsmeyerۥ s equations), in dissolution medium (2). 
kinetic Zero-order 
plots 
First-order 
plots 
Higuchi's 
plots 
     Korsmeyer's 
     plots  
Tablets 
code No 
Regression 
coefficient 
(R2) 
Regression 
coefficient 
(R2) 
Regression 
coefficient 
(R2) 
 
Slope 
(n) 
Regression 
Coefficient 
(R2) 
TFF0 0.9984 0.0123 0.9591 1.31 0.9973 
TSR01 0.9029 0.7665 0.7919 2.58 0.9964 
TSR02 0.9189 0.7467 0.8112 2.28 0.9994 
TSR03 0.9278 0.7268 0.8249 2.09 0.9997 
TSR04 0.9578 0.7581 0.8721 2.18 0.9977 
TSR05 0.9205 0.7025 0.8148 2.49 0.9953 
TSR06 0.9199 0.6966 0.8124 2.01 0.9891 
TSR07 0.9283 0.7592 0.8253 2.33 0.9987 
TSR08 0.9251 0.7540 0.8202 1.99 0.9928 
TSR09 0.9423 0.6408 0.8456 2.21 0.9993 
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◙ Table (3-28): Summary of kinetic values (R2) when the drug (Fe+2) release data of the 
formulations (TFF0 & TSR1-9) were plotted according to (Zero-order, First-order, Higuchi’s, and 
Korsmeyerۥ s equations), in dissolution medium (3). 
kinetic Zero-order 
plots 
First-order 
plots 
Higuchi's 
plots 
     Korsmeyer's 
     plots  
Tablets 
code No 
Regression 
coefficient 
(R2) 
Regression 
coefficient 
(R2) 
Regression 
coefficient 
(R2) 
 
Slope 
(n) 
Regression 
Coefficient 
(R2) 
TFF0 0.9850 0.9507 0.9967 1.23 0.9668 
TSR01 0.9451 0.8919 0.8438 1.99 0.9729 
TSR02 0.9423 0.8925 0.8397 1.89 0.9588 
TSR03 0.9563 0.8708 0.8617 1.86 0.9653 
TSR04 0.9653 0.8851 0.8772 1.75 0.9789 
TSR05 0.9546 0.8955 0.8596 1.67 0.9774 
TSR06 0.9895 0.9125 0.9337 1.76 0.9888 
TSR07 0.9828 0.9083 0.9160 1.75 0.9873 
TSR08 0.9802 0.9141 0.9110 1.55 0.9835 
TSR09 0.9418 0.9045 0.8403 1.68 0.9678 
 
 
 
 
◙ Table (3-29): Summary of kinetic values (R2) when the drug (Fe+2) release data of the 
formulations (TFF0 & TSR1-9) were plotted according to (Zero-order, First-order, Higuchi’s, and 
Korsmeyerۥ s equations), in dissolution medium (4). 
kinetic Zero-order 
plots 
First-order 
plots 
Higuchi's 
plots 
     Korsmeyer's 
     plots  
Tablets 
code No 
Regression 
coefficient 
(R2) 
Regression 
coefficient 
(R2) 
Regression 
coefficient 
(R2) 
 
Slope 
(n) 
Regression 
Coefficient 
(R2) 
TFF0 0.8141 0.9166 0.6830 0.79 0.7213 
TSR01 0.8429 0.9166 0.6381 1.09 0.7785 
TSR02 0.8913 0.9166 0.7663 1.53 0.8523 
TSR03 0.9352 0.9168 0.8299 1.79 0.9455 
TSR04 0.8893 0.9166 0.7457 2.91 0.8659 
TSR05 0.8738 0.9166 0.7480 1.69 0.8863 
TSR06 0.9169 0.9168 0.8098 1.56 0.9801 
TSR07 0.9006 0.9166 0.7770 1.19 0.8033 
TSR08 0.9430 0.9166 0.8507 1.45 0.9944 
TSR09 0.9260 0.9166 0.8237 1.37 0.9863 
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1. Zero order Kinetic models: 
Applying the zero order models, the following was observed:  
(a) With dissolution medium (1): In the case of TFF0 tablets, it was very difficult to calculate 
linear regression, as at the end of the first hour, the drug was released totally in acidic media 
(0.1N HCl). With matrix tablets (TSR01 to TSR09), the linear regression ranged from R2: 
0.8254 to 0.9492. 
(b) With dissolution medium (2): Conventional tablet, TFF0 gave a linear regression of (R2: 
0.9984); whereas in the matrix tablets (TSR01 – TSR09) the linear regression ranged from 
R2:0.9029 to 0.9984. 
(c) With dissolution medium (3): Conventional tablets TFF0 linear regression was (R2:0.9850); 
whereas matrix tablets (TSR01- TSR09) linear regression ranged from R2:0.9418 to 0.9895. 
(d) With dissolution medium (4): Conventional tablets TFF0 linear regression was (R2: 0.8141), 
and matrix tablets, (TSR01 - TSR09) ranged from R2: 0.8429 to 0.9430. 
 
2. First-order Kinetic model: 
(a) With dissolution medium (1): For the results for the conventional tablets (TFF0), linear 
regression was not calculated. For matrix tablets (TSR01 – TSR09) linear regression ranged 
from R2:0.7681 to 0.8190. 
(b) With dissolution medium (2): Conventional tablet results (TFF0) gave linear regression of 
(R2: 0.0123), and the matrix tablets, (TSR01-TSR09) gave linear regression ranging from R2: 
0.6408 to 0.7592. 
(c) With dissolution medium (3): Results of conventional tablets, (TFF0) had linear regression 
of (R2:0.9507); whereas in the matrix tablets (TSR01–TSR09) it ranged from   R2: 0.8708 to 
0.9141. 
(d) With dissolution medium (4): Conventional tablets (TFF0) had a linear regression of (R2: 
0.9166); where as matrix tablets (TSR01–TSR09) showed a linear regression ranging from R2: 
0.9166 to 0.9168. 
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3. Higuchi’s Kinetic model: 
(a) With dissolution medium (1): Results of linear regression for conventional tablets (TFF0) 
was not calculated, and for matrix tablets (TSR01–TSR09) ranged from R2: 0.6930 to 0.8548. 
(b) With dissolution medium (2): Results of linear regression for (TFF0) was (R2: 0.9591), and 
for matrix (TSR01–TSR09) ranged from R2: 0.7919 to 0.8721. 
(c) With dissolution medium (3): Results, regression for (TFF0) tablets, was (R2: 0.9967), and 
for matrix (TSR01–TSR09) ranged from R2: 0.8397 to 0.9337. 
(d) With dissolution medium (4): Results for (TFF0) tablets, was (R2: 0.6830), and for the 
matrix tablet, (TSR01 – TSR09) it was R2: 0.6381 to 0.8507. 
 
 
4. Korsmeyer et al kinetic model: 
(a) With dissolution medium (1): Result of linear regression of the conventional tablet, (TFF0) 
was not calculated, and for matrix tablets (TSR01–TSR09) ranged from R2: 0.5905 to 0.9059. 
(b) With dissolution medium (2): Result of linear regression of the conventional tablet, (TFF0) 
was (R2: 0.9973); whereas for the matrix tablets, (TSR01 – TSR09) ranged from R2: 0.9891 to 
0.9997. 
(c) With dissolution medium (3): Result of linear regression of the conventional tablet, (TFF0) 
was (R2: 0.9668), and for the matrix tablets, (TSR01 – TSR09) ranged from R2: 0.9588 to 
0.9888. 
(d) With dissolution medium (4): Linear regression of the conventional tablet, (TFF0) was (R2: 
0.7213), and for the matrix tablets, (TSR01 – TSR09) ranged from R2: 0.7785 to 0.9944. 
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3.1.8 Results of Drug (Fe+2) release mechanism: 
The kinetic parameter values (n: release exponent, k: kinetic rate constant, and MDT: mean 
dissolution time) of drug (Fe+2) release of the formulations (TFF0 and TSR01-9) were calculated 
in different dissolution media. In addition, different mechanism like, fickian, non–fickian, and 
super case II, were observed. 
 
◙ Table (3-30): Summary of kinetic parameters n: release exponent, k: kinetic rate       
constant, and MDT: mean dissolution time, when the drug (Fe+2) release data in         
dissolution medium (1), were plotted according to Korsmeyer’s equation.                  
Dissolution medium (1) Formulation 
Code No n k MDT mechanism 
TFF0 - - - - 
TSR01 0.52 5.58 0.0125 Non- Fickian (Anomalous) 
TSR02 0.64 1.93 0.1397 Non- Fickian (Anomalous) 
TSR03 0.65 2.18 0.1188 Non- Fickian (Anomalous) 
TSR04 0.33 7.91 4.71X10-4 Fickian (Case І) 
TSR05 0.46 4.79 0.011 Fickian (Case І) 
TSR06 0.65 1.98 0.138 Non- Fickian (Anomalous) 
TSR07 1.02 0.17 2.87 Non- Fickian (Anomalous) 
TSR08 0.94 0.33 1.36 Non- Fickian (Anomalous) 
TSR09 0.96 0.324 1.58 Non- Fickian (Anomalous) 
 
 
 
 
◙ Table (3-31) Summary of kinetic parameters n: release exponent, k: kinetic rate 
constant, and MDT: mean dissolution time, when the drug (Fe+2) release data in 
dissolution medium (2), were plotted according to Korsmeyer’s equation.                   
Dissolution medium (2) Formulation 
Code No n k MDT mechanism 
TFF0 1.31 0.11 3.06 Non- Fickian (Super case II) 
TSR01 2.58 8.13 X10-6 67.70 Non- Fickian (Super case II) 
TSR02 2.28 6.31 X10-5 48.32 Non- Fickian (Super case II) 
TSR03 2.09 2.45 X10-4 36.13 Non- Fickian (Super case II) 
TSR04 2.18 1.41 X10-4 40.04 Non- Fickian (Super case II) 
TSR05 2.49 1.86 X10-5 56.65 Non- Fickian (Super case II) 
TSR06 2.01 3.89 X10-4 33.20 Non- Fickian (Super case II) 
TSR07 2.33 4.68 X10-5 50.49 Non- Fickian (Super case II) 
TSR08 1.99 4.07 X10-4 33.64 Non- Fickian (Super case II) 
TSR09 2.21 1.48 X10-4 37.22 Non- Fickian (Super case II) 
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◙ Table (3-32) Summary of kinetic parameters n: release exponent, k: kinetic rate 
constant, and MDT: mean dissolution time, when the drug (Fe+2) release data in 
dissolution medium (3), were plotted according to Korsmeyer’s equation.                   
Dissolution medium (3) Formulation 
Code No n k MDT mechanism 
TFF0 1.23 0.054 5.92 Non- Fickian (Super case II) 
TSR01 1.99 2.09 X10-4 47.03 Non- Fickian (Super case II) 
TSR02 1.89 3.63 X10-4 43.22 Non- Fickian (Super case II) 
TSR03 1.86 7.24 X10-4 31.73 Non- Fickian (Super case II) 
TSR04 1.75 1.41 X10-3 27.08 Non- Fickian (Super case II) 
TSR05 1.67 1.95 X10-3 26.24 Non- Fickian (Super case II) 
TSR06 1.76 9.12 X10-4 34.03 Non- Fickian (Super case II) 
TSR07 1.75 8.71 X10-4 35.67 Non- Fickian (Super case II) 
TSR08 1.55 2.00 X10-3 33.50 Non- Fickian (Super case II) 
TSR09 1.68 1.10 X10-4 36.16 Non- Fickian (Super case II) 
 
 
 
 
◙ Table (3-33) Summary of kinetic parameters n: release exponent, k: kinetic rate 
constant, and MDT: mean dissolution time, when the drug (Fe+2) release data in 
dissolution medium (4), were plotted according to Korsmeyer’s equation.               
Dissolution medium (4) Formulation 
Code No n k MDT mechanism 
TFF0 0.79 9.55 X10-3 159.12 Non- Fickian (Anomalous)   
TSR01 1.09 1.26 X10-3 238.50 Non- Fickian (Super case II) 
TSR02 1.53 9.33 X10-5 260.40 Non- Fickian (Super case II) 
TSR03 1.79 3.89 X10-5 186.62 Non- Fickian (Super case II) 
TSR04 2.91 1.17 X10-8 395.75 Non- Fickian (Super case II) 
TSR05 1.69 4.27 X10-5 241.92 Non- Fickian (Super case II) 
TSR06 1.56 1.35 X10-4 184.26 Non- Fickian (Super case II) 
TSR07 1.19 7.08 X10-4 241.06 Non- Fickian (Super case II) 
TSR08 1.45 2.04 X10-4 207.63 Non- Fickian (Super case II) 
TSR09 1.37 2.88 X10-4 222.00 Non- Fickian (Super case II) 
 
(a) Dissolution medium (1): For conventional tablet, (TFF0) it was difficult to calculate the 
kinetic parameters. In case of the matrix tablets (TSR01- TSR09) the value of n ranged from 
0.33 to 1.02, k ranged from 0.17 to 7.91, whereas MDT ranged from 0.000471 to 2.87. See 
(table 3-30). 
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(b)  Dissolution medium (2): with conventional tablet, (TFF0), the values of n, k, and MDT 
were 1.31, 0.11, and 3.06 respectively. For the matrix tablets (TSR01- TSR09), n: ranged from 
1.99 to 2.58, k ranged from 8.13×10-6 to 4.07×10-4, and MDT ranged from 33.20 to 67.70. See 
(table 3-31). 
(c) Dissolution medium (3): The conventional tablet (TFF0) had the values of n, k, and MDT 
as 1.23, 0.054, and 5.92 respectively. The matrix tablets (TSR01 - TSR09) had the following 
observations: n: ranged from 1.55 to 1.99, k: ranged from 1.10 × 10-4 to 2.00 × 10-3, and MDT: 
ranged from 26.24 to 47.03. See (table 3-32). 
(d) Dissolution medium (4): The conventional tablet (TFF0) had the values of n, k, and MDT 
as 0.79, 9.55× 10-3, and 159.12 respectively. In case of matrix tablets (TSR01 - TSR09) the 
kinetic parameter values ranged from, n: 1.09 to 2.91, k: 1.17 × 10-8 to 1.26 × 10-3, and MDT: 
184.26 to 395.75. See (table 3-33). 
 
3.1.9 Results of the effect of various surfactants on Drug (Fe+2) release into 
media simulated to intestinal fluid:  
(a) Anionic surfactant (0.5% w/v sodium lauryl sulfate): (n=2 tablets). The drug (Fe+2) released 
from (TFF0) tablets after 1 hr was 0.48% and after 15 hrs was 3.56% table (2-45). With the 
above condition the matrix tablets (TSR01–TSR09) were also tried and the drug release (Fe+2) 
was estimated after 1 hr through 15 hrs, as shown in figures below: 
 (b) Non-ionic surfactant (0.5% w/v Tween 80): (n=2 tablets) for the conventional tablets 
(TFF0) and all the matrix tablets (TSR01–TSR09), the drug (Fe+2) release (%) after 1 hr and 15 
hrs were practically similar. There was no significant increase in drug release. 
(c) Cationic surfactant (0.5% w/v Cetrimide agar): (n=2 tablets) 
For the conventional tablets (TFF0), the drug (Fe+2) release after 1hr was 4.72% and after 15 hrs 
the release was 17.03%. With matrix tablets (TSR01–TSR09), the same phenomena were 
observed as with conventional tablet, as shown in figures below: 
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Fig (3-10): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from conventional 
tablet TFF0. (n=2) 
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Fig (3-11): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR01. (n=2)                                                                                                                  
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Fig (3-12): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR02. (n=2)                                                                                                                  
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Fig (3-13): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR03. (n=2) 
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Fig (3-14): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR04. (n=2) 
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Fig (3-15): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR05. (n=2) 
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Fig (3-16): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR06. (n=2)                                                                                                                  
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Fig (3-17): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR07. (n=2) 
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Fig (3-18): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR08. (n=2)                                                                                                                  
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Fig (3-19): Effect of addition of 0.5% w/v of anionic, nonionic and cationic surfactant respectively to 
dissolution medium (4); (phosphate buffer pH 6.8), on drug (Fe+2) release profile from hydrophilic 
matrix TSR09. (n=2)                                                                                                                  
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3.2 Discussion:  
3.2.1The effect of different concentrations of hydrophilic polymer (HPMC) and 
excipients on the physical properties of granules:- 
The granules for the conventional tablets and sustained release matrix tablets were prepared 
according to the formulations given in tables (2-1) and (2-3) respectively. In conventional 
tablets (TFF0) starch paste was used as the binder as opposed to P.V.P-K-30 dissolved in 
ethanol, which was used in the sustained release matrix tablets (TSR01-9). The granules of all 
these different formulations were evaluated to give the angle of repose, LBD, TBD, 
compressibility index, total porosity and sieve analysis test, tables (3-1), (3-2), and (3-3). The 
result of the angle of repose which was (< 30) indicates good flow properties of the granules 
(Martin, 2001). In this study the angles of repose for (TFF0&TSR01-9) ranged from 18.41 to 
22.93, which indicates that the granules have good flow and hence there was no significant 
difference between them.  
Bulk densities (LBD and TBD) of granules prepared by using starch paste as the granulating 
agent (TFF0) were found to be considerably higher than those of granules prepared by PVP 
(TSR01-9). Due to this the compressibility index of (TFF0) was 21.54% whereas the values for 
(TSR01-9) ranged from 5.44% to 10.07%. Generally, the compressibility index values below 
15% result in good to excellent flow properties, (Aulton and wells, 1988). The percentage 
porosity values of (TFF0) formulation which was 21.43%, was found to be more than that of 
(TSR01-9) which ranged from 4.76% to 10.00%.  
The percentage porosity values of TSR01, TSR03 TSR04, TSR08, and TSR09, were very close 
to each other and ranged from 4.76 to 6.25 which were of the lower values. The level of HPMC 
was 30%, 20%, 30%, 25%, and 20% respectively, and the level of lactose in these formulations 
was 0%, 0%, 10.93%, 5.46%, and 5.46% respectively. The percentage porosity values of 
TSR02, TSR05, TSR06 and TSR07 ranged from 9.10% to 10.00% which were of the higher 
values. Here the amount of HPMC was 25%, 25%, 20%, and 30% respectively, and the level of 
lactose was 0%, 10.93, 10.93, and 5.46% respectively. Therefore the different levels of HPMC 
and lactose do not appear to play a key role in the total porosity percentages. 
Generally, the different combinations of HPMC with different levels of MCC, starch, and 
lactose produce different sizes of granules, which results in different packing of the granules 
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and this generates variations in the LBD and TBD. Generally all the selected excipients namely 
MCC, starch, and lactose, in all levels of design for hydrophilic matrix (TSR01-9) gave adequate 
flow properties for granules with different levels of HPMC. Moreover, the result of sieve 
analysis for granules doesn’t give any odd result that worth much attention. 
3.2.2 Comparison between the physical characteristics of the conventional and 
matrix tablets: 
The uncoated tablets of different formulations (TFF0&TSR01-9) were subject to various 
evaluation tests, such as thickness, diameter, and uniformity of weight, hardness, friability, and 
in-vitro disintegration time for conventional tablets.  
All the formulations showed uniform thickness and diameter. In a weight variation test, the 
pharmacopoeia limit for the percentage deviation for tablets of more than 250 mg is ± 5%. The 
average percentage deviation of all tablets formulations (TFF0 & TSR01-9) was found to be 
around the mean value (366mg ±2.7%), and hence all formulations passed the test for 
uniformity of weight as per official requirements. This is also an evidence of good flow 
properties of the granules. The formulations (TSR01 to TSR09) showed high hardness values 
ranging from 203.2N to 281.8N. This could be due to the presence of HPMC. The conventional 
tablets (TFF0) showed high hardness values of (127.80N), which could be due to the use of 
starch paste as binder. Another measure of a tablet’s strength is friability. In this study, the 
percentage friability for all the formulations (TFF0 & TSR01-9) was below 1%, indicating that 
the tablets passed friability test. For in-vitro disintegration time, the conventional tablets (TFF0) 
disintegrated in 13 minutes and 38 second. The matrix tablets, (TSR01-9) swell due to the 
presence of hydrophilic polymer (HPMC) in the tablets contents. HPMC, one of the polymers, 
have been well known to retard the drug release by swelling in aqueous media (Michailova, 
2000). For more elaboration, HPMC is mixed alkyl hydroxyalkyl cellulose ether containing 
methoxy and hydroxypropyl groups. The hydration rate of HPMC depends on the nature of 
these constituents. Specifically, the hydration rate of HPMC increases with an increase in the 
hydroxypropyl content. The solubility of HPMC is pH independent (Hogan, 1989). 
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3.2.3 The effect of dissolution media and tablet constituents on drug (Fe+2) releases: 
The in-vitro drug (Fe+2) release characteristics for (TFF0 & TSR01-9) were studied in simulated 
gastric fluid (0.1N HCl), D.M water at pH6, phosphate buffer pH 4.5, and simulated intestinal 
fluid (phosphate buffer at pH 6.8), for a period of 15 to 16 hours using USPXXIII dissolution 
apparatus II. 
The results of drug (Fe+2) release in these media are statistically analyzed by using Microsoft 
programmed (Minitab –V14 – Taguchi design of Experiment) (DOE). 
Taguchi Design (L9 orthogonal array), which is used initially to plan a minimum number of 
experiments (TSR01 to TSR09), Table (2-2). To make the best use of data obtained, a scientific 
approach is followed; (a) firstly, to arrive at the best combination that gives a minimum drug 
(Fe+2) release in acidic media after 1 hour, (b) secondly, to get the ideal t90 for drug (Fe+2) 
release, (c) thirdly, to have a clear picture in comparison between conventional and matrix 
tablet, and (d) finally to know the effects of different excipient levels on drug (Fe+2) release 
profiles.  
3.2.4 Use of Taguchi method: 
The Taguchi method utilizes orthogonal arrays from design of experiments theory to study a 
large number of variables with a small number of experiments. Using orthogonal arrays 
significantly reduces the number of experimental configurations to be studied. The conclusions 
drawn from small scale experiments are valid over the entire experimental region spanned by 
the control factors and their settings (Phadke, 1989). This method can reduce research and 
development costs by improving the efficiency of generating information needed to design 
systems that are sensitive to usage conditions, manufacturing variation, and deterioration of 
parts. As a result, development time can be shortened significantly and important design 
parameters affecting operation, performance, and cost can be identified. Furthermore, the 
optimum choice of parameters can result in wider tolerances, so that low cost components and 
production processes can be used. Thus, manufacturing and operations cost can also be greatly 
reduced. To achieve all the above in pharmaceutical research, the best possible quantitative 
formula for a product must be found. Also the best possible set of experimental conditions 
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(input values) needed to run the process must be prepared. Hence, a brief over view of the 
process followed by Taguchi’s approach to parameter design is provided in Figure (3-20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (3-20): Flowchart of the Taguchi method. 
 
 
These steps can be grouped as: (Taguchi, 1988) 
• Planning a matrix experiment to determine the effects of the control factors. 
• Conducting the matrix experiment, and 
• Analyzing and verifying the results.  
In this research, a Taguchi method is used initially to plan a minimum number of experiments. 
Orthogonal array experiments are used as these allow simultaneous variation of several 
parameters and the investigation of interactions between parameters. The matrix experiment 
selected for this research is given in table (2-2). It consists of 9 individual experiments 
corresponding to the rows. In this array, the columns are mutually orthogonal. That is, for any 
pair of columns, all combinations of factor levels occur and they occur on an equal number of 
times. It should be noted that this design reduces 81 (34) configurations to 9 experimental 
evaluations.  
Therefore, an L9 Orthogonal array is employed in this research to evaluate the effects of the 
main control factors (A: HPMC, B: MCC, C: starch, and D: lactose) in formulating the matrix 
Determine the quality 
characteristic to be 
optimized 
Identify the noise factors 
and test conditions 
Identify the control factors 
and their alternative levels 
Design the matrix 
experiment and define the 
data analysis procedure 
Conduct the matrix experiment 
Analyses the data and determine 
optimum levels for control factor  
Predict the performance at these 
levels  
Conduct a confirmation 
experiment 
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tablets (TSR01-9) and the corresponding release (%) results. These effects can be determined or 
studied by using statistical analysis, such as ANOVA, to determine the relationship between the 
factors, the corresponding levels and the obtained results (Responses). 
3.2.5 Analyzing Taguchi Design to Select the Best Combinations that give least 
release (%) of drug (Fe+2) in acidic medium:  
To determine the best combination in terms of giving the least release percentage of drug (Fe+2) 
in acidic medium, the data obtained from in-vitro dissolution study in dissolution medium (1) 
was used as follows: The numerical values (%) of drug (Fe+2) release is taken as a response at 
the end of the first hour as illustrated in table (3-34).  
◘ Table (3-34): Matrix experiment, control factors & Response (%) at the end of 1st hr in HCl 
                                  CONTROL FACTORS Exp. 
No. A: HPMC   B: MCC C: STARCH   D: LACTOSE 
Response Drug (Fe+2) release 
(%) 
TSR01 +1 -1 +1 -1 60.70 
TSR02 0 0 +1 -1 38.79 
TSR03 -1 +1 +1 -1 46.51 
TSR04 +1 -1 -1 +1 40.63 
TSR05 0 0 -1 +1 43.23 
TSR06 -1 +1 -1 +1 44.68 
TSR07 +1 -1 0 0 16.79 
TSR08 0 0 0 0 27.79 
TSR09 -1 +1 0 0 27.02 
 
After conducting the matrix experiment, the optimal test parameter configuration within the 
experiment design must be determined. In order to analyze the results, the Taguchi method used 
a statistical measure of performance called signal – to – noise (S/N) ratio. The S/N ratio takes 
both the mean and the variability into account. In its simplest form, the S/N ratio is the ratio of 
mean (signal) to the standard deviation (noise). The S/N equation depends on the criterion for 
the quality characteristic to be optimized.  
The mean release in acidic media for each level of the factors can be obtained as listed in table 
(3-35). An ANOVA analysis for estimating the error variance for the factor effects and variance 
of the prediction error is given in table (3-36). This analysis of variance is conducted through 
Microsoft programmed (Minitab –V14 – Taguchi design of Experiment) (DOE). 
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◘ Table (3-35): Average of signal – to – noise ratio (S/N). 
Levels Factors 
-1 0 +1 
A: HPMC  39.40 36.60 39.37* 
B: MCC 39.37* 36.60 39.40 
C: STARCH 42.85 23.87* 48.67 
D: LACTOSE 48.67 23.87* 42.85 
* Indicates the optimum level; overall mean = 38.46 
  
 
 ◘ Table (3-36): ANOVA analysis for release (%) after the in HCl. 
Factors 
Degrees of 
Freedom 
(D.F) 
Sums of 
Square  (S.S) 
Mean Square 
(M.S) 
Variance Rate 
(V.R) 
A: HPMC 2 15.50* 7.75 0.041 
B: MCC 2 15.50* 7.75 0.041 
C: STARCH 2 336.40 168.2 0.895 
D: LACTOSE 2 336.40 168.2 0.895 
Error 2 720.75 360.40  
Total 10 1424.55   
(Error) (4) (751.75) (187.94)  
        *Indicates sum of squares added together to estimate the pooled error sum of squares indicated by parentheses.   
 
 
In the above table, the number of independent parameters associated with a matrix experiment 
or a factor is called “degrees of Freedom”. The matrix experiment with nine rows has eight 
degrees of freedom associated with the total sum of squares (S.S); each factor with three levels 
have 2 independent parameters (n-1), and hence, 2 degrees of freedom. Therefore, six degrees 
of freedom are used for estimating the factor effects and the degrees of freedom for estimating 
the error turned out to be two (Phillip, 1988). 
To estimate the relative importance of the factors, the sum of square value to different factors is 
obtained. In order to determine the percentage of contribution for each factor, the  
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sum of squares of factors is divided by the total sum of squares. For A: HPMC and B: MCC the 
result was 1.09 % and for C: starch and D: lactose the result was 23.61 %. In fact the larger the 
contribution of C and D to the total sums of squares, the larger the ability of these factors to 
influence the drug (Fe+2) releases (%) in acidic media (HCl) after 1hr. 
The next step in data analysis was to determine the optimum formulation that gives the least 
drug (Fe+2) release (%) in the acidic medium.  
This can be graphically represented between the average S/N ratio and the corresponding, 
various levels of the factors (HPMC, MCC, starch, and lactose) as illustrated in Figure (3-21). 
The optimum level for each factor is the level that gives the lowest value of S/N ratio of release 
in the experimental region (Smallest –is– best quality characteristic). Therefore, from the main 
effects plot for the means the observations, is that the optimum choice of factor (A: HPMC), (B: 
MCC), (C: Starch), and (D: Lactose) is middle i.e. A2, B2, C2, and D2 respectively.    
The additive model is used to predict the value of drug (Fe+2) release (%) after 1hr in HCl, 
under the optimum conditions as in table (3-37). Since the contributions of C2: Starch and D2: 
lactose is very small, they aren't included in the contribution under optimum conditions. 
Therefore the predicted value of drug Fe+2 releases (%) in HCl, under optimum conditions is 
calculated by adding the overall mean which agree well with the S/N ratio in table (3-35), to the 
contribution of factors A2 and B2 only i.e. [38.46+(-1.86)+ (-1.86)] equal to 34.74%.  
what is expected to be gained by using these observations in this statistical analysis is shown in 
table (3-37), that summarizes the optimum formulation that is expected to give the least drug 
(Fe+2) release in 0.1N HCl pH1.2 media at the end of the first hour.  
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Fig (3-21): Main effects plot (data means) for response: release % after 1hr in HCl. 
  
 ◘ Table (3-37): prediction of the least drug (Fe+2) release in HCl after 1hr.  
Optimum Condition Control 
Factors Best (factor / level) Optimum level Contribution* 
A: HPMC A2 36.6 (-1.86) 
B: MCC B2 36.6 (-1.86) 
C: STARCH C2 23.87 0.00 (-ve) 
D: LACTOSE D2 23.87 0.00 (-ve) 
Overall mean   38.46 
TOTAL  34.74 
      *By contribution we mean the deviation from the overall mean caused by the particular factor level 
 
3.2.6 The influences of HPMC, MCC, Starch, and Lactose on drug (Fe+2) releases 
(%) in HCl pH1.2:  
In dissolution medium (1), the results of drug (Fe+2) release of the (TSR01, TSR02, and TSR03) 
at the end of the first hour was 60.70%, 38.79%, and 46.51% respectively. These results were 
showed that; formulation TSR01 (30% HPMC, 0% MCC, 10.93% starch, and 0% lactose) was 
slightly higher release (%), if compared with TSR02 (25% HPMC, 5% MCC, 10.93% starch, 
and 0% lactose) and TSR03 (20% HPMC, 10% MCC, 10.93% starch, and 0% lactose). These 
results indicate that MCC did not produce any relevant effect on the drug (Fe+2) release rate. 
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The formulations TSR04, TSR05, and TSR06 released 40.63%, 43.23%, and 44.65% of the 
drug (Fe+2) at the end of the first hour, and 23.72%, 36.30%, and 48.60% of the drug (Fe+2) at 
the end of 16th hour, respectively. In these formulations the percentage of starch is zero, and the 
lactose percentage is constant (10.93%) for all the three formulations. HPMC was graded 
descending from 30%, 25%, and 20%, respectively, unlike the MCC which was graded 
ascending from 0%, 5%, and 10% respectively. Comparing the results of the three formulations 
(TSR04, TSR05, TSR06) with the three previous ones (TSR01, TSR02, TSR03) it is observed 
that absence of starch with the MCC affects the percentage of the initial release as well as the 
rate of release. In the formulations (TSR07, TSR08, and TSR09) the drug (Fe+2) release was 
16.79%, 27.79% and 27.02% at the end of first hour, and 51.86%, 57.44%, and 57.79% at the 
end of the 16th hours, respectively. For these matrix tablets formulations, it is found that the 
percentage of the starch and lactose is equal to 5% for all of them. But the HPMC and MCC are 
the same as in the first six formulations. It is observed that the release percentage dropped to the 
approved half by the end of the first hour in these last three matrix tablets.  
From all the above results it is concluded that the different concentrations of HPMC that were 
used have no significant effect on the pattern or rate of release. The case is different in the 
existence of starch in different concentrations, as it has an effect on the control of the released 
drug (Fe+2) percentage. That is because the starch forms a gel layer around the swelling that 
occur by HPMC in an aqueous dissolution media, which in turn affects the quantity of water 
penetration to the tablet core and hence drug diffused out.  
This previous interpretation can be compared with the plot interaction for data means between 
response (release at the end of first hour for “(TSR01-9) in HCl” and the data mean for the main 
factors. An interaction is clear between the different main factors used as shown in figure (3-22) 
that is designed by Microsoft programmed–Minitab Taguchi design of Experiment DOE). 
Similarly, the same program is used to determine the effect of each of the main factors in the 
response as shown in response surface plot, figure (3-23). The Graph shows the effect of 
(HPMC) percentage and (Starch) percentage on the drug (Fe+2) release after 1 hour in 0.1N HCl 
pH 1.2.  
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     Fig (3-22): Interaction plot (data means) for response; Release after 1hr in HCl / Dissolution medium(1)      
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Fi(3-23): Response surface plot; of release in HCl after 1hr vs. HPMC& Starch 
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3.2.7 Analysis (Taguchi design) to select the best combination that gives maximum 
t90 of drug (Fe+2) in D.M Water pH6: 
In the dissolution medium (1), it was noted that all the (TSR01-9) formulations released part of 
the drug by the end of the first hour in the acidic medium (0.1N HCl pH1.2); the remaining part 
was released in D.M water which constitute the second part of the dissolution medium (1). For 
the above mentioned reason it turned out to be difficult to determine the best formulation that 
gives the longest or ideal release in terms of time. Therefore, the obtained results from the drug 
release in the dissolutions medium (2) i.e. D.M water at pH6, was used to determine the best 
combination that gives the required ideal t90 value. For the analysis the same (Microsoft 
programmed Minitab –V14, Taguchi design of Experiment. DOE) was used. First, the matrix 
experiment was conducted by expressing the response by putting different release times for 
(TSR01-9) that gives 90% and above with the different levels of the four main factors as shown 
in table (3-38). 
◘ Table (3-38): Matrix experiment, Response, t90 (minutes). 
                                   CONTROL FACTORS Exp. No. 
A: HPMC B: MCC C: STARCH D: LACTOSE 
Response: t90 in DM. water 
at pH6 
TSR01 +1 -1 +1 -1 900 
TSR02 0 0 +1 -1 900 
TSR03 -1 +1 +1 -1 840 
TSR04 +1 -1 -1 +1 720 
TSR05 0 0 -1 +1 825 
TSR06 -1 +1 -1 +1 825 
TSR07 +1 -1 0 0 945 
TSR08 0 0 0 0 990 
TSR09 -1 +1 0 0 705 
 
Then, to statistically analyze the matrix experiment, it was necessary to calculate the mean for 
signal – to – noise (S/N). This can be calculated by taking the mean times (t90) for each level of 
the four main factors as in table (3-39). 
   ◘ Table (3-39): Average of signal – to – noise (S/N) ratio. 
Levels Factors 
-1 0 +1 
A: HPMC  790 905* 855 
B: MCC 855 905* 790 
C: STARCH 790 880 880* 
D: LACTOSE 880* 880 790 
* Indicates the optimum level; overall mean = 850 
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The next step, an orthogonal array and ANOVA Analysis, was used to determine the influence 
of the main factors at a 3-level and the percentage contribution of each factor, was applied to 
evaluate the relative importance of the effect of various factors. An ANOVA analysis for 
estimating the error variance for the factor effects and the variance of the prediction error is 
given in table (3-40).  
  ◘ Table (3-40): ANOVA analysis for t90 (min). 
Factors 
Degrees of 
Freedom 
(D.F) 
Sums of 
Square  (S.S) 
Mean Square 
(M.S) 
Variance Rate 
(V.R) 
A: HPMC 2 6650 3325 1.52× 10-4 
B: MCC 2 6650 3325 1.52× 10-4 
C: STARCH 2 5400* 2700 1.23× 10-4 
D: LACTOSE 2 5400* 2700 1.23× 10-4 
Error 2 87480000* 43740000  
Total 10 87504100   
(Error) (4) (87490800) (21872700)  
      *Indicates sum of squares added together to estimate the pooled error sum of squares indicated by parentheses. 
 
The same analysis technique is used to determine t90 value. In table (3-40) (ANOVA analysis 
for t90), the A: HPMC and B: MCC results, turned to be larger than C: Starch and D: Lactose 
results when calculating the percentage of contribution. They were 0.0076% for (A&B) and 
0.0062% for (C&D) respectively. This also shows that all the factors have an effect on t90 but 
(A&B) have more contribution to the sum of squares.  
Likewise, the Minitab- Taguchi (DOE) Microsoft is used to determine the optimum 
combination of formulation that has the required ideal t90.  
This can be illustrated through figure (3-24) that shows the average S/N ratio at the various 
levels for these factors (HPMC, MCC, Starch, and Lactose). 
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 Fig (3-24): Main effects plot (data means) for response; time required for 90% release in D.M water. 
 
Due to what was explained earlier, when the optimum levels for factors are chosen from the 
plots of factor effects, the highest values of S/N ratio is taken (the biggest – is – best quality 
characteristics), to give the max. t90. 
The above Graphs show the optimum TSR formulations that have the required max t90. Looking 
at the graph it can be seen that A: HPMC optimum value is the middle plotted value (A2). 
Similarly, B: MCC optimum value is the middle plotted value (B2). Whereas C: starch and D: 
lactose optimum values can both be in the middle as well as the lowest plotted value (C1 or C2 
& D1 or D2). In the same manner, and as used in the prediction of ideal release in acidic media 
after the 1hr, in (Table 3-37), the additive model is used to predict the value of t90 under 
optimum conditions. Table (3-41) summarizes the optimum values for factors and factor levels 
that are expected to give the required ideal t90 (960 minutes), which is the total value of time 
obtained from the overall mean added to the contribution of factors A2 and B2. Likewise C2 and 
D2 are ignored.  
 
 
   135 
  
      ◘ Table (3-41): Prediction of the least drug (Fe+2) release in HCl after 1hr. 
Optimum Condition Control Factors 
Best (factor / level) Optimum level Contribution* 
A: HPMC A2 905 55 
B: MCC B2 905 55 
C: STARCH C2 880 0.0 
D: LACTOSE D2 880 0.0 
Overall mean   850 
TOTAL   960 
      * By contribution we mean the deviation from the overall mean caused by the particular factor level. 
 
3.2.8 The influences of the combination of (HPMC, MCC, Starch, and Lactose) on 
the overall release in D.M Water:  
In dissolution medium (2), the drug (Fe+2) release percentage of the matrix tablets (TSR01 to 
TSR09) at the end of the first hour ranged from (0.28% min to 2.12% max). Furthermore, from 
the 1st to 16th hours, all the tablets slowly released the drug (Fe+2). According to the basic 
concept of the sustained release, a suitable sustained- release formulation should release the 
required amount of drug in the initial hours, followed by slow release. So the matrix tablet, 
(TSR01-9) complied with the above concept and no significant difference was observed. All the 
formulations (TSR01-9) have similar (t90) with reasonable variations that ranged from (705 to 
990 minutes). This makes it difficult to determine the effect of any single factor or combined 
effect of any two or more factors on the pattern or rate of the overall release. Nevertheless, the 
effects of these factors with each other can be compared by referring to interaction plot figure 
(3-25) that is designed by (Microsoft – Minitab Taguchi design of Experiment – DOE). This 
figure shows the relation between the main factors and their corresponding levels used and the 
response (t90).          
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By using the same Microsoft – Minitab –V14 programmed, the effect of any two factors on the 
Response (t90) is illustrated in the Response surface plot; see Figure (3-26) as an example, 
which shows the effect of HPMC percentage and starch percentage, on t90 in dissolution 
medium (2): D.M water at pH6. 
1 1 0
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    Fig (3-26): Response Surface plot of; Time required for 90% release (t90) vs. HPMC, Starch.      
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3.2.9 Effects of changing the dissolution media on the drug (Fe+2) releases 
kinetic: 
In order to know the mechanism of drug (Fe+2) release for formulations (TFF0 & TSR01-9), the 
results obtained from the study of drug release in the different 4 dissolution media were treated 
according to: Zero-order equation (cumulative amount of drug released VS time), Higuchis 
equation; (cumulative percentage of drug released Vs square root of time) (Higuchis, 1963), and 
Korsmeyer’s equation, (log cumulative percentage of drug vs. log time) (Korsmeyer, 1983). 
In tables (3-26) and (3-30) that show the kinetic values in dissolution medium (1), it was 
observed that all the formulations didn’t follow all the 4 kinetic equations above.  This may be 
due to the change in the dissolution medium by the end of the first hour from acidic 0.1N HCl 
to D.M water at pH6. When calculating the release (%) at the end of the 1st hour (First point) 
with the release (%) in D.M water (the rest of the points) it was found that all kinetic equations 
show low linearity with the overall regression values estimated around (0.9492). This value is 
considered to be relatively high when zero-order equation is applied for the formulations 
(TSR01-9), whereas is considered to be completely low when first-order equation for the 
formulations (TSR01-9) is applied. Generally, this can be interpreted by the fact that; all the 
matrix tablet, released a significant amount of the drug (Fe+2) by the end of the 1st hour, which 
in turn affect the application of the first-order equation which was originally a plot between the 
remaining drug and time. As for the formulations (TSR07-9), they showed the same linearity 
when plotted according to the zero-order, Higuchi's, and Korsmeyer’s kinetic equations. This 
was due to the equality of starch and lactose in the tablets contents (5.46%). 
As in table (3-30), in dissolution medium (1) the release exponent (n) was found to range from 
0.52 to 0.65 for TSR01-6 but for TSR08-9 ranged from 0.94 to 1.02. This indicates that the drug 
(Fe+2) release of these formulations demonstrated two type of mechanism called, Fickian (case 
I) and non-Fickian (anomalous). As for (TSR07) formulation, the release exponent value (n) was 
found 1.02 which indicate that the drug (Fe+2) release has the tendency to zero-order or case II 
transport.  
This can be further illustrated by studying the kinetic values results obtained from drug (Fe+2) 
release in the dissolution medium (2). From tables (3-27), (3-31) it is observed that the in-vitro 
release profiles of drug (Fe+2) from all the formulations (TFF0 & TSR01-9) showed high 
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linearity, when plotted according to the zero-order Higuchi's, and Korsmeyer’s kinetic 
equations. On the other hand, it is observed that the drug (Fe+2) release data, when plotted 
according to the zero-order equation for all formulations (TFF0 & TSR01-9), showed a fair 
linearity with regression values between (R2: 0.9029-0.9984). When the release exponent 
value(n) is compared with what was mentioned earlier, the drug release kinetic for all the matrix 
tablets (TSR01-9), where n>1 (i.e. ranging between 1.31 to 2.58) was found to be nearer to zero-
order or case II transport rather than non-fickian case I. 
The conclusion from the above manipulation is that the drug (Fe+2) release kinetic in both 
dissolution media (1&2) followed a zero-order release pattern. 
When the drug (Fe+2) release data obtained from dissolution medium (3) (phosphate buffer at 
pH 4.5), were plotted according to the 4 kinetic equations, it was observed that all formulations 
(TFF0 & TSR01-9) showed a fair linearity with regression values between (R2: 0.9418 to 0.9895) 
for zero-order plot. Similarly the regression values were between (R2: 0.8397 to 0.9967) for 
Higuchi’s plot which is referred to as "square root kinetic". Whereas the regression values were 
between (R2: 0.9588 to 0.9888) for Korsmeyer’s plots. 
From table (3-32), the release exponent (n) for all formulations (TFF0 & TSR01-9) ranged from 
(1.23 to 1.99). This means that the drug (Fe+2) release kinetics was Non- Fickian (Super case II).  
For all formulations, (TFF0 & TSR01-9), in the dissolution medium (4) (phosphate buffer pH 
6.8) the calculated regression coefficient for zero-order, first-order, Higuchi, and Korsmeyer's 
plot, showed low linearity. When compared to medium (3), it is obvious that the pH for the 
phosphate buffer has a significant effect on the drug (Fe+2) release pattern. This is due to the 
extent of drug (Fe+2) release pattern, attributed to solubility in different phosphate buffer pH. 
From all the above mentioned, the drug (Fe+2) release of the matrix tablets in all formulations 
(TSR01-9) were either zero-order release kinetic or Non- Fickian (Super case II). On the other 
hand, in the conventional tablets (TFF0) the release exponent (n) was less value in all in-vitro 
dissolution study media. This was due to the HPMC absence in the conventional tablets.  
With reference to tables (3-5), axial swelling, and (3-6) radial swelling, the existence of HPMC 
resulted in both axial and radial swelling of the matrix tablets (TSR). When such tablets come 
in contact with a dissolution medium, the surface layer undergoes gel formation. The gel layer 
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characteristics (viscosity, thickness) determine the pattern of drug release. In other words, the 
release of the drug from a matrix tablet that contain hydrophilic polymer like HPMC, generally 
involves factors of diffusion. 
This diffusion is related to transport of drug from the dosage matrix into the dissolution fluid, 
due to polymer relaxation and is characterized by the formation of a gel-like network 
surrounding the system. The mechanical property of the surface hydrated gelatinous barrier 
plays an important role in overall drug release rate (Talukder, 1996). This is what exactly have 
been arrived at in this study as the drug (Fe+2) release pattern in all four dissolution media for 
the matrix tablets (TSR01-9) follow two mechanisms. At first, an anomalous mechanism as drug 
diffusion occurs. The swelling rate increases till the matrix tablet reaches the maximum 
swelling, then the overall release profile follows a zero-order release kinetic.  
Figure (3-27) below is a trial to represent the above graphically, to illustrate clearly what 
happened to the matrix tablets in dissolution media.  
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3.2.10 The effect of HPMC loading and physcio-chemical properties of drug (Fe+2) 
in the release mechanism: 
The calculated MDT values for the matrix tablets TSR07, TSR08 and TSR09 obtained from 
drug (Fe+2) release in dissolution medium (1) showed higher values of 2.87, 1.36, and 1.58 
respectively. In the first matrix the HPMC level is the maximum percentage (30%), but for the 
hydrophilic excipients, starch and lactase is equal (5.46%) and MCC is the lowest (0%). As for 
TSR04 which contains HPMC (30%), MCC (0%), starch (0%), and lactose (10.93%), its MDT 
value is the lowest compared to the above matrix. Nevertheless TSR05 calculated MDT is far 
lower than the TSR08 matrix tablets (0.011). TSR05 contains HPMC (25%), MCC (5%), starch 
(0%), and lactase (10.93%). This indicates that MCC increase and HPMC decrease affect the 
MDT value.  
When MDT value is calculated from drug (Fe+2) release data obtained from in-vitro study in 
dissolution medium (2), it is found that the MDT values are of closer values range from (33.20 
– 67.70) and higher than values which calculated from dissolution medium (1) data. In this 
medium (2) the value of MDT for (TFF0) are to some extent nearer to the MDT values of the 
all formulations in dissolution medium (1). That means the dissolution medium has an effect on 
MDT value. This could be clearer when MDT values were calculated from the obtained drug 
(Fe+2) release data of the matrix tablets (TSR01-9) in dissolution media (3) and (4). These values 
were ranged from 26.24 to 47.03 for medium (3), and 184.26 to 395.75 for medium (4) as in 
tables (3-32) and (3-33). It is obvious that these values are much higher than the values of MDT 
in dissolution medium (1). This might be due to the extent of drug (Fe+2) solubility in 
dissolution medium. As known from previous study that the drug (Fe+2) release percentage 
decrease gradually when phosphate buffer changed for pH 4.5 to pH 6.8. So from all the results 
above it is clear that there is a direct relation between MDT value and drug solubility in 
addition to the ability of hydrophilic exipients (starch and lactose) to make the drug more liable 
to solubility.  
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Conclusion: 
• The in vitro dissolution study for release of folic acid from both conventional (TFF0) and 
matrix tablet, (TSR01-9) was performed according to USP 27 specifications, using HPLC 
method for analysis. The content of folic acid was not determined. Folic acid content is 
small (0.5mg) compared to the quantity of ferrous fumarate (200mg/tablet) and the total 
quantity of other excipients (165.5mg/tablet). Based on the same technique folic acid tablets 
of different concentrations (0.5mg,5mg,50mg) were prepared but without addition of iron. 
They were tried under same conditions i.e.: same medium, same apparatus and same 
detection wavelength. The observation were as appear in figures (A,B,C) as follows: 
Chromatogram (A): 0.5 mg of folic acid was tried in 1000ml of dissolution medium       
(D.M water) when it was analyzed in HPLC, no peak observed (Fig. A) 
      
 
 
 
 
     Chromatogram (B): 5 mg of folic acid was put in 1000ml of dissolution medium (D.M 
water) when it was analyzed in HPLC, un-detectable peak was observed (Fig. B) 
     
 
 
 
 
     Chromatogram (C): 50 mg of folic acid was taken in 1000ml of dissolution medium (D.M 
water) in this case a nice peak was observed at the same retention time (Fig. C) 
 
                                                                       
   
 
(A) 
(B) 
(C) 
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• There is no significant difference in drug (Fe+2) release between hydrophilic matrix tablets 
(TSR01-9) when HPMC concentration was either in the higher or lower percentages. This 
indicates that the addition of hydrophilic polymer (HPMC) alone could not control drug 
(Fe+2) release without the addition of the other excipients (i.e.; MCC. starch, lactose) to the 
matrix tablets. There is a direct correlation between the different concentrations of these 
excipients and drug Fe+2 release profile. 
• The application of Taguchi experimental method (L9 orthogonal array experiment) 
facilitates the study of several variables from different data by conducting small number of 
experiments. On one hand when an ANOVA analysis was applied, the relative importance of 
effect was determined for various factors at different levels. From statistical analysis 
generated from (L9 orthogonal array), the middle level factors (A2: HPMC, B2: MCC, C2: 
Starch, and D2: Lactose) give the lowest drug (Fe+2) release percentage at the end of the first 
hour in acidic media as well as the ideal t90 in D.M water at pH 6. 
• The data analysis generated from in-vitro drug (Fe+2) release study for hydrophilic matrix 
shows that the best fit of drug release kinetic with the highest correlation coefficients R2 was 
achieved with the korsmeyer's plots (log cumulative (%) of drug release vs. log time) 
followed by zero-order plots (cumulative (%) drug release vs. time) in dissolution media 
D.M water at pH 6. 
• When studying the drug (Fe+2) release for all hydrophilic matrix tablets (TSR01-9) in the 
previously mentioned dissolution media, it is clear that there are tow types of kinetic: an 
anomalous (non-fickian) and (zero-order) associated with the rate of swelling occurring in 
the tablets during the dissolution media. 
• The addition of cationic surfactant (0.5% w/v cetrimide agar) to the dissolution medium (4) 
– phosphate buffer at pH 6.8 (SIF), results in significant increase in drug (Fe+2) release in all 
formulations namely TFF0 & TSR01-9 as shown in figure (3-10 to 3-19). This indicates 
strongly the possibility of food effect on drug Fe+2 releases. 
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Recommendations: 
• The study at hand covered some aspects about sustain release of the solid dosage from in a 
practical using the available equipments in Sudan. So it is recommended that, this work can 
be extended in the first place by using on-line dissolution testers to facilitate the sampling 
and analysis process for as long time as possible. Then going over the details of the technical 
work, some points need to be further studied regarding the following: - 
• As mentioned in the study the folic acid quantity was less, that the progress of drug release 
was not identified. So more analytical methods are needed to identify the small quantity of 
drug release over time. 
• The very high peaks with specific retention times that were observed from HPLC-
chromatograms need further study to be identified; so if it was due to the organic part at the 
(Fe+2) then it could be used for its analysis. 
• The best combination that gives the lowest drug (Fe+2) release in the acidic medium and the 
ideal t90 in DM-water at pH6 could be properly studied. Then an in vitro-in vivo correlation 
study could be carried out compared with the dissolution of pellets. 
• Different sustain release polymers could be used in the tablets to compare and study the 
advantages and disadvantages of different polymers. 
• On-going and accelerated stability studies could be carried out for the above-mentioned best 
combination.                        
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